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The important research goals in chemical biology are to discover small-molecule 
modulators that can disrupt the biological system and to identify the protein-
protein interactions in which these small molecules modulate the biological 
system. Therefore, in order to discover new small-molecule modulators that can 
selectively regulate protein-protein interactions, development of drug-like small 
molecules is required, which have high molecular diversity and biological 
relevance. In this study, we proposed molecules possessing the characteristics of 
natural products to be suitable for constitution of compounds meeting the 
aforementioned requirements. For high biological relevance, we used compounds 
containing a pyrimidine unit as a privileged structure and explored various 
derivatives of three-dimensional structural diversity in order to discover 
compounds different from the conventionally synthesized flat molecules. 
 
Chapter 1 introduces the different attempts made to obtain compounds with 
various molecular structures having high biological relevance to increase the 
possibility of discovering modulators of physiological activities. 
Chapter 2 describes the development of pDOS (privileged substructure-based 
diversity-oriented synthesis) pathways involving pyrimidine. This chapter 
ii 
describes the pathways for the synthesis of compounds with unique three-
dimensional structures, in which pyrimidine and a 7-membered ring are fused, by 
using pyrimidodiazepine as a starting material. It has been demonstrated that the 
compounds obtained from the pathways can modulate the actual protein-protein 
interaction. 
Chapter 3 describes the newly discovered reactivity of pyrimidodiazepine 
derivatives under gold catalysis. Using this reactivity, the skeletal transformation 
of molecular structures can be efficiently achieved in a single-step reaction. In 
addition, this method provides an effective way to access the pyrimidine-
containing macrocycle through skeletal diversification. 
Finally, Chapter 4 deals with the construction of a small-molecule library using 
the aforementioned gold-catalyzed reaction. We proposed construction of a small 
molecule library with high structural diversity by using pyrimidine-containing 
medium-sized ring compounds. The medium-sized rings can be converted to 
macrocyclic structures or other types of medium-sized rings through a gold 
catalyzed single-step reaction. 
 
Through our research described in Chapters 2–4, we have obtained a large 
number of small molecules with three-dimensional structural diversity and 
discovered small-molecule modulators that can regulate the actual protein-protein 
interaction, thereby proving the usefulness of the pDOS libraries. The 
pyrimidine-based natural-product-like small molecules described in this 
dissertation should have high potential for deriving new physiologically active 
molecules in the future. 
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Chapter 1. Introduction 
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1.1 Purpose of Research 
Currently, the most notable method in drug discovery, especially in the 
development of first-in-class drugs, is phenotype-based screening.1 The method 
involves the observation of phenotypic changes in a cell or organism to identify the 
substance that expresses a desired phenotype. The development of high-throughput 
screening (HTS) and high-content screening (HCS) has enabled rapid and efficient 
investigation of biological activities, which require a large number of compound 
libraries.2 The important aspect here is not the size of the library, but the skeletal 
and stereochemical diversity of compound structures. Most libraries constructed 
from a limited number of core skeletons have not been very successful in 
populating the multi-dimensional chemical descriptor space.3 Moreover, although 
the total chemical space is estimated to cover more than 1063 distinct organic 
molecules, some of them are synthetically inaccessible and only a small portion of 
this huge chemical space is applicable to biomedical fields.4 Therefore, there is a 
demand for efficient construction of small molecule libraries with a wide range of 
molecular diversity. 
Natural products are known to exhibit excellent molecular diversity and their 
analogs have been widely used as therapeutic agents or functional modulators of 
specific biological processes.5 However, there are drawbacks associated with the 
use of natural products as small molecule modulators, which are difficult to 
structurally modify and subsequently scale-up. Therefore, it is advantageous to 
synthesize a natural product-like compound containing the characteristics of a 
natural product. The characteristic of natural products is complexity, including rich 
saturated bonds, and stereo centers.6 The more complex molecules have the ability 
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to access larger chemical spaces. Hence, there is greater potential to identify 
compounds with better specificity to the target biopolymer.7 Importantly, the 
saturated compound might also result in greater selectivity, resulting in fewer off-
target effects.8 As small molecules are discovered during the initial drug discovery 
stage and converted into drugs through clinical trials, more saturated small 
molecules are more likely to succeed in this drug discovery process.9 Another 
descriptor of complexity, the presence of a stereo center, is also often observed in 
drugs that have been successfully discovered through clinical trials.10 Therefore, 
effective synthetic strategy needs to be developed for a new collection of natural 
product-like small molecules. 
To address these demands, Schreiber et al. developed the diversity-oriented 
synthesis (DOS) strategy,11 which efficiently populates the chemical space with 
skeletally and stereochemically diverse small molecules synthesized from simple 
building blocks via complexity-generating reactions. The resulting collection of 
organic molecules has been successfully utilized for the efficient discovery of 
bioactive small-molecule modulators and therapeutic agents.12 As a result, the 
DOS-derived libraries have been of great value in the discovery of drug candidates, 
and thus DOS has emerged as an essential tool in chemical biology and drug 
discovery.13 
However, an important challenge is to introduce improved biological relevance 
with maximize molecular diversity. Privileged structures are important for the 
discovery of bioactive small molecules.14 Therefore, incorporating a privileged 
structure into the core skeleton can improve specific interactions between small 
molecule and various biopolymers.15 To address these needs in order to maximize 
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molecular diversity with high biological relevancy, our group presented a 
privileged-substructure-based DOS (pDOS) strategy and attempted to emphasize 
the importance of skeletal diversity through creative reconstruction of privileged 
substructures embedded in polyheterocyclic molecular frame-works.16 This is 
because privileged substructures with three-dimensionally diverse skeleton are 
expected to exhibit high affinity toward various biopolymers owing to the natural 
selection process and the evolutionary similarity between gene products. The 
importance of privileged substructure such as benzopyran,17 oxopiperazine,18 and 
pyrimidine19 in pDOS library compounds has been clearly demonstrated in our 
laboratory by screening of bioactive small molecules and the subsequent 
identification of appropriate target biomolecules.20,19c Bioactive compounds with 
particular specificities derived from pDOS, show that a privileged structure could 
serve as a chemical “navigator” toward biologically relevant chemical spaces.21 
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2.1 Introduction 
The molecular diversity and complexity in a screening collection of drug-like small 
molecules is a paramount breakthrough in the discovery of novel small-molecule 
modulators for currently “undruggable” targets, including protein–protein 
interactions (PPIs) and protein–nucleic acid interactions.1–3 Toward this end, a 
strategy termed diversity-oriented synthesis (DOS) was devised, which seeks to 
populate the vast area of new chemical space made up of diverse and three-
dimensional (3D) complex drug-like compounds.4–6 Although DOS has emerged as 
an indispensable tool to promote the unbiased screening of compounds and their 
interactions with diverse biological targets, one of the key challenges in this field is 
the identification of appropriate chemical structures that will exhibit improved 
biological relevance and high molecular diversity. To address this issue, synthetic 
community has been developing many DOS-based approaches for the generation of 
compound libraries embodying core scaffolds of natural products or its mimetics.7–
11 Natural products have inherent bioactivity and high bioavailability; thus, the 
natural product-inspired DOS libraries with biological relevance could be of great 
value for the identification of bioactive compounds.12–14 
With the goal of targeting unexplored biologically relevant chemical space, we 
postulated that privileged structures could also serve as “chemical navigators” and 
therefore reported a privileged substructure-based DOS (pDOS) strategy, which 
targets the synthesis of diverse polyheterocyclic skeletons containing privileged 
substructures through complexity-generating reactions in order to maximize the 
unbiased coverage of bioactive space.15–17 By incorporating privileged 
substructures into a rigid core skeleton, we envisioned that the resulting 
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compounds would exhibit enhanced interactions with various bio macromolecules 
including proteins and DNA/RNA. Consequently, we demonstrated the importance 
of pDOS strategy through the discovery of new bioactive small molecules that 
interact with a wide range of biological targets.18–19 
As a continuation of our previous work, we identified pyrimidine as a new 
privileged substructure that could be used to navigate through bioactive chemical 
space. The pyrimidine moiety is commonly present in various bioactive small 
molecules, and it plays a critical role as a nucleoside analog in various kinase 
inhibitors or adenosine receptor modulators due to its hydrogen bonding ability 
(Fig. 2-1a).20–22 Therefore, many synthetic efforts toward pyrimidine-containing 
species have been focused on aromatic monocyclic or bicyclic skeletons, which 
limits the structural diversity of the pyrimidine-containing core skeletons. In 
addition, the 3D structural complexity of the core skeletons becomes important 
because planar frameworks less frequently comprise FDA-approved chemical 
entities, especially in regard to ‘undruggable’ targets.23–25 
In order to expand the molecular diversity beyond monocyclic and bicyclic 
pyrimidine skeletons, we develop a new pDOS strategy towards the divergent 
synthesis of natural product-like polyheterocycles containing pyrimidodiazepine or 
pyrimidine. Diazepine is also often found in complex natural products that exhibit 
a wide range of biological activities, and is known to be a prominent privileged 
structure that can improve the bioavailability and bioactivity of compounds.26,27 In 
addition, 7-membered rings that are fused to aromatic rings generally have higher 
conformational flexibility and a greater number of reactive sites than 6- or 5-
membered fused ring systems, as confirmed by the direct comparison of 
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Figure 2-1. Diversity-oriented synthetic strategy with pyrimidine as a privileged structure. 
a) Pyrimidine-containing bioactive compounds. b) 3D chemical space of pyrimidine and the 
comparison between pyrimidine-containing tricyclic 6/6/6 and 6/7/6 systems in terms of 3D 
diversity and complexity by overlaying energy-minimized conformers aligned along the 
pyrimidine substructure. c) Synthetic strategy for diversity-oriented synthesis of 
pyrimidodiazepine- or pyrimidine-containing polyhetero-cycles through divergent pairing 
pathways. 
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pyrimidine-embedded tricyclic 6/6/6 and 6/7/6 systems by overlaying the energy-
minimized conformers aligned along the pyrimidine substructure (Fig. 2-1b). Thus, 
pyrimidodiazepine can serve as a versatile intermediate to access highly diverse 
and complex polyheterocycles through the incorporation of additional ring systems, 
which forms the basis of a new pyrimidodiazepine-based pDOS pathway. To 
establish the pDOS pathway, we first design and synthesize highly functionalized 
pyrimidodiazepine intermediates 1 containing 5 reactive sites (A–E). In our pDOS 
strategy, intermediates 1 can be transformed into 9 distinct pyrimidodiazepine- or 
pyrimidine-containing scaffolds (I–IX) via pairing different functional groups at 
each reactive site (Fig. 2-1c). Then, we conduct ELISA-based high-throughput 
screening (HTS) of leucyl-tRNA synthetase (LRS)-Ras-related GTP-binding 
protein D (RagD) interaction28 to validate whether our distinct scaffolds can target 
unexplored biologically relevant chemical space. This screening exercise lead to 
the identification of an effective hit compound, 21f, which regulates the amino 
acid-dependent activation of mechanistic target of rapamycin complex 1 
(mTORC1) activity via specific inhibition of LRS-RagD interaction. 21f can serve 
as a research tool with a novel mode of action for specific modulation of mTORC1 
signaling pathway. Collectively, we confirm that pDOS is an appropriate strategy to 
target challenging biological targets. 
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2.2 Result and Discussion 
Pairing strategies for scaffolds I–III 
For the synthesis of scaffolds I–III through A-B or B-C pairs, suitable functional 
groups at the B position were imperative as they participated in the pairing reaction 
(Fig. 2-2). First, substrates 1a-e were readily synthesized through a series of 
transformations (Supplementary Fig. 1-3). For the synthesis of scaffold I, 
substrates 1a-c were treated with sodium borohydride (NaBH4) to afford secondary 
amines; the resulting secondary amines were protected with Boc and aniline was 
N-alkylated, which allowed for the formation of intermediates A. Scaffold I was 
efficiently generated via A-B pairing through an intramolecular substitution 
reaction, when intermediates A were subjected to debenzylation and the resultant 
alcohols were subsequently activated with methanesulfonyl chloride (MsCl). 
Consequently, we obtained stereochemically enriched tetracycles 2a, 3b, and 4c 
(scaffold I), containing a pyrimidinium moiety, in moderate yields.  
Next, we employed ring-closing metathesis (RCM) for the synthesis of scaffolds 
II and III via B-C pairing; in this case, a vinyl group was introduced at the C 
reactive site of the key substrate. Accordingly, 1d and 1e were subjected to N-
alkylation with benzyl bromide to afford iminium ions. Diastereoselective 
nucleophilic addition of allyl or homoallyl Grignard reagents to the resultant 
iminium ions generated intermediates B and C; RCM with Grubbs’ 2nd generation 
catalyst provided 5d, 6d, and 7e (scaffold II), fused with 6-, 7-, and 10-membered 
rings, with good to excellent diastereoselectivity. Notably, this diastereoselectivity 
without chiral auxiliaries or catalysts could be rationalized by the preferential  
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Figure 2-2. A-B and B-C paring pathways for synthesis of scaffolds I-III. Reagents and 
conditions: i) NaBH4, MeOH, 0 oC→r.t. then Boc2O, TEA, DCM, 0 oC→r.t.; ii) EtI, NaH, 
DMF, 0 oC→r.t.; iii) Pd(OH)2/C, H2, MeOH, then MsCl, TEA, DCM, 0 oC→r.t.; iv) BnBr, 
ACN, 80 oC, then RMgBr, THF, –78 oC→r.t.; v) Grubbs’ 2nd generation catalyst (20 mol%), 
toluene, reflux; vi) NaBH4, MeOH, 0 oC→r.t., then allyl bromide, TEA, DMF, 0 oC→r.t. 
TIPS, triisopropylsilyl; TEA, triethylamine; MsCl, methanesulfonyl chloride; BnBr, 
benzylbromide; ACN, acetonitrile. [a]Determined by LC-MS analysis of crude reaction 
mixture and by 1H NMR analysis of samples purified by short silica-gel column. [b]Yield of 
the isolated major diastereomer. [c]Determined by LC-MS analysis of crude reaction 
mixture.
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approach of Grignard reagents toward the less hindered re-face of the imine in 1d 
and 1e. The stereochemistry of each product was confirmed by nuclear Overhauser 
effect (NOE) spectroscopy. To generate scaffold III, 1e was treated with NaBH4. 
Allylation of the resulting secondary amine and subsequent RCM with Grubbs’ 2nd 
generation catalyst yielded 8e (scaffold III), fused with 10-membered rings, in 
44% overall yield.  
 
Pairing strategies for scaffolds IV-IX  
As shown in Fig. 2-3, the reactive site B did not participate in the pairing reactions 
for the synthesis of scaffolds IV-IX. Therefore, we synthesized 1f as a key 
substrate containing an N-benzyl-N-methyl amine moiety at the B position 
(Supplementary Fig. 2). For the preparation of scaffolds IV and V, the imine 
moiety of 1f was the major synthetic functionality. Unlike in other pairing 
pathways, the imine moiety acts as both a nucleophile and electrophile concurrently, 
and thus, other cyclic structures could be introduced at the C position. First, we 
employed the rhodium-catalyzed oxygenative [2+2] cycloaddition of the alkyne 
and imine to generate a -lactam ring.29 The imine moiety of 1f reacted with 
rhodium-complexed ketene species generated by the catalytic oxidation of the 
metal vinylidene complex to form zwitterionic intermediate D, which could be 
subjected to a conrotatory electrocyclic ring-closure reaction. After reaction 
condition screening, trans isomers 9f and 10f (scaffold IV) were obtained in 61% 
and 46% yields, respectively, with good to excellent diastereoselectivity. We 
performed NOE analysis and gradient-selected COSY experiment to confirm the 
relative stereochemistry of 9f and 10f. To construct another ring system, 1f was 
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reacted with N-benzyl-2-chloroacetamide to afford the iminium ion; intramolecular 
nucleophilic attack of the amide on the iminium ion provided imidazolidinone-
containing 11f (scaffold IV) as a diastereomeric mixture (d.r = 6:1) in 61% overall 
yield. Moreover, without the incorporation of an additional ring structure, we 
obtained stereochemically enriched and highly functionalized pyrimidodiazepine 
12f (major, scaffold IV) and 12f'(minor, scaffold IV) in 70% and 8.3% yields, 
respectively, via the reaction of 1f with benzyl bromide, followed by re-face 
selective nucleophilic addition of an ethynyl Grignard reagent on the iminium ion. 
To generate scaffold V, 1f was subjected to N-alkylation with methyl iodide, 
followed by nucleophilic addition of vinylmagnesium bromide to the resultant 
iminium ion afforded SI-7 (Supplementary Fig. 4). Oxidation of SI-7 with 3-
chloroperbenzoic acid (m-CPBA) and conversion of 7-membered ring into 10-
membered ring via in situ [2,3]-sigmatropic ring expansion of the resultant N-oxide 
provided 13f (scaffold V) with excellent (E)-selectivity (Supplementary Fig. 4).30 
For the synthesis of scaffolds VI-VIII, the C-D pairing pathways were 
investigated. Deprotection of the triisopropylsilyl (TIPS) group from 1f provided 
an alcohol product, that was readily converted to the desired bridged oxazolidines 
14f, 15f, and 16f (scaffold VI) in good to excellent yields upon treatment with 
various N-modifying agents such as Boc anhydride (Boc2O), benzyl isocyanate, 
and 3-nitrobenzene sulfonyl chloride (m-NsCl) through iminium formation and 
subsequent intramolecular nucleophilic addition of the hydroxyl moiety.31 The 
structure of bridged oxazolidine 16f was confirmed by X-ray crystallographic 
analysis (Supplementary Fig. 5, CCDC number 1500586). To generate scaffold VII, 
1f was subjected to N-alkylation with methyl iodide, followed by nucleophilic 
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Figure 2-3. C, C-D and D-E paring pathways for synthesis of scaffolds IV-VII. Reagents 
and conditions: i) Rh(PPh3)3Cl (10 mol%), 4-picoline N-oxide, 4-ethynylanisole or 
phenylacetylene, ACN, -wave, 90 oC, 35 min; ii) N-benzyl-2-chloroacetamide, NaBr, 
DMF, -wave, 110 oC, 30 min, then DBU, DMF; iii) BnBr, ACN, 80 oC, then 
ethynylmagnesium bromide, THF, ‒78 oC→r.t.; iv) MeI, ACN, 40 oC, then vinylmagnesium 
bromide, THF, ‒78 oC→r.t.; v) m-CPBA, DCM, then 3-chlorobenzoic acid; vi) 
HF/pyridine/THF, then electrophiles (Boc2O, benzyl isocyanate or m-NsCl), DCM; vii) MeI, 
ACN, 40 oC, then benzylmagnesium bromide, THF, ‒78 oC →r.t.; viii) TBAF, THF; ix) 
Tf2O, toluene, ‒40 oC, then NaN3, ‒78 oC→r.t.; x) NaBH4, MeOH, 0 oC →r.t., then 
chloromethanesulfonyl chloride or chloroacetic anhydride, TEA, DCM, 0 oC→r.t.; xi) 
TBAF, THF, then Cs2CO3, DMF, 90 oC; xii) NaBH4, MeOH, 0 oC→r.t., then Boc2O, TEA, 
DCM, 0 oC →r.t.; xiii) BnBr, 3,5-dimethylbenzyl bromide or Allyl bromide, NaH, DMF, 0 
oC→r.t.; xiv) TBAF, THF, then TFA, DCM; xv) PS-PPh3, DEAD, THF; xvi) TBAF, THF, 
then NaH, THF, 0 oC→r.t.; xvii) TBAF, THF, then Dess-Martin periodinane, DCM; xviii) 
Ph3P+CH3Br–, MeLi, THF, 0 oC→r.t.; xix) Grubbs’ 2nd generation catalyst (20 mol%), 
toluene, reflux. DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; m-CPBA, 3-chloroper-benzoic 
acid; m-NsCl, 3-nitrobenzenesulfonyl chloride; TBAF, tetra-n-butylammonium fluoride; 
Tf2O, trifluoromethanesulfonic anhydride; PS-PPh3, polystyrene triphenylphosphine; 
DEAD, diethyl azodicarboxylate. [a]Yield of isolated major diastereomer. [b]Determined by 
LC-MS analysis of crude reaction mixture. [c]Yield of the mixture of diastereomers. 
[d]Determined by 1H NMR spectroscopy. [e]Yield of isolated diastereomer. [f]Determined 
from purified yield of each diastereomer. [g]Determined by LC-MS analysis of crude 
reaction mixture after treatment of 3-chlorobenzoic acid.  
 
 
addition of benzylmagnesium bromide to the resultant iminium ion and subsequent 
removal of the TIPS group afforded SI-8 (Supplementary Fig. 6). Then, the 
hydroxyl moiety of SI-8 was activated with trifluoromethanesulfonic anhydride to 
provide an aziridium intermediate and the subsequent nucleophilic ring expansion 
with azide anion afforded 17f (scaffold VII) containing an eight-membered 
diazocane ring. In fact, benzodiazocine is known as an important pharmacophore, 
but the synthesis of diazocane has not been extensively studied due to the 
unfavorable transannular strain in medium-sized rings.32 The stereochemistry of 
17f was confirmed by nuclear Overhauser effect (NOE) spectroscopy. For the 
preparation of scaffold VIII, 1f was treated with NaBH4 to afford a secondary 
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amine, which underwent sulfonamide or amide formation upon treatment with 
chloromethane sulfonyl chloride or chloroacetic anhydride. The subsequent 
removal of the TIPS group and intramolecular nucleophilic attack of the resultant 
alcohols with electrophiles afforded 18f or 19f (scaffold VIII), fused with 6-
membered sultam or lactam rings. Furthermore, to generate 20f and 21f (scaffold 
VIII) containing an aziridine ring, 1f was treated with NaBH4, and the resulting 
secondary amine was protected with Boc and aniline was N-alkylated to provide 
intermediates F (R5 = Benzyl or 3,5-dimethylbenzyl). The removal of the TIPS and 
Boc group of intermediate F, followed by subsequent cyclization, produced 20f or 
21f (scaffold VIII) in 51% and 53% overall yields, respectively. Finally, 
oxazolidinone-containing 22f (scaffold VIII) was obtained through the TIPS 
deprotection of intermediate F (R5 = allyl) and subsequent cyclization. For the 
synthesis of scaffold IX via D-E pairing, the removal of the TIPS group of 
intermediate F (R5 = allyl) followed by Dess-Martin periodinane oxidation 
provided an aldehyde. The resulting unstable aldehyde was immediately subjected 
to Wittig olefination, followed by RCM with Grubbs’ 2nd generation catalyst to 
afford 23f (scaffold IX) containing bridgehead [4,3,1] ring systems.  
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Cheminformatics analysis  
Through this pDOS strategy, we synthesized 16 distinct pyrimidodiazepine- or 
pyrimidine-containing polyheterocycles with high 3D complexity, skeletal diversity, 
and biological relevancy (Fig. 2-4a). Notably, unique architectures of bioactive 
natural products such as medium-sized rings33 (E, F, I, and K), bridge-head 
bicyclic structures34 (J and P), and -lactam rings35,36 (G), were successfully 
incorporated into the pyrimidine-containing core skeletons. When we overlaid the 
energy-minimized conformers of each scaffold in 3D space by aligning the 
pyrimidine substructure, we clearly demonstrated the skeletal diversity and 
structural complexity of the resulting polyheterocycles (Fig. 2-4b). To 
quantitatively analyze the molecular diversity of this pDOS pathway, we performed 
principal moment of inertia (PMI) analysis to compare the degree of shape 
diversity of the representative polyheterocycles (Supplementary Fig. 8) of this 
study with the collection of 15 FDA-approved drugs containing pyrimidine 
moiety37 (Supplementary Fig. 9) and 71 bioactive natural products.38 The reference 
set of drugs containing pyrimidine moiety were narrowly dispersed in the region of 
rod-and disc-like shapes. On the other hand, our compounds were widely dispersed 
in the PMI plot, similar to natural products, and possessed more spherical 
characteristics than the FDA-approved drug set, which indicates the excellent 
shape diversity of newly synthesized core skeletons in this study (Fig. 2-4C, 
Supplementary Fig. 7). 
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Figure 2-4. Chemoinformatic analysis for structural diversity and 3D complexity of pDOS 
library. a) Core skeletons of 16 natural product-like pyrimidodiazepine- or pyrimidine-
containing polyheterocycles. b) Overlay of energy-minimized conformers of 16 core 
skeletons aligned by the pyrimidine substructure. c) Principal moment of inertia (PMI) plot. 
The 3D molecular shape of pDOS library (red squares) was quantitatively compared with 
that of 15 FDA-approved drugs embedded with pyrimidine moiety (blue squares) and 71 
bioactive natural products (grey dots).
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Biological evaluation 
Diversification of the 3D molecular shapes of drug-like core skeletons may lead to 
various interactions with diverse biopolymers and allow for the identification of 
specific modulators of challenging targets such as PPIs and protein-nucleic acid 
interactions. To investigate this possibility, we have attempted to identify novel 
chemical inhibitors of the LRS-RagD interaction28 for the modulation of mTORC1-
a dominant effector that regulates cellular growth, proliferation, and autophagy.39 
Upon activation of mTORC1 by multiple upstream inputs such as growth factors, 
energy status, and amino acids, particularly the branched-chain amino acid leucine 
(Leu), mTORC1 plays a crucial role in triggering eukaryotic cell growth and 
proliferation through stimulating protein biosynthesis and other anabolic processes 
while suppressing a catabolic process, namely autophagy.40 Consequently, the 
dysregulation of mTORC1 activation could lead to malfunction in central 
biological pathways that could lead to cancer cell growth, survival, and 
proliferation.41 
LRS catalyzes the conjugation of Leu to its cognate tRNA to form an aminoacyl-
tRNA, which serves as a precursor for protein synthesis.42 In addition to its 
canonical role in protein biosynthesis, a recent study suggested a noncanonical role 
of LRS in amino acid-dependent mTORC1 activation by sensing intracellular Leu 
concentration.28 According to this study, LRS can mediate Leu signaling to 
mTORC1 via direct binding to RagD-GTP protein and form a LRS-RagD protein 
complex in a Leu-dependent manner, which leads to the translocation of mTORC1 
to the lysosome membrane and subsequent activation of mTORC1 (Fig. 2-5a). 
Thus, LRS-RagD interactions could serve as a Leu sensing mechanism in the 
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Figure 2-5. Discovery of chemical modulator for LRS-RagD interaction. a) Noncanonical 
role of LRS. Leucine-loaded LRS binds to RagD, which promotes the translocation of 
mTORC1 to lysosomal surface and subsequent activation. b) Dose-response curves in 
ELISA of 20f and 21f. The results represent the mean of three biological replicates; error 
bars represent the s.e.m. c) Effects of 20f and 21f on mTORC1 signaling pathway. 
HEK293T cells were treated with 20 μM of 20f and 21f for 3 h. As a negative control, cells 
were deprived of leucine for 3 h. Level of phospho-T389 S6K1 were quantified against a 
DMSO control. The bar graph represents the mean of five biological replicates; error bars 
represent the s.e.m. d) Sensorgrams of surface plasmon resonance (SPR) spectroscopy of 
21f showed its concentration-dependent binding to purified LRS. The concentration plotted 
are 1, 2.5, 5, 10, 12.5, 15, 17.5 and 20 M, in order of increasing 21f. The curve fittings are 
shown in black. The sensorgrams represent the mean of two biological replicates. 
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amino acid-dependent activation of mTORC1.28,41 Given that the LRS-RagD 
interaction and structures of human LRS and RagD have not yet been fully 
characterized, the discovery of novel small-molecule PPI inhibitors of LRS and 
RagD could shed light on the molecular mechanism of mTORC1 activation in an 
amino acid-dependent manner. In addition, they could serve as lead compounds for 
the development of potential therapeutic agents with new modes of action to treat 
human diseases linked to the oncogenic activation of mTORC1.39,41 
To identify novel small-molecule PPI modulators of the LRS-RagD interaction, 
our pDOS library was subjected to ELISA-based HTS using purified human LRS 
and GST (glutathione-S-transferase)-tagged RagD (Fig. 2-5b and Supplementary 
Fig. 10), where the antibody-based signal was lowered upon treatment with LRS-
RagD interaction inhibitors. This is screening exercise led to the identification of 
aziridine-containing 20f and 21f as dose-dependent inhibitors of the LRS-RagD 
interaction. Based on this initial data, we hypothesized that 20f and 21f might 
inhibit the LRS-mediated Leu signaling to mTORC1 via direct disruption of the 
LRS-RagD interaction. As shown in Fig. 2-5c, the level of phosphorylated p70 
ribosomal protein S6 kinase 1 (S6K1),43 a typical mTORC1 kinase substrate, was 
decreased in the absence of Leu. Similarly, 20f and 21f suppressed the 
phosphorylation of S6K1 even in the presence of Leu. Based on the reduction of 
LRS-RagD interaction by ELISA (20f 15.5%; 21f 30.2%) and the suppression of 
phosphorylated S6K1 by western blotting (20f 16.4%; 21f 48.9%), we selected 21f 
as the candidate compound and subjected it to further analysis. The subsequent 
biophysical study using SPR revealed the binding affinity patterns of 21f and other 
pyrimidodiazepine-containing scaffolds (14f and 19f) toward purified LRS. We 
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clearly observed the 1:1 binding event in the SPR sensorgrams of 21f with KD 
value of 4.8 (± 0.46) M and the saturation event at the high dosage (Fig. 2-5d and 
Supplementary Fig. 11), whereas 14f and 19f showed no dose-dependent responses 
without any specific binding events (Supplementary Fig. 11), which supported that 
21f specifically binds LRS and disrupts the interaction between LRS and RagD. 
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2.3 Conclusion 
In this study, we developed a new pDOS strategy using pyrimidodiazepine as a 
privileged substructure. Highly functionalized substrate 1 allowed for the 
preparation of 16 distinct pyrimidodiazepine- or pyrimidine-containing 
polyheterocycles through different pairing reactions of 5 unique reactive sites (A-
E) within an average of 2.2 steps. The newly synthesized natural product-like core 
skeletons with high sp3 carbon fractions exhibited much higher skeletal diversity 
than existing pyrimidine-based drugs, as demonstrated by PMI analysis. 
Considering privileged substructures as chemical “navigators” to efficiently access 
unexploited regions of bioactive chemical space, the pDOS synthetic pathway 
using pyrimidodiazepine provides unique collections of polyheterocyclic 
compounds with biological relevancy. Therefore, this pDOS library could play a 
pivotal role in the perturbation of a wide range of challenging biological targets in 
a selective and specific manner. To demonstrate this, we performed ELISA-based 
HTS with this pDOS library and identified 21f, a new small-molecule PPI inhibitor 
of the LRS-RagD interaction, which mediates Leu sensing in the mTORC1 
signaling pathway. Through a series of biological experiments including western 
blotting, biophysical study using SPR, we confirmed that 21f could selectively 
inhibit mTORC1 activity, even in the presence of Leu by disrupting the LRS-RagD 
interaction. Therefore, this PPI inhibitor could be a powerful tool to specifically 
delineate unrevealed amino acid-dependent biological processes of mTORC1. 
Furthermore, it could act as a lead structure in the development of novel 
therapeutic agents to treat diseases linked to the oncogenic activation of mTORC1, 
thus highlighting the great potential of the pDOS strategy to address unmet 
therapeutic challenges.
 
 26 
2.4 References 
[01] Dandapani, S.; Marcaurelle, L. A. Nat. Chem. Biol. 2010, 6, 861. 
[02] Swinney, D. C.; Anthony, J. Nat. Rev. Drug Discov. 2011, 10, 507. 
[03] O'Connor, C. J.; Laraia, L.; Spring, D. R. Chem. Soc. Rev. 2011, 40, 4332.  
[04] Schreiber, S. L. Science, 2000, 287, 1964. 
[05] Schreiber, S. L. Nature, 2009, 457, 153.  
[06] Galloway, W. R. J. D.; Isidro-Llobet, A.; Spring, D. R. Nat. Commun. 
2010, 1, 80.  
[07] Kopp, F.; Stratton, C. F.; Akella, L. B.; Tan, D. S. Nat. Chem. Biol. 2012, 
8, 358. 
[08] Beckmann, H. S. G.; Nie, F.; Hagerman, C. E.; Johansson, H.; Tan, Y. S.; 
Wilcke, D.; Spring, D. R. Nat. Chem. 2013, 5, 861. 
[09] Huigens III, R.; Morrison, K.; Hicklin, R.; Flood Jr, T.; Richter, M.; 
Hergenrother, P. Nat. Chem. 2013, 5, 195. 
[10] Mizoguchi, H.; Oikawa, H.; Oguri, H. Nat. Chem. 2014, 6, 57. 
[11] Zhang, J.; Wu, J.; Hong, B.; Ai, W.; Wang, X.; Li, H.; Lei, X. Nat. 
Commun. 2014, 5, 4614. 
[12] Rizzo, S.; Waldmann, H. Chem. Rev. 2014, 114, 4621. 
[13] Ibbeson, B. M.; Laraia, L.; Alza, E.; O' Connor, C. J.; Tan, Y. S.; Davies, 
H. M.; McKenzie, G.; Venkitaraman, A. R.; Spring, D. R. Nat. Commun. 
2014, 5, 3155. 
[14] Garcia-Castro, M.; Kremer, L.; Reinkemeier, C. D.; Unkelbach, C.; 
Strohmann, C.; Ziegler, S.; Ostermann, C.; Kumar, K. Nat. Commun. 
2015, 6, 6516. 
[15] Oh, S.; Park, S. B. Chem. Commun. 2011, 47, 12754. 
[16] Kim, H.; Tung, T. T.; Park, S. B. Org. Lett. 2013, 15, 5814. 
[17] Kim, J.; Kim, H.; Park, S. B. J. Am. Chem. Soc. 2014, 136, 14629. 
 
 27 
[18] Park, J.; Oh, S.; Park, S. B. Angew. Chem. Int. Ed. 2012, 51, 5447. 
[19] Lee, S.; Nam, Y.; Koo, J. Y.; Lim, D.; Park, J.; Ock, J.; Suk, K.; Park, S. 
B. Nat. Chem. Biol. 2014, 10, 1055. 
[20] Wakeling, A. E.; Guy, S. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; 
Barker, A. J.; Gibson, K. H. Cancer Res. 2002, 62, 5749. 
[21] Wunder, F. Mol. Pharmacol. 2005, 68, 1775. 
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2.5 Experimental Section 
2.5.1 Supplementary Figures 
 
Supplementary Figure 1. Synthetic procedure for the tert-butyl (S)-(1-((6-chloro-
5-formylpyrimidin-4-yl)amino)-3-((triisopropylsilyl)oxy)propan-2-yl)carbamate 
(SI-2)  
 
 
Supplementary Figure 2. General procedure for the preparation of 1a–c and 1e–f. 
 
 
Supplementary Figure 3. Synthetic procedure for the preparation of (S)-4-(prop-
1-en-2-yl)-7-(((triisopropylsilyl)oxy)methyl)-8,9-dihydro-7H-pyrimido[4,5-
e][1,4]diazepine (1d). 
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Supplementary Figure 4. Synthetic procedure for the preparation of 13f and 13f́.  
 
 
Supplementary Figure 5. X-ray structure of 16f. Deposition number in 
Cambridge Structural Database: CCDC1500586. 
 
 31 
 
 
 
Supplementary Figure 6. Synthetic procedure for the preparation of 17f and 17f́. 
 
 
 
 
Supplementary Figure 7. Principal moment of inertia (PMI) plot. 
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Supplementary Figure 8. Complete pDOS Library used in PMI analysis  
 
 
 
 
Supplementary Figure 9. FDA-approved drugs embedded with pyrimidine 
moieties.1 
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Supplementary Figure 10. Dose-response curves in ELISA with 14f, 15f, 18f, 19f, 
22f and 23f. 
 
 
Supplementary Figure 11. SPR curves showing concentration-dependent binding 
to purified LRS. Normalized RUs are plotted over a time course. a) SPR curves 
with 14f with 1, 5, 10, 12.5 and 15 μM concentrations. b) SPR curves with 19f with 
1, 2.5, 7.5, 10, 12.5 and 15 μM concentrations. c) SPR curves with 21f with 1, 2.5, 
5, 10, 12.5, 15, 17.5 and 20 μM concentrations.
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2.5.2. General Information of Synthetic Protocols  
NMR spectra were obtained on an Agilent 400-MR DD2 Magnetic Resonance 
System (400 MHz, Agilent, USA), JEOL JNM-LA400 with LFG [400 MHz, Jeol, 
Japan], Varian/Oxford As-500 [500 MHz, Varian Assoc., Palo Alto, USA] or 
Bruker Avance III HD 800 MHz NMR Spectrometer [800 MHz, Bruker, Germany]. 
Chemical shifts values were recorded as parts per million (δ), referenced to 
tetramethylsilane (TMS) as the internal standard or to the residual solvent peak 
(CDCl3, 1H: 7.26, 13C: 77.16, CD3OD, 1H: 3.31, 13C: 49.00, DMSO-d6, 1H: 2.50, 
13C: 39.52). Multiplicities were indicated as follows: s (singlet), d (doublet), t 
(triplet), q (quartet); m (multiplet); dd (doublet of doublet); dt (doublet of triplet); 
td (triplet of doublets); br s (broad singlet) and so on. Coupling constants were 
reported in hertz (Hz). IR spectra were measured on a Thermo Scientific NicoletTM 
6700 FT-IR spectrometer. Low resolution mass spectra were obtained on a 
Finnigan Surveyor MSQ Plus LC/MS [Thermo], LCQ LC/MS [Thermo] or 
Shimadzu LCMS-2020 using the electrospray ionization (ESI) method. High 
resolution mass spectra were analyzed at the Mass Spectrometry Laboratory of 
National Instrumentation Center for Environmental Management (NICEM) in 
Seoul on a LCQ LC/MS [Thermo] using the electrospray ionization (ESI) method 
or by Ultra High Resolution ESI Q-TOF mass spectrometer (Bruker). All 
commercially available reagents were used without further purification unless 
noted otherwise. Commercially available reagents were obtained from Sigma-
Aldrich, TCI, Acros, or Alfa Aesar. All solvents were obtained by passing them 
through activated alumina columns of solvent purification systems from Glass 
Contour. Analytical thin-layer chromatography (TLC) was performed using Merck 
Kiselgel 60 F254 plates, and the components were visualized by observation under 
UV light (254 and 365 nm) or by treating the plates with ninhydrin followed by 
thermal visualization. Flash column chromatography was performed on Merck 
Kieselgel 60 (230–400 mesh). Microwave reactions were performed using the 
CEM Discover Benchmate and microwave reaction conditions were as indicated in 
the Experimental Section. HPLC purification was performed on an Agilent 1260 
Infinity system with an YMC-Pack silica column (SL12S05-2520WTX, 250 
mm×20 mm, 5 μm). 
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2.5.3. Synthesis and Characterization of Substrates 
Synthetic procedure for the preparation of Benzyl tert-butyl (3-((triisopropyl-
silyl)oxy)propane-1,2-diyl)(S)-dicarbamate (SI-1).  
 
Lithium borohydride (LiBH4) (2.0 M solution in THF, 56.8 ml, 113.5 mmol) was 
slowly added to a stirring solution of methyl (S)-3-(((benzyloxy)carbonyl)amino)-
2-((tert-butoxycarbonyl) amino)propanoate3 (20.00 g, 56.76 mmol) in 
tetrahydrofuran (THF) (570.0 ml) at 0 oC. Then, the resulting mixture was left to 
stir and allowed to warm to r.t. After completion of the reaction as indicated by 
TLC, the reaction mixture was quenched with saturated NH4Cl(aq) and extracted 
twice with dichloromethane (DCM). The combined organic layer was dried over 
anhydrous Na2SO4(s) and filtered. The organic layer was condensed under reduced 
pressure, and the crude resultant was dissolved in dry DCM (570.0 ml) under argon 
atmosphere. To this solution were sequentially added triethylamine (Et3N) (15.83 
ml, 113.5 mmol) and triisopropylsilyl trifluoromethanesulfonate (TIPS-OTf) (22.88 
ml, 85.14 mmol) at 0 °C. The resulting mixture was left to stir and allowed to 
warm to r.t. After completion of the reaction as indicated by TLC, the resultant was 
quenched with saturated NH4Cl(aq) and extracted twice with DCM. The combined 
organic layer was dried over anhydrous Na2SO4(s) and filtered. The filtrate was 
condensed under reduced pressure, followed by silica-gel flash column 
chromatography to afford the desired product SI-1 (22.37 g, 82% yield) as a 
colorless oil (Supplementary Fig. 1). 
Rf = 0.4 (hexane/EtOAc 5:1); 1H NMR (400 MHz, CDCl3)  7.35–7.29 (m, 5H), 
5.32 (br s, 1H), 5.10 (s, 2H), 5.00 (br s, 1H), 3.77–3.73 (m, 3H), 3.47–3.39 (m, 2H), 
1.43 (s, 9H), 1.06 (m, 21H); 13C NMR (100 MHz, CDCl3) 157.0, 156.1, 136.7, 
128.6, 128.11, 128.07, 79.6, 66.8, 64.3, 51.8, 43.5, 28.4, 18.0, 11.9LRMS(ESI+): 
Calcd for C25H45N2O5Si+ [M+H]+ 481.31, found 481.11.  
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Synthetic procedure for the preparation of tert-butyl (S)-(1-((6-chloro-5-
formylpyrimidin-4-yl)amino)-3-((triisopropylsilyl)oxy)pro-pan-2-yl)carbamate 
(SI-2).  
 
To a solution of SI-1 (22.37 g, 46.54 mmol) in methanol (MeOH) (470.0 ml) was 
carefully added 10 wt. % Pd/C (11.19 g) and the mixture was vigorously stirred 
under H2 atmosphere (1 atm) at r.t. After completion of the reaction as indicated by 
TLC, the reaction mixture was filtered through Celite®  while washing with ethyl 
acetate. The filtrate was condensed under reduced pressure and the crude resultant 
was dissolved in chloroform (CHCl3, 470.0 ml). To this solution were sequentially 
added Et3N (9.737 ml, 69.81 mmol) and 4,6-dichloropyrimidine-5-carboxaldehyde 
(8.237 g, 46.54 mmol) at 0 oC and left to stir. After 30 min, the reaction mixture 
was quenched with saturated NH4Cl(aq). The resultant was extracted twice with 
CHCl3, dried over anhydrous Na2SO4(s), and filtered. The filtrate was condensed 
under reduced pressure and purified by silica-gel flash column chromatography to 
afford the desired product SI-2 (15.19 g, 67% yield) as a colorless oil 
(Supplementary Fig. 1).  
Rf = 0.5 (hexane/EtOAc 3:1); 1H NMR (400 MHz, CDCl3)  10.28 (s, 1H), 9.30 (t, 
J = 5.7 Hz, 1H), 8.34 (s, 1H), 4.99 (d, J = 8.6 Hz, 1H), 3.90–3.62 (m, 5H), 1.33 (s, 
9H), 1.06 (m, 21H); 13C NMR (100 MHz, CDCl3)  191.1, 165.3, 161.7, 160.7, 
155.6, 108.2, 79.5, 63.7, 51.4, 42.4, 28.3, 17.9, 11.9; LRMS (ESI+): Calcd for 
C22H40ClN4O4Si+ [M+H]+ 487.25, found 487.03. 
 
General procedure for the preparation of 1a–c and 1e–f. 
To a stirring solution of SI-2 (500 mg, 1.026 mmol) and K2CO3 (283.6 mg, 2.052 
mmol) in N,N-dimethylformamide (DMF) (10.0 ml) was added amine4,5 (1.539 
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mmol) and the resulting mixture was stirred at 40 oC. After completion of the 
reaction as indicated by TLC, the resultant was quenched with saturated NH4Cl(aq) 
and extracted twice with ethyl acetate. The combined organic layer was dried over 
anhydrous Na2SO4(s) and filtered. The organic solvent was evaporated under 
vacuum to afford a crude oil, which was purified by silica-gel flash column 
chromatography to afford SI-3. To obtain the cyclic imine product 1, SI-3 was first 
treated with 10% trifluoroacetic acid (TFA) in DCM (20.0 ml) at r.t. After the 
starting material was consumed as indicated by TLC, any excess TFA was 
removed by azeotropic evaporation with toluene under reduced pressure, and the 
crude resultant was dissolved in 1% acetic acid (AcOH) in CHCl3 (100.0 ml). The 
resulting mixture was stirred at 40 oC. After completion of the reaction as indicated 
by TLC, the resultant was quenched with saturated NaHCO3(aq) and extracted 
twice with CHCl3. The combined organic layer was dried over anhydrous 
Na2SO4(s) and filtered. The filtrate was condensed under reduced pressure, 
followed by silica-gel flash column chromatography to afford the desired product 1 
(Supplementary Fig. 2). 
 
(S)-4-((S)-2-((benzyloxy)methyl)pyrrolidin-1-yl)-7-(((tri-
isopropylsilyl)oxy)methyl)-8,9-dihydro-7H-pyrimido[4,5-
e][1,4]diazepine (1a). A pale yellow oil; Rf = 0.2 
(DCM/MeOH = 20:1); 403.1 mg, 75% overall yield; 1H 
NMR (400 MHz, CDCl3)  8.11 (s,1H), 7.98 (s, 1H), 7.29 
(m, 5H), 5.97 (br s, 1H), 4.74 (m, 1H), 4.54, 4.53 (ABq, JAB = 12.1 Hz, 2H), 4.18 
(dd, J = 9.8, 4.7 Hz, 1H), 3.90 (m, 1H), 3.80 (dd, J = 12.5, 5.5 Hz, 1H), 3.73 (m, 
2H), 3.67 (m, 1H), 3.60 (dd, J = 9.4, 5.9 Hz, 1H), 3.47 (m, 1H), 3.34 (dd, J = 11.3, 
7.0 Hz, 1H), 2.15 (m, 1H), 1.96 (m, 2H), 1.71 (m, 1H), 1.08 (m, 21H); 13C NMR 
(100 MHz, CDCl3)  164.5, 160.9, 159.1, 157.4, 138.6, 128.4, 127.6, 127.5, 93.1, 
73.3, 71.1, 65.1, 64.2, 58.0, 55.2, 47.8, 28.0, 26.1, 18.2, 12.0; HRMS(ESI+): Calcd 
for C29H46N5O2Si+ [M+H]+ 524.3415, found 524.3414, Δppm –0.19. 
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(S)-4-((R)-2-((benzyloxy)methyl)pyrrolidin-1-yl)-7-
(((triisopropylsilyl)oxy)methyl)-8,9-dihydro-7H-
pyrimido[4,5-e][1,4]diazepine (1b). A pale yellow oil; Rf 
= 0.2 (DCM/MeOH = 20:1); 408.4 mg, 76% overall yield; 
1H NMR (400 MHz, CDCl3)  8.14 (s, 1H), 7.96 (s, 1H), 
7.30 (m, 5H), 6.20 (br s, 1H), 4.74 (m, 1H), 4.53 (s, 2H), 4.19 (dd, J = 9.7, 3.1 Hz, 
1H), 4.02 (m, 1H), 3.84 (m, 1H), 3.74 (m, 2H), 3.63 (m, 2H), 3.46 (t, J = 9.7 Hz, 
1H), 3.14 (m, 1H), 2.14 (m, 1H), 1.99 (m, 2H), 1.74 (m, 1H), 1.09 (m, 21H); 13C 
NMR (100 MHz, CDCl3)  165.0, 164.2, 156.4, 154.0, 138.4, 128.2, 127.4, 127.4, 
92.0, 73.1, 70.8, 65.3, 65.0, 57.9, 55.2, 46.6, 27.8, 25.8, 18.0, 11.8; HRMS(ESI+): 
Calcd for C29H46N5O2Si+ [M+H]+ 524.3415, found 524.3415. 
(S)-4-((S)-2-(2-(benzyloxy)ethyl)pyrrolidin-1-yl)-7-
(((triisopropylsilyl)oxy)methyl)-8,9-dihydro-7H-
pyrimido[4,5-e][1,4]diazepine (1c). A colorless oil; Rf = 
0.35 (DCM/MeOH = 20:1); 419.4 mg, 76% overall yield; 1H 
NMR (400 MHz, CDCl3) 8.07 (s, 1H), 7.99 (s, 1H), 7.33 
(m, 4H), 7.29–7.26 (m, 1H), 6.17 (br s, 1H), 4.61 (m, 1H), 4.53, 4.26 (ABq, JAB = 
11.94 Hz, 2H), 4.18 (dd, J = 9.8, 4.3 Hz, 1H), 3.92 (m, 1H), 3.81–3.62 (m, 3H), 
3.60–3.56 (m, 2H), 3.45 (m, 1H), 3.33 (m, 1H), 2.33–2.25 (m, 1H), 2.19–2.13 (m, 
1H), 1.91–1.87 (m, 1H), 1.80–1.66 (m, 3H), 1.08 (m, 21H); 13C NMR (100 MHz, 
CDCl3) 164.8, 161.1, 159.0, 157.4, 138.6, 128.4, 127.8, 127.6, 93.2, 73.0, 67.7, 
65.1, 64.3, 56.9, 55.1, 47.6, 34.1, 31.0, 26.2, 18.1, 12.0; HRMS(ESI+): Calcd for 
C30H48N5O2Si+ [M+H]+ 538.3572, found 538.3571, Δppm –0.19. 
(S)-N-(but-3-en-1-yl)-N-(4-methoxyphenethyl)-7-
(((triisopropylsilyl)oxy)methyl)-8,9-dihydro-7H-
pyrimido[4,5-e][1,4]diazepin-4-amine (1e). A pale 
yellow oil; Rf  = 0.4 (DCM/MeOH = 20:1); 364.2 mg, 
66% overall yield; 1H NMR (400 MHz, CDCl3) 8.05 (s, 1H), 7.98 (d, J = 1.9 Hz, 
1H), 7.07 (d, J = 8.6 Hz, 2H), 6.80 (d, J = 8.6 Hz, 2H), 6.42 (m, 1H), 5.72 (dddd, J 
= 16.8, 10.1, 6.6, 6.6 Hz, 1H), 5.02 (m, 2H), 4.18 (dd, J = 9.7, 4.3 Hz, 1H), 3.84 (m, 
3H), 3.77 (s, 3H), 3.69 (m, 2H), 3.46 (m, 1H), 3.34 (m, 2H), 2.83 (t, J = 7.4 Hz, 
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2H), 2.33 (q, J = 7.0 Hz, 2H), 1.08 (m, 21H); 13C NMR (100 MHz, CDCl3)  167.2, 
161.9, 158.2, 157.8, 157.1, 135.2, 131.0, 129.7, 117.0, 114.0, 94.3, 65.2, 64.5, 55.3, 
53.5, 51.2, 47.6, 33.7, 32.6, 18.1, 12.0; HRMS(ESI+): Calcd for C30H48N5O2Si+ 
[M+H]+ 538.3572, found 538.3572. 
(S)-N-benzyl-N-methyl-7-
(((triisopropylsilyl)oxy)methyl-)8,9-dihydro-7H-
pyrimido[4,5-e][1,4]diazepin-4-amine (1f). A colorless 
oil; Rf = 0.35 (DCM/MeOH = 20:1); 349.1 mg, 75% overall 
yield; 1H NMR (400 MHz, CDCl3)  8.17 (d, J = 1.9 Hz, 
1H), 8.06 (s, 1H), 7.35–7.25 (m, 5H), 6.99 (br s, 1H), 4.81, 4.71 (ABq, JAB = 15.2 
Hz, 2H), 4.18 (dd, J = 9.8, 4.3 Hz, 1H), 3.89 (m, 2H), 3.66 (t, J = 10.0 Hz, 1H), 
3.32 (ddd, J = 13.0, 7.1, 2.5 Hz, 1H), 3.03 (s, 3H), 1.08 (m, 21H); 13C NMR (100 
MHz, CDCl3)  167.4, 162.4, 157.2, 157.1, 137.3, 128.7, 127.7, 127.4, 92.7, 65.1, 
64.5, 56.6, 47.3, 40.1, 18.0, 11.9; HRMS(ESI+): Calcd for C25H40N5OSi+ [M+H]+ 
454.2997, found 454.2996, Δppm –0.22. 
 
(S)-4-(prop-1-en-2-yl)-7-(((triisopropylsilyl)oxy)methyl)-8,9-dihydro-7H-
pyrimido[4,5-e][1,4]diazepine (1d). 
 
Palladium tetrakis(triphenylphosphine) Pd(PPh3)4 (119.0 mg, 0.103 mmol, 10 
mol%) was added to a vigorously stirring solution of SI-2 (500 mg, 1.026 mmol), 
isopropenylboronic acid pinacol ester (0.290 ml, 1.539 mmol), and Na2CO3 (380.6 
mg, 3.591 mmol.) in toluene–water solvent mixture (25.0 ml/25.0 ml) at r.t. The 
resulting mixture was stirred at 80 oC. After completion of the reaction as indicated 
by TLC, the reaction mixture was diluted with ethyl acetate, washed with brine, 
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dried over anhydrous Na2SO4(s), and filtered. The filtrate was condensed under 
reduced pressure and the residue was purified with silica-gel flash column 
chromatography to provide compound SI-4 (379.2 mg, 75% yield). To obtain the 
cyclic imine products 1d, SI-4 (379.2 mg, 0.770 mmol) was first treated with 10% 
TFA in DCM (100.0 ml). After the starting material was consumed as indicated by 
TLC, the resultant was quenched with saturated NaHCO3(aq) and extracted twice 
with DCM. The combined organic layer was dried over anhydrous Na2SO4(s) and 
filtered. The filtrate was condensed under reduced pressure and the crude resultant 
was dissolved in DCM (100.0 ml). To this solution was added Na2SO4(s) (2.915 g, 
20.52 mmol) and the resulting mixture was stirred at 40 oC. After completion of the 
reaction as indicated by TLC, the reaction mixture was filtered and concentrated in 
vacuo. The residue was purified with silica-gel flash column chromatography to 
afford the desired cyclic imine product 1d (234.4 mg, 81% yield, 61% overall 
yield) as a colorless oil (Supplementary Fig. 3).  
Rf = 0.2 (DCM/MeOH 20:1); 1H NMR (400 MHz, CDCl3)  8.47 (d, J = 2.3 Hz, 
1H), 8.43 (s, 1H), 7.37 (br d, J = 5.0 Hz, 1H), 5.54 (s, 1H), 5.10 (s, 1H), 4.27 (dd, J 
= 9.7, 4.7 Hz, 1H), 3.95 (dd, J = 13.0, 7.0 Hz, 1H), 3.81 (m, 1H), 3.69 (t, J = 10.1 
Hz, 1H), 3.19 (m, 1H), 2.17 (s, 3H), 1.08 (m, 21H); 13C NMR (100 MHz, CDCl3)  
172.2, 161.0, 158.0, 157.9, 142.2, 120.9, 107.3, 65.2, 64.8, 47.4, 22.3, 18.1, 11.9; 
HRMS(ESI+): Calcd for C20H35N4OSi+ [M+H]+ 375.2575, found 375.2574, Δppm 
–0.27. 
 
Synthetic procedure for the preparation of 2a  
 
Compound 2a. To a stirring solution of 1a (403.1 mg, 0.770 mmol) in MeOH (8.0 
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ml) was added sodium borohydride (NaBH4) (145.6 mg, 3.850 mmol) at 0 °C. The 
resulting mixture was left to stir and allowed to warm to r.t. After completion of 
the reaction as indicated by TLC, the resultant was quenched with saturated 
NaHCO3(aq) and extracted twice with DCM. The combined organic layer was 
dried over anhydrous Na2SO4(s) and filtered. The organic solvent was evaporated 
under reduced pressure, and the crude resultant was dissolved in DCM (8.0 ml). To 
this solution were sequentially added Et3N (0.215 ml, 1.540 mmol) and di-tert-
butyl dicarbonate (Boc2O) (218.5 mg, 1.001 mmol) at 0 °C. The resulting mixture 
was left to stir and allowed to warm to r.t. After completion of the reaction as 
indicated by TLC, the resultant was quenched with saturated NH4Cl(aq) and 
extracted twice with DCM. The combined organic layer was dried over anhydrous 
Na2SO4(s) and the filtrate was condensed under reduced pressure, followed by 
silica-gel flash column chromatography to afford SI-5 (260.3 mg, 54% yield). To a 
solution of SI-5 (260.3 mg, 0.416 mmol) in DMF (4.0 ml) under argon atmosphere 
was added NaH (60% dispersion in mineral oil, 33.28 mg, 0.832 mmol) at 0 oC and 
left to stir. After 30 min, ethyl iodide (0. 067 ml, 0.832 mmol) was slowly added 
and the mixture was allowed to slowly warm to r.t. After the starting material was 
consumed as indicated by TLC, the reaction mixture was quenched with saturated 
NH4Cl(aq). The resultant was extracted twice with ethyl acetate, dried with 
anhydrous Na2SO4(s), filtered, and concentrated in vacuo. The residue was purified 
by silica-gel flash column chromatography to obtain intermediate A (258.5 mg, 
95% yield). To a solution of intermediate A (258.3 mg, 0.395 mmol) in MeOH (4.0 
ml) was added 20 wt. % Pd(OH)2/C (25.9 mg) and then, the mixture was 
vigorously stirred under H2 atmosphere (1 atm) at r.t. After completion of the 
reaction as indicated by TLC, the reaction mixture was filtered through Celite®  
while washing with ethyl acetate. The filtrate was condensed under reduced 
pressure and the crude resultant was dissolved in DCM (4.0 ml). To this solution 
were sequentially added Et3N (0.165 ml, 1.185 mmol) and methanesulfonyl 
chloride (MsCl) (0.061 ml, 0.790 mmol) at 0 oC. The resulting mixture was 
allowed to slowly warm up to r.t. After completion of the reaction indicated by 
TLC, the reaction mixture was diluted with DCM and washed twice with 1N HCl. 
The resultant was dried with anhydrous Na2SO4(s), filtered, condensed under 
reduced pressure, and purified by silica-gel flash column chromatography to afford 
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the desired product 2a (280.6 mg, 61 % yield, 31% overall yield) as a white solid;  
Rf  = 0.1 (DCM/MeOH = 10:1); 1H NMR (400 MHz, DMSO-d6, 100 oC)  8.50 (s, 
1H), 4.64 (m, 2H), 4.48 (m, 2H), 4.33 (m, 2H), 4.13 (m, 1H), 3.82 (m, 2H), 3.76 (m, 
1H), 3.69 (m, 1H), 3.62 (dd, J = 15.1, 4.6 Hz, 1H), 3.57 (m, 1H), 3.42 (m, 1H), 
2.14 (m, 1H), 2.04 (m, 2H), 1.66 (m, 1H), 1.32 (br s, 9H), 1.17 (t, J = 7.1 Hz, 3H), 
1.08 (m, 21H); 13C NMR (100 MHz, DMSO-d6, 100 oC)  162.0, 155.8, 154.0, 
146.5, 79.3, 62.8, 62.4., 50.8, 50.2, 48.9, 45.1, 29.6, 27.4, 25.7, 17.2, 12.4, 11.0; IR 
(neat) νmax: 2940, 2866, 1698, 1638, 1523, 1174 cm–1; HRMS(ESI+): Calcd for 
C29H52N5O3Si+ [M]+ 546.3834, found 546.3831, Δppm –0.55; mp: 136–138 oC.  
Compound 3b. A pale yellow solid; Rf = 0.1 
(DCM/MeOH = 10:1); 38% overall yield; 1H NMR (400 
MHz, DMSO-d6, 100 oC)  8.42 (s, 1H), 4.88 (d, J = 16.9 
Hz, 1H), 4.58 (d, J = 16.9 Hz, 1H), 4.54 (dd, J = 10.8, 
9.4 Hz, 1H), 4.38 (m, 2H), 4.27 (dd, J = 10.9, 8.2 Hz, 
1H), 4.16 (dd, J = 15.1, 11.9 Hz, 1H), 3.86 (m, 2H), 3.80 (m, 2H), 3.70 (m, 2H), 
3.65 (m, 1H), 2.17 (m, 3H), 1.73 (m, 1H), 1.41 (s, 9H), 1.18 (t, J = 6.9 Hz, 3H), 
1.09 (m, 21H); 13C NMR (100 MHz, DMSO-d6, 100 oC)  162.3, 153.8, 152.8, 
146.5, 93.0, 79.8, 63.2, 62.5, 56.9, 50.6, 49.0, 48.0, 46.1, 36.7, 29.2, 27.5, 26.6, 
17.2, 12.3, 10.9; IR (neat) νmax: 2944, 2863, 1698, 1636, 1517, 1166 cm–1; 
HRMS(ESI+): Calcd for C29H52N5O3Si+ [M]+ 546.3834, found 546.3833, Δppm –
0.18; mp: 77–79 oC. The product was synthesized according to the synthetic 
procedure for the preparation of 2a from 1b. 
Compound 4c. A pale yellow solid; Rf = 0.2 
(DCM/MeOH = 10:1); 40 % overall yield; 1H NMR (400 
MHz, DMSO-d6, 100 oC)  8.34 (s, 1H), 4.48 (m, 2H), 
4.23 (m, 2H), 4.05 (m, 1H), 3.85 (m, 2H), 3.79 (m, 2H), 
3.71 (m, 3H), 3.61 (dd, J = 15.0, 4.6 Hz, 1H), 3.53 (m, 
1H), 3.06 (br s, 1H), 3.00 (m, 1H), 2.18 (m, 1H), 1.91 (m, 3H), 1.29 (br s, 9H), 
1.18 (t, J = 7.0 Hz,2 3H), 1.09 (m, 21H); 13C NMR (100 MHz, DMSO-d6, 100 oC) 
 161.5, 153.1, 149.2, 149.2, 71.7, 63.9, 56.3, 55.8, 49.7, 49.0, 46.8, 30.5, 28.4, 
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25.0, 23.6, 18.2, 13.7, 12.0; IR (neat) νmax: 2946, 2867, 1694, 1625, 1529, 1457, 
1116 cm–1; HRMS(ESI+): Calcd for C30H54N5O3Si+ [M]+ 560.3990, found 
560.3993, Δppm –0.54.; mp: 71–73 oC. The product was synthesized according to 
the synthetic procedure for the preparation of 2a from 1c. 
 
Synthetic procedure for the preparation of 5d   
Intermediate B (n=1). To a stirring solution of 1d (100 mg, 0.267 mmol) in 
acetonitrile (ACN) (13.5 ml), benzyl bromide (0.048 ml, 0.401 mmol) was added 
and the resulting mixture was stirred at 80 oC. After completion of the reaction 
indicated by TLC, the organic solvent was removed under reduced pressure and the 
crude resultant was washed with hexane to remove any excess benzyl bromide. To 
a cooled solution of resultant iminium ion in dry THF (27.0 ml) was added 
allylmagnesium bromide (1.0 M solution in diethyl ether, 1.335 ml, 1.335 mmol) 
dropwise over 30 min at –78 °C. The reaction mixture was allowed to slowly warm 
to r.t over an 18 h period. The resultant was quenched with saturated NH4Cl(aq) 
and extracted twice with DCM. The combined organic layer was dried over 
anhydrous Na2SO4(s) and filtered. The filtrate was condensed under reduced 
pressure, followed by flash column chromatography to afford intermediate B (n= 1, 
115.0 mg, 85% yield, d.r. >99:1) as a pale yellow oil.  
Rf = 0.5 (hexane/EtOAc = 1:1); 1H NMR (400 MHz, CDCl3) 8.40 (s, 1H), 7.32–
7.29 (m, 3H), 7.24–7.20 (m, 2H), 5.88–5.78 (m, 2H), 5.03 (m, 2H), 4.94 (s, 1H), 
4.69 (s, 1H), 4.29 (dd, J = 9.4, 5.9 Hz, 1H), 3.86 (d, J = 15.3 Hz, 1H), 3.78 (dd, J = 
9.6, 3.7 Hz, 1H), 3.64–3.57 (m, 3H), 3.50–3.40 (m, 2H), 2.84 (m, 1H), 2.22 (m, 
1H), 1.81 (s, 3H), 1.01 (s, 21H); 13C NMR (100 MHz, CDCl3)  168.4, 164.6, 
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155.6, 143.0, 140.1, 136.0, 128.4, 127.7, 126.9, 116.7, 116.3, 116.0, 64.4, 59.3, 
57.9, 53.0, 43.3, 37.1, 23.0, 18.1, 11.9; HRMS(ESI+): Calcd for C30H47N4OSi+ 
[M+H]+ 507.3514, found 507.3516, Δppm +0.39. The diastereomeric ratio was 
determined by LC-MS analysis of crude reaction mixture and by 1H NMR analysis 
of samples purified by short silica-gel column (Supplementary Fig. 7 and 34). 
Intermediate B (n=2). A yellow oil; Rf = 0.5 
(hexane/EtOAc = 1:1); 120.8 mg, 87% yield; d.r. >99:1; 1H 
NMR (400 MHz, CDCl3)  8.40 (s, 1H), 7.33–7.21 (m, 5H), 
5.78 (m, 1H), 5.55 (d, J = 5.1 Hz, 1H), 5.01 (dd, J = 17.2, 
1.2 Hz, 1H), 4.94 (m, 2H), 4.72 (s, 1H), 4.21 (dd, J = 10.2, 
5.1 Hz, 1H), 3.84 (m, 2H), 3.64–3.54 (m, 3H), 3.48–3.37 (m, 
2H), 2.33–2.17 (m, 2H), 2.11–2.04 (m, 1H), 1.83 (s, 3H), 1.45–1.36 (m, 1H), 1.06 
(m, 21H); 13C NMR (100 MHz, CDCl3)  168.5, 164.7, 155.6, 143.1, 140.2, 138.2, 
128.4, 127.8, 127.0, 117.7, 116.0, 114.9, 64.7, 59.2, 57.5, 52.6, 43.4, 31.7, 30.9, 
23.1, 18.1, 12.0; HRMS(ESI+): Calcd for C31H49N4OSi+ [M+H]+ 521.3670, found 
521.3670. The product was synthesized according to the synthetic procedure for 
the preparation of Intermediate B (n=1) from 1d and 3-butenylmagnesium 
bromide (0.2 M solution in THF). The diastereomeric ratio was determined by LC-
MS analysis of crude reaction mixture and by 1H NMR analysis of samples 
purified by short silica-gel column (Supplementary Fig. 8 and 35). 
Compound 5d. To a solution of intermediate B (115.0 mg, 0.227 mmol) in toluene 
(11.5 ml) was added 2nd generation Grubbs’ catalyst (38.20 mg, 0.045 mmol, 20 
mol%) and the mixture was left to stir at reflux. After the starting material was 
indicated as by TLC, the organic solvent was removed under reduced pressure, and 
the residue was purified by silica-gel flash column chromatography to obtain the 
desired product 5d (79.34 mg, 73 % yield, 62% overall yield) as a pale yellow oil. 
Rf = 0.4 (hexane/EtOAc = 2:1); 1H NMR (400 MHz, CDCl3)  8.43 (s, 1H), 7.34–
7.18 (m, 5H), 6.08 (br s, 1H), 5.87 (d, 6.3 Hz, 1H), 5.08 (t, J = 11.0 Hz, 1H), 4.16, 
3.99 (ABq, JAB = 14.9 Hz, 2H), 3.87 (t, J = 13.3 Hz, 1H), 3.54–3.41 (m, 3H), 3.17 
(m, 1H), 2.54 (d, J = 10.5 Hz, 2H), 2.03 (s, 3H), 0.97 (m, 21 H); 13C NMR (100 
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MHz, CDCl3)  164.2, 160.4, 156.4, 141.1, 132.6, 130.4, 128.3, 128.1, 126.7, 
110.9, 66.1, 61.8, 54.6, 50.5, 46.7, 29.5, 18.3, 17.9, 11.8; IR (neat) νmax: 3241, 3028, 
2940, 2865, 1565, 1460, 1116, 1066 cm–1; HRMS(ESI+): Calcd for C28H43N4OSi+ 
[M+H]+ 479.3201, found 479.3206, Δppm +1.04. The stereochemistry of this 
product was confirmed by Nuclear Overhauser Effect (NOE) spectroscopy. 1D-
NOE result supported the stereochemistry as shown in Supplementary Fig. 37.  
Compound 6d. A yellow oil; Rf = 0.4 (hexane/EtOAc = 
2:1); 87.95 mg, 72% yield, 63% overall yield; 1H NMR 
(400 MHz, CDCl3)  8.42 (s, 1H), 7.22–7.12 (m, 5H), 6.10 
(t, J = 6.7 Hz, 1H), 5.82 (d, J = 5.5 Hz, 1H), 3.84–3.76 (m, 
5H), 3.65 (dd, J = 11.7, 7.0 Hz, 1H), 3.49 (m, 1H), 2.89 (m, 
1H), 2.48 (m, 1H), 2.10 (m, 2H), 1.91 (s, 3H), 1.84 (m, 1H), 
1.26 (m, 21H); 13C NMR (100 MHz, CDCl3)  164.5, 164.1, 154.9, 140.0, 137.4, 
131.8, 128.1, 127.4, 126.7, 117.1, 62.3, 61.2, 57.6, 56.3, 43.0, 35.4, 23.6, 20.1, 17.9, 
11.8; IR (neat) νmax: 3241, 2944, 2865, 1570, 1462, 1102, 883 cm–1; HRMS(ESI+): 
Calcd for C29H45N4OSi+ [M+H]+ 493.3357, found 493.3349, Δppm +0.41. The 
product was synthesized according to the synthetic procedure for the preparation of 
5d from Intermediate B (n=2). The stereochemistry of this product was confirmed 
by NOE spectroscopy. 1D-NOE result supported the stereochemistry as shown in 
Supplementary Fig. 39.  
 
Synthetic procedure for the preparation of 7e 
Compound 7e. To a stirring solution of 1e (120 mg, 0.223 mmol) in acetonitrile 
(ACN) (11.0 ml), benzyl bromide (0.040 ml, 0.335 mmol) was added and the 
resulting mixture was stirred at 80 oC. After completion of the reaction indicated by 
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TLC, the organic solvent was removed under reduced pressure and the crude 
resultant was washed with hexane to remove any excess benzyl bromide. To a 
cooled solution of resultant iminium ion in dry THF (22.0 ml) was added 3-
butenylmagnesium bromide (0.2 M solution in THF, 5.575 ml, 1.115 mmol) 
dropwise over 30 min at –78 °C. The reaction mixture was allowed to slowly warm 
to r.t over an 18 h period. The resultant was quenched with saturated NH4Cl(aq) 
and extracted twice with DCM. The combined organic layer was dried over 
anhydrous Na2SO4(s) and filtered. The filtrate was condensed under reduced 
pressure, followed by flash column chromatography to afford intermediate C 
(122.0 mg, 80% yield, d.r. 95:5). The diastereomeric ratio was determined by LC-
MS analysis of crude reaction mixture (Supplementary Fig. 9). To a solution of 
intermediate C (122.0 mg, 0.178 mmol) in toluene (36.0 ml) was added 2nd 
generation Grubbs’ catalyst (30.22 mg, 0.036 mmol, 20 mol%) and the mixture 
was left to stir at reflux. After the starting material was indicated as by TLC, the 
organic solvent was removed under reduced pressure, and the residue was purified 
by silica-gel flash column chromatography to obtain the desired product 7e (85.24 
mg, 73 % yield, 58% overall yield) as a pale yellow oil.  
Rf = 0.2 (hexane/EtOAc = 3:1); 1H NMR (400 MHz, CDCl3)  8.15 (s, 1H), 7.15–
7.05 (m, 5H), 6.99 (d, J = 8.6 Hz, 2H), 6.80 (d, J = 8.2 Hz, 2H), 5.47 (m, 1H), 5.37 
(m, 2H), 4.30 (dd, J = 11.9, 2.2 Hz, 1H), 4.13 (m, 1H), 3.80 (s, 3H), 3.75 (m, 2H), 
3.72 (m, 1H), 3.39 (m, 4H), 3.11 (m, 1H), 2.80 (m, 1H), 2.59 (m, 3H), 2.33 (m, 1H), 
2.01 (m, 1H), 1.88 (m, 1H), 1.77 (m, 2H), 1.50 (m, 1H), 0.92 (m, 21H); 13C NMR 
(100 MHz, CDCl3)  167.4, 165.0, 158.0, 155.4, 140.2, 132.1, 131.6, 129.8, 128.8, 
128.3, 128.2, 126.8, 113.9, 106.1, 64.5, 60.9, 59.2, 59.1, 57.6, 55.3, 46.9, 43.8, 34.7, 
29.2, 26.3, 23.8, 18.0, 11.9; IR (neat) νmax: 3245, 3000, 2942, 2865, 1572, 1512, 
1247, 1113 cm–1; HRMS(ESI+): Calcd for C39H58N5O2Si+ [M+H]+ 656.4354, found 
656.4345, Δppm –1.37. The stereochemistry of 7e was confirmed by NOE 
spectroscopy. 1D-NOE result supported the stereochemistry as shown in 
Supplementary Fig. 41. 
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Synthetic procedure for the preparation of 8e  
Compound 8e. To a stirring solution of 1e (120 mg, 0.223 mmol) in MeOH (2.2 
ml) was added NaBH4 (42.18 mg, 1.115 mmol) at 0 °C and the resulting mixture 
was warmed to r.t. After the starting material was consumed as indicated by TLC, 
the resultant was quenched with saturated NaHCO3(aq) and extracted twice with 
DCM. The combined organic layer was dried over anhydrous Na2SO4(s) and 
filtered. The solvent was evaporated under vacuum, and then the crude resultant 
was dissolved in DMF (2.2 ml). To this solution were sequentially added Et3N 
(0.062 ml, 0.446 mmol) and allyl bromide (0.025 ml, 0.290 mmol) at 0 °C. The 
reaction was allowed to slowly warm to r.t. After completion of the reaction 
indicated by TLC, the resultant was quenched with saturated NH4Cl(aq) and 
extracted twice with ethyl acetate. The combined organic layer was dried over 
anhydrous Na2SO4(s) and filtered. The filtrate was condensed under reduced 
pressure, followed by silica-gel flash column chromatography to afford SI-6 (81.47 
mg, 63% yield). To a solution of SI-6 (81.47 mg, 0.140 mmol) in toluene (28.0 ml) 
was added second generation Grubbs’ catalyst (23.77 mg, 0.028 mmol, 20 mol%) 
and the mixture was left to stir at reflux. After completion of the reaction as 
indicated by TLC, solvent was removed under reduced pressure and the residue 
was purified by silica-gel flash column chromatography to obtain the desired 
product 8e (54.08 mg, 70% yield, 44% overall yield) as a yellow oil.  
Rf = 0.3 (DCM/MeOH = 20:1); 1H NMR (400 MHz, CDCl3)  8.35 (s, 1H), 7.02 (d, 
J = 8.6 Hz, 2H), 6.79 (d, J = 8.2 Hz, 2H), 5.74 (br d, J = 5.1 Hz, 1H), 5.67 (td, J = 
11.2, 4.5 Hz, 1H), 5.51 (td, J = 10.9, 4.5 Hz, 1H), 4.58 (d, J = 16.0 Hz, 1H), 4.06 
(ddd, J = 14.6, 10.9, 3.1 Hz, 1H), 3.97 (d, J = 16.0 Hz, 1H), 3.76 (s, 3H), 3.59 (dd, 
J =10.0, 4.1 Hz, 1H), 3.46 (m, 2H), 3.37 (m, 2H), 3.08 (m, 2H), 2.92 (m, 2H), 2.73 
(m, 1H), 2.54 (m, 1H), 2.39 (ddd, J = 13.4, 10.7, 5.7, 1H), 2.18 (m, 1H), 1.76 (br d, 
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J = 12.1 Hz, 1H), 1.07 (m, 21H); 13C NMR (100 MHz, CDCl3)  168.2, 165.8, 
157.9, 157.7, 134.3, 132.0, 129.5, 127.4, 113.7, 113.3, 69.4, 64.7, 58.1, 55.3, 52.0, 
50.5, 43.9, 40.5, 33.8, 25.9, 18.0, 11.9; IR (neat) νmax: 3239, 3006, 2945, 2866, 
1574, 1512, 1265 cm–1; HRMS(ESI+): Calcd for C31H50N5O2Si+ [M+H]+ 552.3728, 
found 552.3722, Δppm –1.09. 
 
General procedure for the preparation of 9f and 10f  
To a microwave vessel tightly sealed with a cap, were added 1f (90.00 mg, 0.198 
mmol), alkyne (0.5 mmol), 4-picoline N-oxide (54.57mg, 0.5 mmol) and 
Rh(PPh3)3Cl (18.50 mg, 0.020 mmol, 10 mol%) in ACN (3.0 ml). The resulting 
mixture was heated under microwave irradiation (100 watt) at 90 °C for 35 min. 
The reaction mixture was diluted with DCM, washed with brine, dried over 
anhydrous Na2SO4(s), filtered, and concentrated in vacuo. The residue was purified 
by silica-gel flash column chromatography to obtain the desired β-lactam product.  
Compound 9f. A pale yellow oil; Rf = 0.3 (DCM/MeOH = 
20:1); 72.69 mg, 61% yield; d.r. >99:1; 1H NMR (400 MHz, 
CDCl3)  8.10 (s, 1H), 7.25 (m, 3H), 7.11 (d, J = 8.2 Hz, 
4H), 6.83 (d, J = 8.2 Hz, 2H), 6.30 (dd, J = 6.5, 4.5 Hz, 1H), 
5.06 (s, 1H), 4.43, 4.31 (ABq, JAB = 14.9 Hz, 2H), 4.21 (dd, 
J =10.2, 3.5 Hz, 1H), 4.12 (m, 1H), 3.87 (m, 2H). 3.81 (s, 
3H), 3.56 (s, 1H), 3.43 (ddd, J = 14.2, 7.3, 4.3 Hz, 1H), 
2.44 (s, 3H), 1.09 (m, 21H); 13C NMR (100 MHz, CDCl3)  168.0, 165.3, 163.0, 
159.2, 155.0, 137.5, 129.0, 128.5, 128.4, 127.3, 127.1, 114.1, 96.9, 65.2, 63.5, 59.5, 
55.3, 55.2, 54.2, 42.9, 38.1, 18.0, 11.8; IR (neat) νmax: 3250, 3056, 2942, 2865, 
1751, 1567, 1119 cm–1; HRMS(ESI+): Calcd for C34H48N5O3Si+ [M+H]+ 602.3521, 
found 602.3528, Δppm +1.16. The diastereomeric ratio was determined by LC-MS 
analysis of crude reaction mixture (Supplementary Fig. 10). The stereochemistry of 
this product was confirmed by NOE spectroscopy. 1D-NOE result supported the 
stereochemistry as shown in Supplementary Fig. 44. 
 
 49 
Compound 10f. A yellow solid; Rf = 0.3 (DCM/MeOH = 
20:1); 54.35 mg, 48% yield; d.r. 90:10; 1H NMR (400 MHz, 
CDCl3) 8.12 (s, 1H), 7.70–7.65 (m, 1H), 7.53 (m, 1H), 
7.46 (m, 1H), 7.30 (m, 2H), 7.23 (m, 3H), 7.09 (m, 2H), 6.35 
(dd, J = 6.7, 4.7 Hz, 1H), 5.11 (d, J = 1.2 Hz, 1H), 4.39 (m, 
1H), 4.23 (m, 2H), 4.13 (m, 1H), 3.87 (m, 2H), 3.60 (d, J = 
1.5 Hz, 1H), 3.43 (ddd, J = 14.4, 7.3, 4.5 Hz, 1H), 2.42 (s, 3H), 1.10 (m, 21H); 13C 
NMR (100 MHz, CDCl3)  167.6, 165.4, 163.0, 155.0, 137.4, 135.0, 132.1, 132.0, 
128.7, 128.4, 127.8, 127.2, 96.9, 65.9, 63.5, 59.4, 55.2, 54.3, 42.8, 37.9, 18.0, 11.8; 
IR (neat) νmax: 3239, 3059, 3030, 2942, 2866, 1755, 1567, 1108 cm–1; 
HRMS(ESI+): Calcd for C33H46N5O2Si+ [M+H]+ 572.3415, found 572.3413, Δppm 
–0.35; mp: 86–88 oC. The diastereomeric ratio was determined by LC-MS analysis 
of crude reaction mixture (Supplementary Fig. 11). The stereochemistry of this 
product was confirmed by NOE spectroscopy. 1D-NOE result supported the 
stereochemistry as shown Supplementary Fig. 46. 
 
Synthetic procedure for the preparation of 11f  
 
Compound 11f. To a microwave vessel tightly sealed with a cap, were added 1f 
(90mg, 0.198 mmol), N-benzyl-2-chloroacetamide (54.54 mg, 0.297 mmol) and 
NaBr (30.56 mg, 0.297 mmol) in DMF (3.0 ml). The resulting mixture was heated 
under microwave irradiation (150 watt) at 110 °C for 30 min. The reaction mixture 
was cooled to r.t. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.059 ml, 0.396 
mmol) was added and left to stir at r.t. After completion of the reaction as indicated 
by TLC, the reaction mixture was diluted with ethyl acetate, washed with saturated 
NaHCO3(aq), dried over anhydrous Na2SO4(s), filtered, and concentrated in vacuo. 
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The residue was purified by HPLC to obtain desired product 11f (72.57 mg, 61%, 
d.r. 6:1) as a pale yellow oil. The diastereomeric ratio was determined by 1H NMR 
spectroscopy (Supplementary Fig. 47). 
Rf = 0.3 (hexane/EtOAc = 1:1); 1H NMR (400 MHz, CDCl3)  8.17 (s, 0.83H, 
major diastereomer), 8.12 (s, 0.13H, minor diastereomer), 7.28 (br s, 3H), 7.19 (br 
s, 3H), 6.89 (br s, 2H), 6.73 (br s, 2H), 6.11 (br s, 0.12H, minor diastereomer), 5.90 
(s, 0.78H, major diastereomer), 5.28 (s, 0.84H, major diastereomer), 5.08 (s, 
0.13H, minor diastereomer), 4.98 (m, 1H), 4.44, 4.34 (ABq, JAB = 16.2 Hz, 2H), 
3.78 (m, 2H), 3.66–3.37 (m, 4H), 3.24 (m, 2H), 2.73 (m, 3H), 1.05–0.95 (m, 21H); 
13C NMR (100 MHz, CDCl3)  173.3, 167.1, 162.9, 157.3, 137.4, 136.0, 128.6, 
128.5, 127.8, 127.1, 126.9, 126.7, 88.1, 77.3, 65.0, 59.6, 57.8, 52.0, 44.1, 42.9, 37.9, 
18.03, 18.02, 11.9; IR (neat) νmax: 3290, 3030, 2943, 2865, 1694, 1629, 1571, 1118 
cm–1; HRMS(ESI+): Calcd for C34H49N6O2Si+ [M+H]+ 601.3681, found 601.3693, 
Δppm +2.00. 
 
Synthetic procedure for the preparation of 12f and 12f́  
To a stirring solution of 1f (180.0 mg, 0.397 mmol) in ACN (20 ml), benzyl 
bromide (0.071 ml, 0.596 mmol) was added and the resulting mixture was stirred at 
80 oC. After the starting material was consumed as indicated by TLC, the organic 
solvent was removed under reduced pressure to afford the crude iminium ion. After 
washing with hexane to remove any excess benzyl bromide, ethynylmagnesium 
bromide (0.5 M solution in THF, 3.970 ml, 1.985 mmol) was added dropwise to a 
cooled solution of resultant iminium ion in dry THF (40 ml) over 30 min at –78 °C. 
The reaction was allowed to slowly warm to r.t over an 18 h period. The mixture 
was quenched with saturated NH4Cl(aq) and extracted twice with DCM. The 
combined organic layer was dried over anhydrous Na2SO4(s) and the filtrate was 
condensed under reduced pressure, followed by silica-gel flash column 
chromatography to afford 12f (major) and 12f́(minor). 
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Compound 12f (major). A pale yellow oil; Rf = 0.4 
(hexane/EtOAc = 3:1); 158.4 mg, 70% yield; 1H NMR 
(400 MHz, CDCl3) 8.16 (s, 1H), 7.33–7.24 (m, 5H), 
7.17–7.14 (m, 3H), 6.79–6.78 (m, 2H), 6.27 (m, 1H), 
4.74 (d, J = 2.3 Hz, 1H), 4.64 (d, J = 14.9 Hz, 1H), 4.31, 
4.26 (ABq, JAB = 15.1 Hz, 2H), 3.92–3.85 (m, 2H), 3.78 
(d, J = 14.5 Hz, 1H), 3.73 (dd, J = 10.0, 3.3 Hz, 1H), 3.54 (ddd, J = 14.4, 7.6, 1.4 
Hz 1H), 2.93 (m, 1H), 2.60 (s, 3H), 2.53 (d, J = 2.3 Hz, 1H), 1.10–1.00 (m, 21H); 
13C NMR (100 MHz, CDCl3)  167.4, 164.2, 155.8, 138.9, 138.3, 128.5, 128.4, 
128.3, 127.6, 127.4, 126.7, 102.0, 83.9, 74.9, 65.3, 62.0, 58.5, 58.2, 48.5, 40.2, 39.6, 
18.1, 12.0; IR (neat) νmax: 3241, 2943, 2865, 1573, 1404, 1101, 669 cm–1; 
HRMS(ESI+) Calcd for C34H48N5OSi+ [M+H]+ 570.3623, found 570.3614, Δppm –
1.58. The stereochemistry of this product was confirmed by NOE spectroscopy. 
1D-NOE result supported the stereochemistry as shown in Supplementary Fig. 49. 
Compound 12f́(minor). A pale yellow oil; Rf = 0.25 
(hexane/EtOAc = 3:1); 18.78 mg, 8.3% yield; 1H NMR 
(400 MHz, CDCl3) 8.21 (s, 1H), 7.33–7.31 (m, 3H), 
7.21–7.17 (m, 5H), 6.84 (m, 2H), 6.34 (m, 1H), 4.79 (m, 
1H), 4.71 (d, J = 2.3 Hz, 1H), 4.54, 4.20 (ABq, JAB = 
15.5 Hz, 2H), 4.07 (t, J = 10.2 Hz, 1 H), 3.84, 3.71 (ABq, JAB = 13.7 Hz, 2H), 3.64 
(dd, J = 9.8, 5.1 Hz, 1H), 3.57 (ddd, J = 15.0, 7.7, 4.7 Hz 1H), 3.37 (m, 1H), 2.68 
(s, 3H), 2.50 (d, J = 2.7 Hz, 1H), 1.04 (br s, 21H); 13C NMR (100 MHz, CDCl3)  
168.7, 164.4, 156.1, 139.0, 138.2, 129.0, 128.5, 128.4, 127.6, 127.3, 126.8, 99.9, 
87.5, 74.8, 68.3, 64.7, 60.7, 58.5, 46.7, 44.0, 38.9, 18.1, 12.0; IR (neat) νmax: 3239, 
2940, 2865, 1571, 1404, 1102, 698 cm–1; HRMS(ESI+): Calcd for C34H48N5OSi+ 
[M+H]+ 570.3623, found 570.3625, Δppm +0.35. The stereochemistry of this 
product was confirmed by NOE spectroscopy. 1D-NOE result supported the 
stereochemistry as shown in Supplementary Fig. 51. 
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Synthetic procedure for the preparation of 13f and 13f́.  
Compound SI-7 
To a stirring solution of 1f (90 mg, 0.198 mmol) in ACN (10.0 ml), iodomethane 
(0.018 ml, 0.297 mmol) was added and the resulting mixture was stirred at 40 oC. 
After the starting material was consumed as indicated by TLC, the organic solvent 
and any excess iodomethane were removed under reduced pressure to afford the 
crude iminium ion. To a cooled solution of resultant iminium ion in dry THF (20.0 
ml) was added vinylmagnesium bromide (1.0 M solution in THF, 0.990 ml, 0.990 
mmol) dropwise over 30 min at –78 °C. The reaction was allowed to slowly warm 
to r.t over an 18 h period. The mixture was quenched with saturated NH4Cl(aq) and 
extracted twice with DCM. The combined organic layer was dried over anhydrous 
Na2SO4(s) and the filtrate was condensed under reduced pressure, followed by 
silica-gel flash column chromatography to afford SI-7 (70.68 mg, 72% yield, d.r. 
9:1) as a yellow oil  (Supplementary Fig. 4). The diastereomeric ratio was 
determined by 1H NMR spectroscopy (Supplementary Fig. 52). 
Rf = 0.27 (DCM/MeOH = 20:1); 1H NMR (400 MHz, CDCl3)  8.22 (s, 0.08 H, 
minor diastereomer), 8.17 (s, 0.71H, major diastereomer), 7.36–7.24 (m, 6H, 
major diastereomer+minor diastereomer), 6.25 (m, 1H), 5.64 (br s, 0.12H, minor 
diastereomer), 5.29 (br s, 0.97H, major diastereomer), 5.20 (d, J = 10.2 Hz, 1H), 
4.88 (d, J = 17.2 Hz, 1H), 4.56–4.45 (m, 3H), 3.84–3.77 (m, 2H), 3.55 (t, J = 9.4 
Hz, 1.11H, major diastereomer), 3.43 (t, J = 9.8 Hz, 0.15 H, minor diastereomer), 
3.19 (m, 1H), 2.86–2.81 (m, 4H), 2.74 (s, 0.38H, minor diastereomer), 2.42 (s, 
0.38H, minor diastereomer), 2.27 (s, 3H, major diastereomer), 1.10–1.02 (m, 25H, 
major diastereomer+minor diastereomer); 13C NMR (100 MHz, CDCl3)  167.6, 
165.5, 155.4, 138.7, 136.5, 128.6, 127.3, 127.1, 118.2, 102.9, 64.9, 63.6, 62.8, 58.3, 
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44.2, 41.4, 39.4, 18.1, 12.0; HRMS(ESI+): Calcd for C28H46N5OSi+ [M+H]+ 
496.3466, found 496.3465, Δppm –0.20.  
 
Compound 13f  
 
To a solution of SI-7 (70.68 mg, 0.143 mmol) in DCM (14.3 ml) was added 3-
chloroperbenzoic acid (m-CPBA, 32.08 mg, 0.186 mmol) and the mixture was left 
to stir at reflux. After 1h, solvent was removed under reduced pressure and the 
residue was purified by silica-gel flash column chromatography to obtain the 
desired product 13f (42.45 mg, 58% yield, 42% overall yield) as a colorless oil 
(Supplementary Fig. 4). 
Rf = 0.3 (hexane/EtOAc = 3:1); 1H NMR (500 MHz, CDCl3)  8.11 (s, 1H), 7.32 
(m, 2H), 7.24 (m, 1H), 7.20 (m, 2H), 6.63 (d, J = 16.1 Hz, 1H), 6.09 (m, 1H), 4.82 
(br s, 3H), 4.09 (m, 3H), 3.71 (m, 2H), 3.45–3.27 (m, 1H), 3.04 (s, 3H), 2.77 (m , 
1H), 2.63–2.55 (m, 3H), 1.08 (m, 21H); ); IR (neat) νmax: 3395, 3254, 3060, 3028, 
2926, 1946, 1713, 1567, 1493, 1452, 1266, 1105 cm–1; HRMS(ESI+): Calcd for 
C28H46N5O2Si+ [M+H]+ 512.3415, found 512.3417, Δ ppm +0.39. The 1H NMR 
spectrum of 13f was too broad to analyze. As shown below, the structure of 13f 
was fully confirmed only after treatment of 3-chlorobenzoic acid as a salt product, 
13f́, when broad peak of 13f converted to sharp and well-resolved NMR signals.    
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Compound 13f́ 
 
To a solution of SI-7 (70.68 mg, 0.143 mmol) in DCM (14.3 ml) was added 3-
chloroperbenzoic acid (m-CPBA, 32.08 mg, 0.186 mmol) and the mixture was left 
to stir at reflux. After 1 h, 3-chlorobenzoic acid (22.39mg, 0.143 mmol) was added 
and left to stir at r.t. After completion of the reaction as indicated by TLC, solvent 
was removed under reduced pressure and the residue was purified by silica-gel 
flash column chromatography to obtain the desired product 13f́(70.72mg, 74% 
yield, 53% overall yield) as a pale yellow oil (Supplementary Fig. 4). The E/Z ratio 
(99:1) was determined by LC-MS analysis of the crude reaction mixtures 
(Supplementary Fig. 12). 
Rf = 0.3 (hexane/EtOAc 1:1); 1H NMR (500 MHz, CDCl3) 8.19 (s, 1H), 7.95 (s, 
1H, 3-chlorobenzoic acid-H), 7.85 (d, J = 7.8 Hz, 1H, 3-chlorobenzoic acid-H), 
7.54 (d, J = 8.3 Hz, 1H, 3-chlorobenzoic acid-H), 7.37 (t, J = 7.8 Hz, 1H, 3-
chlorobenzoic acid-H), 7.29–7.26 (m, 2H), 7.22–7.19 (m, 3H), 6.49 (d, J = 16.6 Hz, 
1H), 5.96 (dt, J = 16.6, 5.9 Hz, 1H), 5.51 (t, J = 6.4 Hz, 1H), 4.74 (m, 2H), 4.66, 
4.62 (ABq, JAB = 15.0 Hz, 2H), 3.96 (m, 2H), 3.70 (dd, J = 9.8, 8.3 Hz, 1H), 3.55 
(dt, J = 14.3, 5.6 Hz, 1H), 2.90 (s, 3H), 2.76 (m, 1H), 2.67 (s, 3H), 1.06 (m, 21H), 
13C NMR (100 MHz, CDCl3) 165.1, 162.8, 161.2, 155.4, 138.4, 134.7, 133.3, 
131.7, 129.84, 129.75, 128.9, 128.6, 127.8, 127.79, 127.2, 127.1, 96.3, 70.2, 65.6, 
61.0, 56.0, 45.2, 40.5, 39.1, 18.1, 11.9; IR (neat) νmax: 3396, 3062, 3026, 2945, 
2863, 1724, 1572, 1253, 1117 cm–1; HRMS(ESI+): Calcd for C35H51ClN5O4Si+ 
[M+H]+ 668.3393, found 668.3387, Δppm –0.90. 
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Synthetic procedure for the preparation of 14f 
Compound 14f. 1f (90.00 mg, 0.198 mmol) was treated with HF/pyridine/THF 
(5/5/90) solution (2 ml) and then, the mixture was stirred at r.t. After the starting 
material was consumed as indicated by TLC, ethoxytrimethylsilane (2 ml) was 
added and allowed to react for 1 h to quench any excess HF (HF/pyridine protocol). 
The reaction mixture was condensed in vacuo to afford the crude product. To a 
solution of crude product in DCM (4 ml) was added Boc2O (56.09 mg, 0.257 
mmol) and then, the mixture was stirred at r.t. After completion of the reaction as 
indicated by TLC, solvent was removed under reduced pressure and the residue 
was purified through the recrystallization in hexane to obtain desired product 14f 
(68.47 mg, 87% overall yield) as a white solid. 
Rf = 0.3 (EA); 1H NMR (400 MHz, CDCl3) 8.13 (s, 1H), 7.35–7.24 (m, 5H), 6.62 
(s, 1H), 5.63 (br s, 1H), 4.76 (m, 2H), 4.55 (d, J = 15.3 Hz, 1H), 4.01 (d, J = 7.0 Hz, 
1H), 3.87 (t, J = 6.7 Hz, 1 H), 3.55 (br d, J = 13.6 Hz, 1H), 3.48–3.43 (m, 1H), 2.98 
(s, 3H), 1.43 (s, 9H); 13C NMR (100 MHz, CDCl3) 166.7, 164.0, 155.8, 153.0, 
138.3, 128.6, 127.9, 127.2, 103.0, 85.2, 81.6, 68.5, 57.5, 53.7, 48.0, 40.7, 28.4; IR 
(neat) νmax: 3248, 2975, 2931, 1700, 1571, 1403, 1162, 1048, 699 cm–1; 
HRMS(ESI+): Calcd for C21H28N5O3+ [M+H]+ 398.2187, found 398.2174, Δppm –
3.26; mp: 50–52 oC. 
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 Compound 15f. A white solid; Rf = 0.4 (EA); 77.57 
mg, 91% yield;  1H NMR (500 MHz, CDCl3) 8.18 (s, 
1H), 7.29–7.28 (m, 2H), 7.25–7.24 (m, 4H), 7.19–7.18 
(m, 2H), 7.14 (d, J = 6.4 Hz, 2H), 6.57 (s, 1H), 5.55 (br 
s, 1H), 4.86 (t, J = 5.4 Hz, 1 H), 4.74 (m, 1H), 4.46 (br d, 
J = 1.5 Hz, 2H), 4.32 (d, J = 5.4 Hz, 2H), 4.02 (dd, J = 
7.3, 1.0 Hz, 1H), 3.91 (m, 1H), 3.55 (m, 1H), 3.38 (dt, J = 13.2, 4.2 Hz, 1H), 2.83 
(s, 3H); 13C NMR (100 MHz, CDCl3) 166.8, 164.1, 156.0, 154.9, 138.8, 137.8, 
128.7, 128.6, 127.7, 127.5, 127.4, 127.3, 104.3, 84.0, 68.7, 58.2, 53.7, 48.0, 44.7, 
40.3; IR (neat) νmax: 3258, 2971, 1633, 1542, 1405, 1049, 698 cm–1; HRMS(ESI+): 
Calcd for C24H27N6O2+ [M+H]+ 431.2190, found 431.2184, Δppm –1.39; mp: 67–
69 oC. The product was synthesized according to the synthetic procedure for the 
preparation of 14f from 1f and benzyl isocyanate (1.3 equiv.). 
Compound 16f. A white solid; Rf = 0.3 (EA); 59.2 mg, 
62% yield; 1H NMR (400 MHz, DMSO-d6)  8.54–8.53 
(m, 2H), 8.02 (s, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.83 (t, J = 
8.2 Hz, 1H), 7.39 (m, 2H), 7.26 (m, 4H), 6.63 (s, 1H), 
4.84 (br s, 1H), 4.65, 4.54 (ABq, JAB = 15.6 Hz, 2H), 3.61 
(d, J = 7.4 Hz, 1H), 3.51–3.45 (m, 1H), 3.28 (d, J = 14.1 
Hz, 1H), 2.88 (m, 4H); 13C NMR (400 MHz, DMSO-d6)  165.6, 163.2, 155.8, 
148.0, 138.9, 138.1, 133.3, 131.7, 128.5, 127.4, 127.1, 122.4, 122.3, 101.4, 87.3, 
66.7, 57.4, 55.8, 54.9, 47.8, 40.0; IR (neat) νmax: 2920, 1573, 1535, 1354, 1176, 734 
cm–1; HRMS(ESI+): Calcd for C22H23N6O5S+ [M+H]+ 483.1445, found 483.1450, 
Δppm +1.03; mp: 101–103 oC. The product was synthesized according to the 
synthetic procedure for the preparation of 14f from 1f and 3-nitrobenzene sulfonyl 
chloride (m-NsCl) (1.3 equiv.). Purified by silica-gel flash column chromatography 
to afford 16f. The structure of 16f was confirmed by X-ray crystallographic 
analysis (Supplementary Fig. 5, Supplementary Table 1–5, CCDC number 
1500586).  
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Synthetic procedure for the preparation of 17f́. 
Compound SI-8.  
 
To a stirring solution of 1f (180 mg, 0.397 mmol) in ACN (20.0 ml), iodomethane 
(0.036 ml, 0.594 mmol) was added and the resulting mixture was stirred at 40 oC. 
After the starting material was consumed as indicated by TLC, the organic solvent 
and any excess iodomethane were removed under reduced pressure to afford the 
crude iminium ion. To a cooled solution of resultant iminium ion in dry THF (40.0 
ml) was added benzylmagnesium bromide (2.0 M solution in THF, 0.99 ml, 1.98 
mmol) dropwise over 30 min at –78 °C. The reaction was allowed to slowly warm 
to r.t over an 18 h period. The mixture was quenched with saturated NH4Cl(aq) and 
extracted twice with DCM. The combined organic layer was dried over anhydrous 
Na2SO4(s) and the filtrate was condensed under reduced pressure, followed by 
filtration through a short pad of silica gel with hexane/EtOAc (1:1) to afford crude 
product. To a solution of crude product in THF (4 ml) was added TBAF (1.0 M 
solution in THF, 0.516 ml, 0.516 mmol). The reaction mixture was then left to stir 
at r.t. After completion of the reaction as indicated by TLC, the solvent was 
removed under reduced pressure and the residue was purified through the silica-gel 
flash column chromatography to obtain product SI-8 (121.8 mg, 76% yield) as a 
white solid (Supplementary Fig. 6). 
Rf = 0.4 (DCM/MeOH = 10:1); 1H NMR (400 MHz, CDCl3) 8.13 (s, 1H), 7.32–
7.25 (m, 3H), 7.20–7.13 (m, 3H), 6.99 (d, J = 7.2 Hz, 2H), 6.73 (d, J = 6.7 Hz, 2H), 
5.40 (d, J = 5.9 Hz, 1H), 4.35, 4.28 (ABq, JAB = 16.0, 15.6 Hz, 2H), 4.19 (dd, J = 
9.6, 4.5 Hz, 1H), 3.60 (dd, J = 10.6, 5.1 Hz, 1H), 3.46 (dd, J = 10.8, 5.7 Hz, 1H), 
3.31–3.04 (m, 4H), 2.88 (dd, J = 12.9, 4.3 Hz, 1H), 2.62 (s, 3H), 2.51 (br s, 1H), 
2.32 (s, 3H); 13C NMR (100 MHz, CDCl3) 168.4, 166.1, 154.9, 139.3, 138.1, 
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129.0, 128.6, 128.1, 127.4, 127.1, 126.2, 103.3, 65.0, 61.7, 58.5, 58.0, 46.2, 38.7, 
38.6, 34.5; HRMS (ESI+): Calcd for C24H30N5O+ [M+H]+ 404.2445, found 
404.2446, Δppm +0.25; mp: 70–72 oC. 
 
Compound 17f and 17f́. To a stirring solution of SI-8 (121.8 mg, 0.302 mmol) in 
toluene (3.0 ml) under argon atmosphere were sequentially added Et3N (0.126 ml, 
0.906 mmol) and trifluoromethanesulfonic anhydride (Tf2O) (0.112 ml, 0.664 
mmol) at –40 °C and left to stir. After 1 h, the temperature of the reaction mixture 
was brought down to –78 °C and NaN3 (58.9 mg, 0.906 mmol) was added. The 
reaction was allowed to slowly warm to r.t over an 18 h period. The resultant was 
quenched with saturated NaHCO3(aq) and extracted twice with DCM. The 
combined organic layer was dried over anhydrous Na2SO4(s) and the filtrate was 
condensed under reduced pressure, followed by silica-gel flash column 
chromatography to afford the 17f (Path A, eight-membered ring) and 17f́(Path B, 
seven-membered ring) as shown in Supplementary Fig. 6.  
 
Compound 17f (Path A, eight-membered ring, 
Supplementary Fig. 6). A white solid; Rf = 0.6 
(hexane/EtOAc = 3:1); 37.2 mg, 22% yield, 17% overall 
yield; 1H NMR (800 MHz, CDCl3) 8.29 (s, 1H), 7.32 (m, 
2H), 7.28 (m, 1H), 7.17 (m, 2H), 7.13 (m, 1H), 7.00 (d, J = 
7.3 Hz, 2H), 6.74 (d, J = 7.3 Hz, 2H), 4.33, 4.27 (ABq, JAB 
= 15.7 Hz, 2H), 4.23 (dd, J = 14.9, 6.6 Hz, 1H), 3.99 (dd, J = 10.3, 3.9 Hz, 1H), 
3.96 (dd, J = 15.7, 1.5 Hz, 1H), 3.89 (m, 1H), 3.38 (dd, J = 14.9, 10.5 Hz, 1H), 
3.07 (m, 1H), 2.98 (dd, J = 12.5, 3.7 Hz, 1H), 2.84 (br dd, J = 16.0, 1.6 Hz, 1H), 
2.66 (s, 3H), 2.59 (s, 3H); 13C NMR (100 MHz, CDCl3)  169.2, 160.3, 154.0, 
138.1, 136.7, 129.1, 128.8, 128.3, 127.64, 127.57, 126.5, 120.7 (q, 1JC,F = 324.4 
Hz), 115.0, 66.0, 59.9, 57.4, 56.0, 52.1, 49.1, 38.8, 37.5; IR (neat) νmax: 3028, 2929, 
2868, 2108, 1566, 1393 cm–1; HRMS(ESI+) Calcd for C25H28F3N8O2S+ [M+H]+ 
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561.2003, found 561.2009, Δppm +1.07; mp: 103–105 oC. The stereochemistry of 
this product was confirmed by NOE spectroscopy. 1D-NOE result supported the 
stereochemistry as shown in Supplementary Fig. 60. 
 
Compound 17f́(Path B, seven-membered ring, 
Supplementary Fig. 6). A white solid; Rf = 0.5 
(hexane/EtOAc = 3:1); 55.9 mg, 33% yield, 25% overall 
yield; 1H NMR (500 MHz, CDCl3) 8.32 (s, 1H), 7.34 (m, 
2H), 7.29 (m, 1H), 7.14 (m, 3H), 6.96 (d, J = 7.3 Hz, 2H), 
6.73 (br d, J = 7.3 Hz, 2H), 4.56, 4.49 (ABq, JAB = 16.5 Hz, 
2H), 4.23 (d, J = 15.2 Hz, 1 H), 3.91 (dd, J = 11.2, 2.9 Hz, 1H), 3.67 (dd, J = 13.7, 
4.4 Hz, 1H), 3.50 (dd, J = 14.9, 10.5 Hz, 1H), 3.32 (m, 1H), 3.19 (dd, J = 13.7, 2.4 
Hz, 1H), 3.10 (t, J = 11.8 Hz, 1H), 2.96 (dd, J = 13.0, 3.2 Hz, 1H), 2.78 (s, 3H), 
2.31 (s, 3H);13C NMR (100 MHz, CDCl3) 168.1, 159.7, 154.7, 138.3, 137.2, 
129.1, 128.8, 128.3, 127.5, 127.0, 126.5, 120.1 (q, 1JC,F = 322.6 Hz), 110.1, 66.6, 
59.6, 57.4, 56.3, 51.5, 42.1, 38.0, 31.5; IR (neat) νmax: 3030, 2930, 2869, 2105, 
1578, 1529, 1391, 1212, 1043 cm–1; HRMS(ESI+) Calcd for C25H28F3N8O2S+ 
[M+H]+ 561.2003, found 561.2011, Δppm +1.43; mp: 140–142 oC. The 
stereochemistry of this product was confirmed by NOE spectroscopy. 1D-NOE 
result supported the stereochemistry as shown in Supplementary Fig. 62.  
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Synthetic procedure for the preparation of 18f 
 
Compound 18f. To a stirring solution of 1f (90mg, 0.198 mmol) in MeOH (2 ml) 
was added NaBH4 (36.88 mg, 0.975 mmol) at 0 °C. The resulting mixture was left 
to stir and allowed to warm to r.t. After the starting material was consumed as 
indicated by TLC, the resultant was quenched with saturated NaHCO3(aq) and 
extracted twice with DCM. The combined organic layer was dried over anhydrous 
Na2SO4(s) and filtered. The solvent was evaporated under reduced pressure, and 
the resulting crude secondary amine was dissolved in DMF (2 ml). To this solution 
were sequentially added Et3N (0.055 ml, 0.396 mmol) and chloromethane sulfonyl 
chloride (0.023 ml, 0.257 mmol) at 0 °C. The resulting mixture was left to stir and 
allowed to warm to r.t. After completion of the reaction as indicated by TLC, the 
resultant was quenched with saturated NH4Cl(aq) and extracted twice with DCM. 
The combined organic layer was dried over anhydrous Na2SO4(s) and the filtrate 
was condensed under reduced pressure, followed by silica-gel flash column 
chromatography to afford SI-9 (97.89 mg, 87% yield). To a solution of SI-9 (97.89 
mg, 0.172 mmol) in THF (2 ml) was added TBAF (1.0 M solution in THF, 0.224 ml, 
0.224 mmol). The reaction mixture was then left to stir at r.t. After completion of 
the reaction as indicated by TLC, the solvent was removed under reduced pressure. 
To a solution of the crude resultant in DMF (2 ml) was added Cs2CO3 (168.1 mg, 
0.516 mmol). Then the resulting mixture was stirred at 90 oC. After completion of 
the reaction as indicated by TLC, the reaction mixture was diluted with ethyl 
acetate, washed with brine, dried over anhydrous Na2SO4(s), filtered, and 
concentrated in vacuo. The residue was purified with silica-gel flash column 
chromatography to obtain desired product 18f (51.02 mg, 79% yield, 69% overall 
yield) as a white solid.  
Rf = 0.4 (DCM/MeOH = 20:1); 1H NMR (400 MHz, DMSO-d6)  7.98 (s, 1H), 
7.34–7.23 (m, 6H), 4.84 (d, J = 11.7 Hz, 1H), 4.71–4.59 (m, 3H), 4.47 (d, J = 15.3 
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Hz, 1H), 4.33 (d, J = 15.7 Hz, 1H), 4.19 (br s, 1H), 3.89 (d, J = 10.4 Hz, 1H), 3.80 
(t, J = 11.2 Hz, 1H), 3.54 (br s, 1H), 3.38 (br s, 1H), 2.81 (s, 3H); 13C NMR (100 
MHz, DMSO-d6)  165.0, 163.2, 153.5, 138.1, 128.4, 127.5, 127.0, 95.6, 62.0, 55.4, 
40.2, 39.4; IR (neat) νmax: 3230, 2926, 1574, 1409, 1155, 736 cm–1; HRMS(ESI+): 
Calcd for C17H22N5O3S+ [M+H]+ 376.1438, found 376.1437, Δppm –0.27; mp: 
196–198 oC. 
Compound 19f. A colorless oil; Rf  = 0.5 (DCM/MeOH = 
20:1); 50.40 mg, 75% overall yield; 1H NMR (400 MHz, 
CDCl3)  8.02 (s, 1H), 7.39–7.33 (m, 4H), 7.27–7.23 (m, 
1H), 6.97 (m, 1H), 5.23 (d, J = 15.7 Hz, 1H), 4.78, 4.41 
(ABq, JAB = 15.7 Hz, 2H), 4.21, 4.12 (ABq, JAB = 16.4 Hz, 
2H), 4.09–4.01 (m, 2H), 3.97–3.87 (m, 2H), 3.78 (t, J = 
11.0 Hz, 1H), 3.00 (dd, J = 15.3, 7.4 Hz, 1H), 2.89 (s, 3H); 13C NMR (100 MHz, 
CDCl3)  166.7, 166.5, 164.3, 154.7, 137.8, 128.5, 127.5, 127.1, 95.4, 67.7, 66.5, 
57.5, 56.2, 42.2, 40.7, 39.1; IR (neat) νmax: 3237, 2908, 1653, 1573, 1408, 1119, 
737 cm–1; HRMS(ESI+): Calcd for C18H22N5O2+ [M+H]+ 340.1768, found 
340.1765, Δppm –0.88. The product was synthesized according to the synthetic 
procedure for the preparation of 18f from 1e and chloroacetic anhydride. 
 
Synthetic procedure for the preparation of 20f  
 
Compound 20f. To a stirring solution of 1f (135.0 mg, 0.298 mmol) in MeOH (3.0 
ml) was added NaBH4 (56.37 mg, 1.490 mmol) at 0 °C. Then the resulting mixture 
was left to stir and allowed to warm to r.t. After the starting material was consumed 
as indicated by TLC, the resultant was quenched with saturated NaHCO3(aq) and 
extracted twice with DCM. The combined organic layer was dried over anhydrous 
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Na2SO4(s) and filtered. The solvent was evaporated under reduced pressure, and 
the resulting crude secondary amine was dissolved in DCM (3.0 ml). To this 
solution were sequentially added Et3N (0.083 ml, 0.596 mmol) and Boc2O (84.55 
mg, 0.387 mmol) at 0 °C. The resulting mixture was left to stir and allowed to 
warm to r.t. After completion of the reaction as indicated by TLC, the resultant was 
quenched with saturated NH4Cl(aq) and extracted twice with DCM. The combined 
organic layer was dried over anhydrous Na2SO4(s) and the filtrate was condensed 
under reduced pressure, followed by silica-gel flash column chromatography to 
afford the Boc-protected product (162.3 mg, 98% yield). To a solution of Boc-
protected product (162.3 mg, 0.292 mmol) in DMF (3.0 ml) under argon 
atmosphere was added NaH (60% dispersion in mineral oil, 23.36 mg, 0.584 
mmol) at 0 oC and left to stir. After 30 min, benzylbromide (0.052 ml, 0.438 mmol) 
was slowly added. The resulting mixture was left to stir and allowed to warm to r.t. 
After completion of the reaction as indicated by TLC, the reaction mixture was 
quenched with saturated NH4Cl(aq). The resultant was extracted twice with ethyl 
acetate, dried with anhydrous Na2SO4(s), filtered, and concentrated in vacuo. The 
residue was purified by silica-gel flash column chromatography to obtain the 
intermediate F (R5 = benzyl, 164.1 mg, 87% yield). Intermediate F (164.1 mg, 
0.254 mmol) was first treated with 10% trifluoroacetic acid (TFA) in DCM (12.5 
ml) at r.t. After the starting material was consumed as indicated by TLC, any 
excess TFA was removed by azeotropic evaporation with toluene under reduced 
pressure. To a solution of the resulting Boc-deprotected product in THF (2.5 ml) 
was added TBAF (1.0 M solution in THF, 0.330 ml, 0.330 mmol) and the mixture 
was stirred at r.t. After completion of the reaction as indicated by TLC, the reaction 
mixture was quenched with saturated NaHCO3(aq). The resultant was extracted 
twice with DCM, dried with anhydrous Na2SO4(s), filtered, and concentrated in 
vacuo, followed by silica-gel flash column chromatography to afford SI-10 (73.21 
mg, 74% yield). To a SI-10 (73.21 mg, 0.188 mmol) in THF (20.0 ml) under argon 
atmosphere was added polymer-bound triphenylphosphine (587.5 mg, 0.94 mmol), 
purchased from Sigma-Aldrich (100-200 mesh, 1.6 mmol/g), and the mixture was 
stirred at r.t. After 30 min, diehtyl azodicarboxylate (DEAD, 0.058 ml, 0.376 
mmol) was slowly added. The mixture was stirred at r.t for 18h. The reaction 
mixture was filtered through Celite®  while washing with DCM. The filtrate was 
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condensed under reduced pressure and purified by silica-gel flash column 
chromatography to afford the desired product 20f (R5 = benzyl) (56.57 mg, 81% 
yield, 52% overall yield) as a pale yellow oil. 
Rf = 0.4 (DCM/MeOH 20:1); 1H NMR (400 MHz, CDCl3)  8.24 (s, 1H), 7.35–
7.27 (m, 10H), 5.10, 4.88 (ABq, JAB = 15.3 Hz, 2H), 4.61, 4.39 (ABq, JAB = 15.3 
Hz, 2H), 4.26 (d, J = 13.7, 1H), 4.09 (dd, J = 15.3, 11.3 Hz, 1H), 3.58 (d, J = 13.7, 
1H), 3.42 (dd, J = 15.5, 4.1 Hz, 1H), 2.82 (s, 3H), 2.43 (m, 1H), 1.78 (d, J = 5.1, 
1H), 1.30 (d, J = 3.1, 1H); 13C NMR (100 MHz, CDCl3) 167.4, 163.8, 155.4, 
138.8, 138.7, 128.7, 128.6, 127.8, 127.6, 127.3, 127.1, 100.3, 57.8, 53.9, 51.5, 48.7, 
39.7, 34.4, 32.8; IR (neat) νmax: 3027, 2920, 2853, 1559, 1356, 735, 700 cm–1; 
HRMS(ESI+): Calcd for C23H26N5+ [M+H]+ 372.2183, found 372.2189, Δppm 
+1.61. 
Compound 21f (R5 = 3,5-dimehtylbenzyl). A pale yellow oil; 
Rf = 0.5 (DCM/MeOH = 20:1); 49.82 mg, 81% yield, 53% 
overall yield; 1H NMR (500 MHz, CDCl3)  8.25 (s, 1H), 7.34–
7.25 (m, 5H), 6.91 (m, 3H), 5.04, 4.78 (ABq, JAB = 15.2 Hz, 2H), 
4.61, 4.38 (ABq, JAB = 15.2 Hz, 2H), 4.26 (d, J = 13.7, 1H), 4.04 
(dd, J = 14.2, 11.7 Hz, 1H), 3.57 (d, J = 13.7, 1H), 3.41 (dd, J = 
15.4, 2.2 Hz, 1H), 2.81 (s, 3H), 2.43(m, 1H), 2.29 (s, 6H), 1.77 (d, J = 2.9, 1H), 
1.28 (s, 1H); 13C NMR (100 MHz, CDCl3) 167.4, 163.8, 155.4, 138.8, 138.6, 
138.3, 129.0, 128.6, 127.8, 127.1, 125.4, 100.3, 57.9, 53.7, 51.5, 48.4, 39.7, 34.5, 
32.7, 29.8, 21.5; IR (neat) νmax: 3026, 2922, 2863, 1564, 1355, 735, 700 cm–1; 
HRMS(ESI+): Calcd for C25H30N5+ [M+H]+ 400.2496, found 400.2495, Δppm –
0.25. The product was synthesized according to the synthetic procedure for the 
preparation of 20f from 1f and 3,5-dimehtylbenzyl bromide.  
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Synthetic procedure for the preparation of 22f 
 
Compound 22f. To a stirring solution of 1f (135.0 mg, 0.298 mmol) in MeOH (3.0 
ml) was added NaBH4 (56.37 mg, 1.490 mmol) at 0 °C. Then the resulting mixture 
was left to stir and allowed to warm to r.t. After the starting material was consumed 
as indicated by TLC, the resultant was quenched with saturated NaHCO3(aq) and 
extracted twice with DCM. The combined organic layer was dried over anhydrous 
Na2SO4(s) and filtered. The solvent was evaporated under reduced pressure, and 
the resulting crude secondary amine was dissolved in DCM (3.0 ml). To this 
solution were sequentially added Et3N (0.083 ml, 0.596 mmol) and Boc2O (84.55 
mg, 0.387 mmol) at 0 °C. The resulting mixture was left to stir and allowed to 
warm to r.t. After completion of the reaction as indicated by TLC, the resultant was 
quenched with saturated NH4Cl(aq) and extracted twice with DCM. The combined 
organic layer was dried over anhydrous Na2SO4(s) and the filtrate was condensed 
under reduced pressure, followed by silica-gel flash column chromatography to 
afford the Boc-protected product (162.3 mg, 98% yield). To a solution of Boc-
protected product (162.3 mg, 0.292 mmol) in DMF (3.0 ml) under argon 
atmosphere was added NaH (60% dispersion in mineral oil, 23.36 mg, 0.584 
mmol) at 0 oC and left to stir. After 30 min, allyl bromide (0.038 ml, 0.438 mmol) 
was slowly added. The resulting mixture was left to stir and allowed to warm to r.t. 
After completion of the reaction as indicated by TLC, the reaction mixture was 
quenched with saturated NH4Cl(aq). The resultant was extracted twice with ethyl 
acetate, dried with anhydrous Na2SO4(s), filtered, and concentrated in vacuo. The 
residue was purified by silica-gel flash column chromatography to obtain the 
intermediate F (R5 = allyl, 141.2 mg, 81% yield). To a solution of intermediate F 
(141.2 mg, 0.237 mnol) in THF (2.5 ml) was added TBAF (1.0 M solution in THF, 
0.308 ml, 0.308 mmol) and the mixture was stirred at r.t. After completion of the 
reaction as indicated by TLC, the reaction mixture was quenched with saturated 
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NaHCO3(aq). The resultant was extracted twice with DCM, dried with anhydrous 
Na2SO4(s), filtered, and concentrated in vacuo. To a solution of the crude resultant 
in THF (2.5 ml) under argon atmosphere was added NaH (60% dispersion in 
mineral oil, 14.22 mg, 0.356 mmol) at 0 oC. Then the resulting mixture was left to 
stir and allowed to warm to r.t. After completion of the reaction as indicated by 
TLC, the reaction mixture was diluted with DCM, washed with brine, dried over 
anhydrous Na2SO4(s), filtered, and concentrated in vacuo. The residue was purified 
with silica-gel flash column chromatography to obtain desired product 22f (56.30 
mg, 65% yield, 53% overall yield) as a white solid.  
Rf = 0.2 (EA); 1H NMR (400 MHz, CDCl3)  8.23 (s, 1H), 7.36–7.31 (m, 4H), 7.28 
(m, 1H), 5.92 (m, 1H), 5.21 (d, J = 10.2 Hz, 1H), 5.15 (dd, J = 17.2, 1.2 Hz, 1H), 
4.72–4.65 (m, 2H), 4.61 (dd, J = 15.5, 4.9 Hz, 1H), 4.55–4.44 (m, 2H), 4.11–4.07 
(m, 2H), 4.02 (d, J = 16.0 Hz, 1H), 3.91 (dd, J = 15.5, 6.5 Hz, 1H), 3.76 (dd, J = 
14.9, 2.0 Hz, 1H), 3.25 (dd, J = 15.1, 3.3 Hz, 1H), 2.91 (s, 3H); 13C NMR (100 
MHz, CDCl3)  166.9, 164.9, 157.3, 155.0, 138.1, 134.2, 128.7, 127.9, 127.3, 
117.8, 97.0, 65.1, 56.9, 56.7, 54.5, 52.4, 42.1, 39.7; IR (neat) νmax: 3049, 2976, 
2917, 1758, 1561, 1410, 1266, 746 cm–1; HRMS(ESI+): Calcd for C20H24N5O2+ 
[M+H]+ 366.1925, found 366.1924, Δppm –0.27; mp: 89–91 oC. 
 
Synthetic procedure for the preparation of 23f 
Compound 23f. To a solution of intermediate F (R5 = allyl, 243.1 mg, 0.408 
mmol) in THF (4.1 ml) was added TBAF (1.0 M solution in THF, 0.530 ml, 0.530 
mmol) and the mixture was stirred at r.t. After completion of the reaction as 
indicated by TLC, the reaction mixture was quenched with saturated NaHCO3(aq). 
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The resultant was extracted twice with DCM, dried with anhydrous Na2SO4(s), 
filtered, and concentrated in vacuo. To a solution of the crude resultant in DCM 
(8.2 ml) was added Dess-Martin periodinane (259.6 mg, 0.612 mmol) and the 
mixture was stirred at r.t. After completion of the reaction as indicated by TLC, the 
reaction mixture was quenched with saturated NaHCO3(aq). The resultant was 
extracted twice with DCM, dried with anhydrous Na2SO4(s), filtered, and 
concentrated in vacuo. The residue was purified by silica-gel flash column 
chromatography to obtain the aldehyde product (148.3 mg, 83% yield). To a 
stirring suspension of methyltriphenylphosphonium bromide (363.3 mg, 1.017 
mmol) in THF under argon atmosphere was added MeLi (1.6 M in diethyl ether, 
0.530 ml, 0.848 mmol) at 0 oC. After 30min, the resulting aldehyde product (148.3 
mg, 0.339 mmol) was added. Then the reaction mixture was allowed to slowly 
warm to r.t over a 12 h period. The reaction mixture was quenched with saturated 
NH4Cl(aq). The resultant was extracted twice with ethyl acetate, dried with 
anhydrous Na2SO4(s), filtered, and concentrated in vacuo, followed by silica-gel 
flash column chromatography to afford SI-11 (130.0 mg, 88% yield). To a solution 
of SI-11 (130.0 mg, 0.298 mmol) in toluene was added second generation Grubbs’ 
catalyst (50.94 mg, 0.060 mmol, 20 mol%) and the mixture was left to stir at reflux. 
After 4h, solvent was removed under reduced pressure and the residue was purified 
by silica-gel flash column chromatography to obtain desired product 23f (44.83 mg, 
52% recovery yield, 31% overall yield) as a yellow oil.  
Rf = 0.2 (hexane/EA = 1:1); 1H NMR (400 MHz, DMSO-d6, 100 oC)  8.06 (s, 1H), 
7.35–7.29 (m, 4H), 7.27–7.23 (m, 1H), 6.35 (ddd, J = 9.9, 5.3, 1.8 Hz, 1H), 5.78 
(ddd, J = 10.1, 3.9, 1.8 Hz, 1H), 4.92 (d, J = 16.5 Hz, 1H), 4.86–4.81 (m, 1H), 4.76 
(d, J = 15.3 Hz, 1H), 4.56 (d, J = 15.9 Hz, 1H), 4.42 (dd, J = 15.3, 1.2 Hz, 1H), 
4.34 (d, J = 15.3 Hz, 1H), 4.00 (dd, J = 4.9, 1.8 Hz, 1H), 3.77 (dq, J = 18.3, 2.2 Hz, 
1H), 3.30 (dd, J = 15.3, 2.4 Hz, 1H), 2.84 (s, 3H), 1.42 (s, 9H); 13C NMR (100 
MHz, DMSO-d6, 100 oC)  166.0, 163.6, 154.6, 153.5, 137.9, 128.0, 127.7, 127.3, 
127.1, 126.3, 99.7, 79.0, 55.4, 49.9, 49.4, 45.7, 41.9, 38.7, 27.7; IR (neat) νmax: 
3031, 2978, 2928, 1690, 1588, 1408, 1164 cm–1; HRMS(ESI+): Calcd for 
C23H30N5O2+ [M+H]+ 408.2394, found 408.2382, Δppm –2.94.
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2.5.4. General Information of Biological Assay 
Kits, reagents and materials  
Micro BCATM protein assay kit was purchased from PIERCE and used for the 
measurement of protein concentration of cell lysate. Cell proliferation enzyme-
linked immunosorbent assay (ELISA) and 5-bromo-2'-deoxyuridine (BrdU) 
colorimetric kit were purchased from Roche, Sigma-Aldrich. Ez-cytox WST-based 
cell viability, proliferation & cytotoxicity assay kit was purchased from Daeil Lab. 
Compounds used for bioassays were prepared in dimethyl sulfoxide (DMSO) 
solution. DMSO was purchased from Acros Organics. Tween®  20 was purchased 
from Sigma-Aldrich. Dulbecco modified eagle medium (DMEM), RPMI 1640, 
fetal bovine serum (FBS), and antibiotic-antimycotic solution were purchased from 
Gibco, Invitrogen. Phosphate-buffered saline (PBS) buffer and leucine-free DMEM 
were purchased from WELGENE. 3,3', 5,5"-tetramethylbenzidine (TMB), a 
substrate of horseradish peroxidase (HRP) conjugated in secondary antibody, was 
purchased from Invitrogen. Protein gel casters and western blot equipments 
including polyvinylidene difluoride (PVDF) membrane were purchased from Bio-
Rad. Amersham ECL prime western blotting detection system (Amersham ECL 
prime solution) was purchased from GE Healthcare Life Science. 100-mm cell 
culture dish, transparent 96-well plate [#3598], and half-bottom 96 well clear plate 
[#3690] were purchased from CORNING. LipofectamineTM 2000 reagent was 
purchased from Invitrogen. Human embryonic kidney (HEK)293T, DU145, Ca Ski, 
and HeLa cells were obtained from American Type Culture Collection [ATCC, VA, 
USA]. NuncTM Lab-TekTM II chambered cover glass was purchased from Thermo 
Scientific. 
Antibodies, plasmids and proteins  
Anti-LC3B (ab51520), anti-S6K1 (ab32359), anti-phsopho-T389 S6K1 (ab2571), 
and HRP-labeled anti-horse IgG secondary antibodies (ab6802) were purchased 
from Abcam. Anti-glutathione-S-transferase (GST) antibody (sc-459) was 
purchased from Santa Cruz Biotechnology. Anti-p62 (CST 5114), anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (CST 2118), anti-phospho-
 
 68 
S65 4E-BP1 (CST 9451), anti-phospho-S757 ULK1 (CST 6888), anti-phospho-
S473 Akt (CST 4058), anti-phospho-T172 AMPKα (CST 2531), and HRP-labeled 
anti-rabbit IgG secondary antibodies (CST 7074) were purchased from Cell 
Signaling Technology. His-tagged LRS and GST-tagged RagD were in our 
laboratory stocks. mCherry-GFP-LC3 plasmid (pBabe vector) was from Dr. 
Heesun Cheong, Division of Chemical Biology, Research Institute, National 
Cancer Center, Korea. 
Instruments and programs  
For developing of ELISA, the absorbance of 96-well plate was measured by 
BioTek Synergy HT Microplate reader. ChemiDocTM MP imaging system from 
Bio-Rad was used for analyzing chemiluminescent signal in western blotting assay. 
Following signal quantification was done by ImageLab 4.0 program provided by 
Bio-Rad.  
DeltaVision Elite imaging system from GE Healthcare was used for imaging 
experiment. Objective lenses were equipped with Olympus IX-71 inverted 
microscope with PLAN APO 60×/Oil (PLAPON60×O), 1.42 NA, WD 0.15 mm. 
sCMOS camera and InSightSSI fluorescence illumination module were equipped 
with the system. Four-color fluorescent protein (Live Cell) filter set [GE 
Healthcare, 52-852113-013] was used for imaging. For live cell imaging, CO2 
supporting chamber with an objective air heater were installed with the system. 
Images were analyzed with SoftWorks program supported by GE Healthcare. 
Graphs and figures provided were analyzed with GraphPad Prism 5 program.  
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2.5.5. Experimental Procedures of Biological Assay 
Cell Culture  
HEK293T cell was cultured in Dulbecco modified eagle medium (DMEM) with 
10% (v/v) fetal bovine serum (FBS) and 1% (v/v) antibiotic-antimycotic solution. 
HeLa, DU145, and Ca Ski cell were cultured in RPMI 1640 medium with 10% 
(v/v) FBS and 1% antibiotic-antimycotic solution. Both cells were maintained in 
100-mm cell culture dish in an incubator at 37 ºC, in a humidified atmosphere with 
5% CO2. 
ELISA 
His-tagged human LRS were diluted in carbonate buffer (100 mM, pH 9.6) at the 
concentration of 0.5 ng μl-1. Solution were distributed to the half-bottom 96 well 
clear plate from CORNING 3690. After incubation overnight at 4 °C (sealed), 
coating solution from each well was removed and washed for three times with 
phosphate buffered saline with 0.05% Tween®  20 (PBST). 5% bovine serum 
albumin (BSA) in PBS solution was treated to each well for blocking step, 
followed by the treatment of each compound and GST-tagged human RagD 
simultaneously for 3 h. GST protein itself was treated as negative control. Diluted 
GST antibody in PBST was added and incubated at room temperature for 1 h. After 
washing with PBST, the HRP-conjugated anti-horse IgG secondary antibody 
diluent was treated and incubated at room temperature for 1 h. TMB was added to 
each well for colorimetric development. Blue color should be developed in positive 
wells. To stop the color reaction, 1 M H3PO4 stopping solution was added. Finally, 
absorbance at 450 nm were measured.  
Western Blotting  
Cells were lysed with radio-immunoprecipitation assay (RIPA) buffer (50 mM Tris, 
pH 7.8, 150 mM NaCl, 0.5% deoxycholate, 1% IGEPAL CA-630, protease 
inhibitor cocktail, and phosphatase inhibitors). Protein was obtained after 
centrifugation at 15000 rpm for 20 min, by transferring supernatant. Protein 
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concentration was normalized with Micro BCATM protein assay kit. Overall protein 
sampling procedure was done at 4 ºC. Prepared protein samples were analyzed with 
SDS-PAGE and following western blot procedure. Protein was transferred into 
nitrocellulose membrane after SDS-PAGE experiment. Membrane was blocked 
with 2% BSA in TBST over 1 h on r.t. Primary antibodies were treated overnight at 
4 ºC , followed by washing with TBST. HRP-labeled anti-rabbit IgG secondary 
antibody (1:5000) was treated at room temperature for 1 h. Antibodies were treated 
with the concentration indicated in antibody manufacturer’s protocol. After 
washing with TBST, membrane was developed by Amersham ECL prime solution. 
Chemiluminescent signal was measured by ChemiDocTM MP imaging system. 
 
Surface Plasmon Resonance (SPR) Assay 
The dissociation rate constant (KD) toward His-LRS was determined by surface 
plasmon resonance (SPR) technique at the national center for inter-university 
research facilities (NCRF) in Seoul National University using a Biacore T100 
instrument from GE Healthcare. The carboxyl group on the surface of CM5 sensor 
chip was replaced with reactive succinimide ester using combination of 1-ethyl-3-
(3-dimethylaminopropyl)-carbodiimide (EDC) and N-hydroxysuccinimide (NHS) 
in flow cells 1 and 2. Human LRS (1.5× PBS, pH 7.3) were immobilized on the 
flow cell 2 (aimed RU; 12000) through formation of amide bond by reacting with 
the resulting NHS ester. The remaining NHS ester on flow cells 1 and 2 was 
quenched by injection of 1 M ethanolamine-HCl (pH 8.0) solution. During the 
immobilization process, PBS was used as running buffer. After the immobilization 
of hLRS, compounds were injected for 60 s at a flow rate of 20 μl min-1 in various 
concentration from 1 μM to 15 μM. At the same flow rate, dissociation of 
compounds from the sensor surface was monitored for 200s. As a running buffer, 
1× PBS (pH 7.3) containing 3% DMSO and 0.005% P20 solution were used. The 
binding events were measured at 25 °C. Data analysis were done by using Biacore 
T100 Evaluation software from GE Healthcare. Final sensorgrams were obtained 
after the elimination of responses from flow cell 1 and buffer-only control. The 
dissociation constant (KD) was calculated by fitting the sensorgrams to the 1:1 
binding model.   
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Chapter 3. Gold-catalyzed unexpected ring transfor-
mation of pyrimidodiazepine derivatives 
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3.1 Introduction  
The chemical and biological properties of privileged heterocycles are of continued 
interest because of the existence of these moieties in many bioactive natural 
products and FDA-approved pharmaceutical drugs.1 Among them, pyrimidine has 
been extensively utilized in pharmaceutics as a key structural motif owing to its 
ability to mimic the structures and properties of nucleosides.2 Pyrimidine and its 
derivatives exhibit diverse biological activities, including antibacterial,3 
antifungal,4 antiviral,5 and anticancer6 properties. 
Recently, we reported the synthesis of pyrimidine-containing polyheterocycles 
via the recombination of a pyrimidine ring with various heterocycles to expand the 
molecular diversity using the privileged substructure-based diversity-oriented 
synthesis (pDOS) strategy.7,8 We also showed that privileged structures serve as 
“chemical navigators” to efficiently access the bioactive chemical space.8,9,10 
Indeed, skeletal diversity has evolved as a key element in the design strategy for 
the construction of drug-like small molecule library,11 and there is a high demand in 
developing efficient methods to increase the skeletal diversity. Thus, we have been 
pursuing new intramolecular transformations of pyrimidine-embedded 
polyheterocycles using transition-metal catalysts. In fact, transition-metal catalysis 
provides an efficient way to induce remarkable changes within molecular 
frameworks in a single step.12 In particular, gold-catalyzed reactions have attracted 
much interest in organic synthesis because of the unique ability of gold catalysts to 
activate unsaturated carbon–carbon bonds so that they can react with various 
nucleophiles.13 Gold catalysts have been widely used as selective alkynophiles for 
inter- and intramolecular nucleophilic reactions under mild conditions with 
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excellent functional group tolerance to afford various heterocyclic products 
(Scheme 3-1A).14 
Scheme 3-1. Unexpected Discovery of a Novel Gold–Catalyzed Reaction 
 
 
As a part of our continuing interest in the diversification of pyrimidine-
embedded molecular frameworks, herein, we report a novel synthetic method using 
a gold catalyst; this involves a retro-Mannich-type C–C bond cleavage in 
pyrimidodiazepines followed by intramolecular cyclization. The unique reactivity 
of the gold catalyst is mainly discussed. Under the AuCl-catalyzed microwave 
reaction conditions, the pyrimidodiazepine moiety can be transformed into 
imidazolidines, oxazinanes, and oxazolidines depending on the location and type of 
intramolecular nucleophiles through an iminium intermediate (Scheme 3-1B). This 
gold-catalyzed ring transformation can be used for the skeletal diversification of 
one pyrimidine-containing macrocycles to another in a single step at the late stage 
of synthesis. Moreover, this gold-catalyzed C–C bond cleavage occurs in 
preference to alkynophilic activation. To the best of our knowledge, no gold-
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catalyzed methodology with orthogonal reactivity of substrates in the presence of 
terminal acetylene moiety has been reported. 
Scheme 3-2. Initial Discovery of a Novel Gold-Catalyzed Reaction  
 
 
We recently focused on the diversification of pyrimidodiazepine using the pDOS 
strategy7,8 to construct various polyheterocyclic scaffolds for molecular diversity to 
systematically explore the protein–protein8 and protein–DNA/RNA interactions.9 
During this exploration, we designed and synthesized substrate 1a bearing a 
terminal acetylene group which can be activated by a gold catalyst; subsequent 
cyclization via the intramolecular nucleophilic attack of primary alcohol group 
would afford a fused morpholine moiety. However, we failed to obtain the fused 
morpholine moiety under typical gold-catalyzed reaction conditions using 
microwave irradiation (Scheme 3-2A). Instead, the terminal acetylene moiety was 
found to be intact by 1H and 13C NMR spectroscopy. Surprisingly, this unexpected 
product 2a was a ring-contracted heterocycle containing an imidazolidine moiety, 
formed by gold-catalyzed C–C bond cleavage and subsequent intramolecular 
nucleophilic cyclization of the anilinic nitrogen. To confirm this transformation, we 
 
 75 
designed and tested 1b containing a terminal acetylene group as substrate 1a and 
no primary alcohol nucleophile. As shown in Scheme 3-2B, the imidazolidine-
containing product 2b was obtained with the terminal acetylene moiety intact, as 
determined by 1H-NMR spectroscopy. The exact structure of 2b was confirmed by 
X-ray crystallography (see Supporting Information). 
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3.2 Result and Discussion 
Table 3-1. Optimization of Reaction Conditions a 
 
entry catalyst conditions b 
s.m. 
(%) c 
product 
(%) c 
1 AuCl DCE, 80 oC, 23 h - 96 
2 AuCl3 DCE, 80 oC, 2 h - 83 
3 Au(PPh3)OTf DCE, 80 oC, 20 h 95 - 
4 AgSbF6 DCE, 80 oC, 20 h 65 21 
5 AgOTf DCE, 80 oC, 20 h 87 - 
6d AuCl DCE, 80 oC, 100 W, 30 min 82 14 
7d AuCl CHCl3, 80 oC, 100 W, 30 min 89 10 
8d AuCl DMF, 80 oC, 100 W, 30 min 55 47 
9d AuCl THF, 80 oC, 100 W, 30 min 96 - 
10d AuCl ACN, 80 oC, 100 W, 30 min - 95 
a Reaction condition: SM, catalyst (10 mol %), solvent (0.1 M). b DCE: 1,2-dichloro
ethane, DMF: dimethylformamide, THF: tetrahydrofuran, ACN: acetonitrile. c Yields 
determined by the 1H-NMR analysis of crude products using an internal standard (1,
3,5-tri-MeO-C6H3). d Microwave conditions 
Intrigued by this unexpected result, we attempted to optimize the gold-catalyzed 
transformation under various conditions (Table 3-1). The feasibility of this process 
was investigated using substrate 1c without the terminal acetylene moiety and 
various coinage metal catalysts and conditions. First, 1c was thermally activated in 
the presence of various gold and silver catalysts (entries 1–5). Among the tested 
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coinage metal catalysts, AuCl showed the efficient transformation of 1c to 2c, but 
this thermal reaction was quite slow (23 h, entry 1). Although the reaction rate of 
AuCl3 was faster than other catalysts, the reaction was not clean (entry 2). In the 
case of microwave-assisted activation, the reaction time was effectively reduced,15 
but the yield was also significantly decreased (entry 6). To solve this problem, 
different solvents were screened; the desired product 2c was obtained in an 
excellent yield within a short reaction time when using acetonitrile (entry 10). 
Scheme 3-3. Priority of the Nucleophiles 
 
Model substrate 1c contains two potential nucleophiles, anilinic nitrogen and 
TIPS-protected alcohol. For the reaction optimization, 1c was used to simplify the 
outcome of this transformation. To investigate the priority of two competing 
nucleophiles, the following experiment were performed by changing the reaction 
sequence. As shown in Scheme 3, the TIPS group of 1c was deprotected using 
tetrabutylammonium fluoride (TBAF) to generate 1c with two competing 
nucleophiles (aniline and primary alcohol), followed by gold-catalyzed ring 
transformation. The resulting product 2c was identical to the product prepared by 
the gold-catalyzed ring transformation of 1c, followed by TIPS deprotection. These 
outcomes clearly confirmed that the anilinic nitrogen has a higher priority over the 
alcoholic nucleophile when both are available.19 
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Table 3-2. Substrate Scope of Gold-catalyzed Ring Transformation Reaction 
a 
 
substrate product b 
 
a Reaction conditions: SM, AuCl (10 mol %), ACN (0.1 M), Microwave, 100 W, 8
0 C 30 min. b Yield of the isolated product. c Based on recovered starting material
s. 
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With the optimized conditions in hand, we performed a series of reactions to 
investigate the substrate scope of this gold-catalyzed ring transformation. As shown 
in Table 3-2, alkyl amines and cyclic amines at the R1 position were well tolerated 
providing imidazolidine products in good-to-excellent yields. Diverse substituents 
on secondary amine at the R2 position were also tolerated, including alkynyl (1a, 
1b, and 1d), allyl (1e), benzyl (1c, 1g, 1i, and 1k–1o) as well as unmodified 
secondary amines (1f, 1h, and 1j). The ester moiety (1h) at the C-7 position and the 
silyl ether moiety (1c–1g and 1i–1k) at the C-7 and C-8 positions of the 
pyrimidodiazepine provided the corresponding products in good yields. However, 
tosyl or carbonyl substituents at the R2 position failed to provide the desired 
products, probably because of the electron-withdrawing nature of the substituents 
at the R2 position for this reaction (data not shown). Next, the ability of alcohol 
nucleophile to form different types of heterocycles (Table 3-2, 1l–1o) was 
investigated. The primary alcohol substituents at the C-7 or C-8 position in the 
gold-catalyzed transformation of pyrimidodiazepine afforded either 1,3-oxazinanes 
(3l and 3m) or oxazolidines (4n and 4o), respectively. To decrease the 
nucleophilicity of aniline, electron-donating alkyl substituents as well as electron-
withdrawing carbonyl substituents were introduced at the R3 position. Notably, 
different reactive nucleophiles in pyrimidodiazepine 1 result in the diverse ring 
transformations, generating different heterocycles from the same skeleton. 
Using the synthetic method for the pyrimidodiazepine core skeleton (see Scheme 
S6), various R4 substituents were introduced at the C-5 position at the stage of the 
formation of iminium intermediate, generated by N-alkylation of SI-4, using 
Grignard reagents. The diastereomeric outcome of the alkyl substituents in 1p–1s  
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Table 3-3. Steric Effects of R2 and R4 Substituents on Diastereomeric Ratio 
 
entry R4 R2 s.m. dr ratio b pdt dr ratio b yield (%) c 
1 Bn Me (1p) 4:1 ≫99:1 (5p) 72 
2 Bn Bn (1q) 3.6:1 ≫99:1 (5q) 81 
3 Me Bn (1r) 2.7:1 2:1 (5r) 70 
4 Me Me (1s) 3.6:1 1.21:1 (5s) 92 
a Reaction conditions: SM, AuCl (10 mol %), ACN (0.1 M), Microwave, 100 W, 80 C. b 
Diastereomeric ratio was determined by 1H-NMR analysis. c Yield of the isolated product. 
varied due to the chiral environment generated by the TIPS-containing substituent 
at the C-7 position of iminium intermediate.8 As shown in Table 3, the 
diastereomeric ratio of the starting materials (1p–1s) was influenced by the size of 
R2 substituent at the N-6 position owing to the facial selectivity of Grignard 
reagents. After the preparation of a full matrix of either methyl or benzyl 
substituent at the C-5 and N-6 positions, the gold-catalyzed ring transformation 
reaction was performed. Surprisingly, a single product (5p and 5q) was observed 
from a 4:1 mixture of 1p and 3.6:1 mixture of 1p, respectively, in a good yield and 
excellent diastereoselectivity under the optimized reaction conditions. However, 
the corresponding diastereoselectivity decreased when the size of R4 substituents at 
the C-5 position was smaller (methyl instead of benzyl) in the case of 1r and 1s. To 
understand the mechanistic origin of this diastereoselectivity, the reactivity of gold-
catalyzed ring transformation was further investigated using a 1:1 mixture of 
pyrimidodiazepine substrate 1p containing benzyl and methyl moieties at the C-5  
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Scheme 3-4. Experimental Investigation to Elucidate the Reaction 
Mechanism of Gold-catalyzed Ring Transformation 
 
and N-6 position, respectively. When this gold-catalyzed reaction of 1p was 
quenched prior to its full conversion, the desired imidazolidine 5p was obtained as 
a single diastereomer, and the remaining starting material 1p was obtained as a 1:1 
mixture as confirmed by crude 1H NMR spectroscopy (Scheme 3-4A). This 
observation indicates that the gold-catalyzed reaction occurred through the 
formation of an identical intermediate from both the diastereomeric starting 
materials with the same reaction rate, followed by the intramolecular nucleophilic 
addition of anilinic nitrogen to afford the desired product 5p as a single 
diastereomer. 
Based on these experimental results, a probable mechanism of this gold-catalyzed 
ring transformation involving an iminium intermediate is proposed (Scheme 5).16 
Strongly nucleophilic trimethylsilyl cyanide (TMSCN) was added to trap the 
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acyclic iminium intermediate of the gold-catalyzed reaction of 1c; the CN-trapped 
product 6c was observed along with the desired imidazolidine product 2c (Scheme 
3-4B).19 Therefore, it can be concluded that this AuCl-catalyzed ring 
transformation of pyrimidodiazepine is mediated via the in situ generation of an 
acyclic iminium intermediate through gold-catalyzed ring opening17 and subsequent 
intramolecular nucleophilic cyclization. The stereochemical enrichment of this 
unusual gold-catalyzed reaction can be attributed to the retro-Mannich-type 
cleavage of C–C bond,18 followed by the face-selective trapping of iminium 
intermediates (Scheme 3-5). 
Scheme 3-5. Plausible Mechanism of Gold-Catalyzed Ring Transformation 
of Pyrimidodiazepine 
 
To demonstrate the potential of this synthetic method, the gold-catalyzed reaction 
was used to transform medium-sized rings into larger macrocycles at the last stage 
of synthesis for skeletal diversification (Scheme 3-6). The starting materials (1t and 
1u) were prepared using our standard synthetic methods including olefin 
metathesis (Scheme S7).8 The 10-membered pyrimidodiazepines (1t and 1u) were 
subjected to the gold- catalyzed reaction, allowing the ring enlargement to 12-
membered 2s and 15-membered 3t via the intramolecular nucleophilic cyclization 
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with aniline and alcohol nucleophiles, respectively. It is noteworthy that 
significantly different macrocycles were obtained from the same skeleton simply 
by switching the reactive nucleophiles. The stereochemical configuration of 2s and 
3t was confirmed by 2D NOESY NMR analysis.19  
Scheme 3-6. Synthetic utility of this method 
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3.3 Conclusion 
In conclusion, a novel orthogonal gold-catalyzed ring trans-formation method was 
developed for pyrimidodiazepine derivatives in the presence of an alkyne moiety. 
This gold-catalyzed reaction is mediated by the in situ generation of acyclic 
iminum intermediates via unusual C-C bond cleavage and subsequent nucleophilic 
cyclization. The formation of imidazolidine, oxazolidine, and oxazinane derivatives 
depends on the type of intramolecular nucleophiles in pyrimidodiazepines. The 
stereo-chemical enrichment of this gold-catalyzed reaction is probably caused by 
the facial selectivity of iminium intermediates. This synthetic method was 
successfully used to synthesize two different types of macrocycles from the same 
skeleton. This method provides a highly concise and effective protocol to 
synthesize novel drug candidates with diverse structures. Further investigations on 
the mechanistic details of this gold-catalyzed reaction are currently underway.
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3.5 Experimental Section 
3.5.1. General information 
NMR spectra were obtained on an Agilent 400-MR DD2 Magnetic Resonance 
System [400 MHz, Agilent, USA], Varian/Oxford As-500 [500 MHz, Varian Assoc., 
Palo Alto, USA] or Bruker Avance 600 [600 MHz, Bruker, Germany]. Chemical 
shift values were recorded as parts per million (δ), referenced to tetramethylsilane 
(TMS) as the internal standard or to the residual solvent peak (CDCl3, 1H: 7.26, 
13C: 77.16, DMSO-d6, 1H: 2.50, 13C: 39.52). Multiplicities were indicated as 
follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of 
doublet), dt (doublet of triplet), td (triplet of doublets), br s (broad singlet) and so 
on. Coupling constants were reported in hertz (Hz). High resolution mass spectra 
(HRMS) were analyzed at the Organic Chemistry Research Center in Sogang 
University on a Ultra High Resolution ESI Q-TOF mass spectrometer [Bruker, 
Germany] using the electrospray ionization (ESI) method. All commercially 
available reagents were used without further purification unless noted otherwise. 
Commercially available reagents were obtained from Sigma-Aldrich, TCI, Acros, 
or Alfa Aesar. All solvents were obtained by passing them through activated 
alumina columns of solvent purification systems from Glass Contour. Analytical 
thin-layer chromatography (TLC) was performed using Merck Kiselgel 60 F254 
plates, and the components were visualized by observation under UV light (254 
and 365 nm) or by treating the plates with ninhydrin followed by thermal 
visualization. Flash column chromatography was performed on Merck Kieselgel 60 
(230-400 mesh). Microwave reactions were performed using the CEM Discover 
Benchmate and microwave reaction conditions were as indicated in the 
Experimental Section. X-ray crystallographic analysis was performed at Ewha 
Womans University, Seoul. 
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3.5.2. Synthesis and Characterization of Substrates 
Scheme S1. Preparation of SI-2 and SI-3 
  
tert-Butyl (S)-(1-((6-chloro-5-formylpyrimidin-4-yl)amino)-3-((triisopropylsilyl)-
oxy)propan-2-yl)carbamate (SI-2) was prepared according to the previous report. 1, 
2,3 
 
Synthetic procedure of SI-3  
To a solution of SI-1 (5.0 g, 10.4 mmol) in dichloromethane (DCM) (0.1 M, 90 mL) 
was treated with trifluoroacetic acid (TFA) (10 mL, 10 vol.%) at r.t. After the 
starting material was consumed as indicated by TLC, any excess TFA was 
removed by azeotropic evaporation with toluene under reduced pressure, and the 
crude resultant was dissolved in chloroform (CHCl3, 0.1 M). To this solution were 
sequentially added Et3N (2.2 mL, 15.6 mmol) and 4,6-dichloropyrimidine-5-
carboxaldehyde (1.8 g, 10.4 mmol) at 0 oC and left to stir. After 30 min, the 
reaction mixture was quenched with saturated NH4Cl(aq). The resultant was 
extracted twice with CHCl3, dried over anhydrous Na2SO4(s), and filtered. The 
filtrate was condensed under reduced pressure and purified by silica-gel flash 
column chromatography to afford the desired product SI-3 (3.4 g, 63% overall 
yield) as a colorless oil. 
                                            
1
 Stojković, M. R.; Piotrowski, P.; Schmuck, C.; Piantanida I. Org. Biomol. Chem. 2015, 13, 1629. 
2
 Kim, J.; Jung, J.; Koo, J.; Cho, W.; Lee, W. S.; Kim, C.; Park, W.; Park, S. B. Nat. Comm. 2016, 7, 
13196. 
3
 Zheng, L.; Yang, F.; Dang, Q.; Bai, X. Org. Lett., 2008, 10, 889. 
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Scheme S2. Preparation of 1f and 1c  
 
To a stirring solution of SI-2 (3.0 g, 6.2 mmol) and K2CO3 (1.7 g, 12.4 mmol) in 
N,N-dimethylformamide (DMF) (0.1 M) was added N-benzylmethylamine (1.2 mL, 
12.4 mmol) and the resulting mixture was stirred at 40 oC. After completion of the 
reaction as indicated by TLC, the resultant was quenched with saturated NH4Cl(aq) 
and extracted twice with ethyl acetate. The combined organic layer was dried over 
anhydrous Na2SO4(s) and filtered. The organic solvent was evaporated under 
reduced pressure to afford a crude oil, which was purified by silica-gel flash 
column chromatography. To obtain the cyclic imine product SI-4, the above 
product was first treated with 10 vol.% of trifluoroacetic acid (TFA) in DCM (100 
mL) at r.t. After the starting material was consumed as indicated by TLC, any 
excess TFA was removed by azeotropic evaporation with toluene under reduced 
pressure, and the crude resultant was dissolved in 1 vol.% acetic acid (AcOH) in 
CHCl3 (100 mL). The resulting mixture was stirred at 40 oC. After completion of 
the reaction as indicated by TLC, the resultant was quenched with saturated 
NaHCO3(aq) and extracted twice with CHCl3. The combined organic layer was 
dried over anhydrous Na2SO4(s) and filtered. The filtrate was condensed under 
reduced pressure, followed by silica-gel flash column chromatography to afford the 
desired product SI-4 (2.3 g, 83%) as a off white powder. 
To a stirring solution of SI-4 (2.3 g, 5.1 mmol) in MeOH (0.1 M) was added sodium 
borohydride (NaBH4) (973.3 mg, 25.5 mmol) at 0 oC. The resulting mixture was 
left to stir and allowed to warm to r.t. After completion of the reaction as indicated 
by TLC, the resultant was quenched with saturated NaHCO3(aq) and extracted 
twice with DCM. The combined organic layer was dried over anhydrous Na2SO4(s) 
and filtered. The filtrate was condensed under reduced pressure, followed by silica-
gel flash column chromatography to afford 1f (2.1 g, 90% yield) as a yellow oil.  
To a solution of the 1f (2.0g, 4.4 mmol) in DMF (0.1 M) were sequentially added 
 
 90 
Et3N (1.2 mL, 8.8 mmol) and benzyl bromide (680.3 L, 5.7 mmol) at 0 oC. The 
resulting mixture was left to stir and allowed to warm to r.t. After completion of 
the reaction as indicated by TLC, the resultant was quenched with saturated 
NH4Cl(aq) and extracted twice with ethyl acetate. The combined organic layer was 
dried over anhydrous Na2SO4(s) and filtered. The filtrate was condensed under 
reduced pressure, followed by silica-gel flash column chromatography to afford 1c 
(2.1 g, 87% yield) as a pale yellow oil. 
Substrates 1d, 1e and 1g were prepared according to Scheme S2. 
Substrate 1a was prepared according to Scheme S2, followed by TIPS deprotection 
with TBAF (1.0 M in THF, 1.5 equiv.).  
 
Scheme S3. Preparation of 1l  
 
To a solution of the 1c (1.0 g, 1.83 mmol) in DMF (0.1 M) under argon atmosphere 
was added NaH (60% dispersion in mineral oil, 146.5 mg, 3.66 mmol) at 0 oC and 
left to stir. After 30 min, iodomethane (170.9 L, 2.74 mmol) was slowly added. 
The resulting mixture was left to stir and allowed to warm to r.t. After completion 
of the reaction as indicated by TLC, the reaction mixture was quenched with 
saturated NH4Cl(aq). The resultant was extracted twice with ethyl acetate, dried 
with anhydrous Na2SO4(s), filtered, and concentrated. To a solution of the crude 
resultant in THF (0.1 M) was added TBAF (1.0 M in THF, 2.7 mL) and the mixture 
was stirred at r.t. After completion of the reaction as indicated by TLC, the reaction 
mixture was quenched with saturated NaHCO3(aq). The resultant was extracted 
twice with DCM, dried with anhydrous Na2SO4(s), filtered, and concentrated in 
vacuo. The residue was purified with silica-gel flash column chromatography to 
obtain desired product 1l (524.3 mg, 71% overall yield) as a colorless oil. 
Substrates 1m, 1n and 1u were prepared according to Scheme S3. 
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Scheme S4. Preparation of 1j and 1i 
 
To a stirring solution of SI-3 (3.0 g, 5.8 mmol) and K2CO3 (1.6 g, 11.5 mmol) in 
N,N-dimethylformamide (DMF) (0.1 M) was added N-benzylmethylamine (1.1 mL, 
8.6 mmol) and the resulting mixture was stirred at 40 oC. After completion of the 
reaction as indicated by TLC, the resultant was quenched with saturated NH4Cl(aq) 
and extracted twice with ethyl acetate. The combined organic layer was dried over 
anhydrous Na2SO4(s) and filtered. The filtrate was condensed under reduced 
pressure and the crude resultant was dissolved in methanol (0.1 M). To this solution 
(1.0 equiv.) was carefully added 10 wt.% Pd/C (1.5 g) and the mixture was 
vigorously stirred under H2 atmosphere (1 atm) at r.t. After completion of the 
reaction as indicated by TLC, the reaction mixture was filtered through Celite®  
while washing with ethyl acetate. The filtrate was condensed under reduced 
pressure, followed by silica-gel flash column chromatography to afford 1j (1.6 g, 
overall 61% yield) as a pale yellow oil.  
To a solution of the 1j (1.5 g, 3.3 mmol) in DMF (0.1 M) were sequentially added 
Et3N (917.5 L, 6.6 mmol) and benzyl bromide (508.9 L, 4.3 mmol) at 0 oC. The 
resulting mixture was left to stir and allowed to warm to r.t. After completion of 
the reaction as indicated by TLC, the resultant was quenched with saturated 
NH4Cl(aq) and extracted twice with ethyl acetate. The combined organic layer was 
dried over anhydrous Na2SO4(s) and filtered. The filtrate was condensed under 
reduced pressure, followed by silica-gel flash column chromatography to afford 1i 
(1.5 g, 83% yield) as a pale yellow oil. 
Substrates 1b, 1h, and 1k were prepared according to Scheme S4. 
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N-benzyl-2-(methylamino)acetamide for the preparation of 1b was prepared via 
acylation and alkylation sequence as follows. 
 
To a solution of benzyl amine (1.0 g, 5.84 mmol) in dry DCM (0.1 M) under argon 
atmosphere was added Et3N (896.4 L, 6.43 mmol) at 0 oC and left to stir. After 15 
min, bromoacetyl bromide was slowly added. The resulting mixture was left to stir 
and allowed to warm to r.t. After completion of the reaction as indicated by TLC, 
the reaction mixture was condensed under reduced pressure. The crude resultant 
was dissolved in THF (0.1 M). To this solution was added methylamine (2.0 M in 
THF, 29.2 mL, 58.4 mmol) and the resulting mixture was stirred at 60 oC. After 
completion of the reaction as indicated by TLC, the resultant was quenched with 
saturated NaHCO3(aq) and extracted twice with DCM. The combined organic layer 
was dried over anhydrous Na2SO4(s) and filtered. The organic solvent was 
evaporated under vacuum to afford a crude oil, which was used without further 
purification in the SNAr reaction according to Scheme S4. 
 
Scheme S5. Preparation of 1o  
 
To a solution of the 1i (545.8 mg, 1.00 mmol) in DCM (0.1 M) were sequentially 
added Et3N (278.8 L, 2.00 mmol) and benzoyl chloride (150.9 L, 1.30 mmol) at 
0 oC. The resulting mixture was left to stir and allowed to warm to r.t. After 
completion of the reaction as indicated by TLC, the resultant was extracted twice 
with brine/DCM. The combined organic layer was dried over anhydrous Na2SO4(s), 
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filtered, and concentrated under reduced pressure. To a solution of the crude 
resultant in THF (0.1 M) was added HF/pyridine/THF (5/5/90) solution (20 mL) 
and the mixture was stirred at r.t. After the starting material was consumed as 
indicated by TLC, ethoxytrimethylsilane (20 mL) was added and allowed to react 
for 1 h to quench any excess HF (based on HF/pyridine protocol). The reaction 
mixture was condensed in vacuo, followed by silica-gel flash column 
chromatography to afford 1o (424.5 mg, 86% yield) as a clear oil. 
  
Scheme S6. Preparation of 1p 
 
To a stirring solution of SI-4 (453.7 mg, 1.00 mmol) in ACN (0.1 M), iodomethane 
(124.5 L, 2.00 mmol) was added and the resulting mixture was stirred at 40 oC. 
After the starting material was consumed as indicated by TLC, the organic solvent 
was removed under reduced pressure to afford the crude iminium ion. After 
washing with hexane to remove any excess iodomethane, benzylmagnesium 
chloride (2.0 M solution in THF, 2.5 mL, 5.00 mmol) was added dropwise to a 
cooled solution of resultant iminium ion in dry THF (0.05 M) over 30 min at –78 °C. 
The reaction was allowed to slowly warm to r.t over an 18 h period. The mixture 
was quenched with saturated NH4Cl(aq) and extracted twice with DCM. The 
combined organic layer was dried over anhydrous Na2SO4(s) and the filtrate was 
condensed under reduced pressure, followed by silica-gel flash column 
chromatography to afford 1p (397.5 mg, 71% yield) as a colorless oil. 
Substrates 1q, 1r, and 1s were prepared according to Scheme S6. 
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Scheme S7. Preparation of 1t 
 
Substrate 1t was prepared according to the previous report.2 To a stirring solution 
of SI-5 (1.0 g, 1.86 mmol) in acetonitrile (ACN) (0.1 M), benzyl bromide (331.7 L, 
2.79 mmol) was added and the resulting mixture was stirred at 80 oC. After 
completion of the reaction indicated by TLC, the organic solvent was removed 
under reduced pressure and the crude resultant was washed with hexane to remove 
any excess benzyl bromide. To a cooled solution of resultant iminium ion in dry 
THF (0.05 M) was added 3-butenylmagnesium bromide (0.5 M solution in THF, 
18.6 mL, 9.30 mmol) dropwise over 30 min at –78 oC. The reaction mixture was 
allowed to slowly warm to r.t over an 12 h period. The resultant was quenched with 
saturated NH4Cl(aq) and extracted twice with DCM. The combined organic layer 
was dried over anhydrous Na2SO4(s) and filtered. The filtrate was condensed under 
reduced pressure, followed by flash column chromatography to afford SI-6 (1.0 g, 
79 %) as a clear oil. To a solution of SI-6 in toluene (0.005 M) was added 2nd 
generation Grubbs’ catalyst (20 mol%) and the mixture was left to stir at reflux. 
After the starting material was indicated as by TLC, the organic solvent was 
removed under reduced pressure, and the residue was purified by silica-gel flash 
column chromatography to obtain the desired product 1t (607.3 mg, 63 % yield) as 
a brown oil. 
Substrate 1u was prepared from 1t according to the Scheme S3.  
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Scheme S8. Preparation of 1c’ 
 
To a solution of 1c (100.0 mg, 0.18 mmol) in THF (0.1 M) was added TBAF (1.0 M 
in THF, 270 L, 0.37 mmol) and the mixture was stirred at r.t. After completion of 
the reaction as indicated by TLC, the reaction mixture was quenched with saturated 
NaHCO3(aq). The resultant was extracted twice with ethyl acetate, dried with 
anhydrous Na2SO4(s), filtered, and concentrated in vacuo. The residue was purified 
with silica-gel flash column chromatography to obtain desired product 1c’ (67.0 
mg, 96% yield) as a white solid. 
Similarly, 2c’ was prepared from 2c according to the Scheme S8 
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(1a) Prepared according to Scheme S2; 56% overall yield, 132.4 
mg; pale yellow oil; 1H NMR (400 MHz, CDCl3):  7.91 (s, 1H), 
6.20 (t, J = 5.1 Hz, 1H), 4.07 (br s, 1H), 3.80 (m, 2H), 3.36–3.47 
(m, 6H), 3.09 (m, 1H), 2.82 (s, 6H), 2.18 (m, 1H); 13C NMR 
(100 MHz, CDCl3) :  167.2, 164.4, 155.0, 95.1, 80.1, 72.9, 63.2, 62.0, 47.4, 45.1, 
44.2, 41.4. 
(1b) Prepared according to Scheme S4; 72% overall yield, 220.1 
mg; white solid; 1H NMR (400 MHz, DMSO-d6):  8.48 (t, J = 
6.1 Hz, 1H), 7.85 (s, 1H), 7.30–7.24 (m, 4H), 7.19 (m, 1H), 6.57 
(t, J = 3.9 Hz, H), 4.29 (d, J = 5.9 Hz, 2H), 3.98 (s, 2H), 3.35–
3.30 (m, 7H), 2.98 (s, 3H), 2.73 (m, 2H); 13C NMR (100 MHz, 
DMSO-d6) :  169.5, 167.7, 164.8, 154.0, 139.5, 128.2, 127.1, 126.7, 96.9, 79.4, 
75.8, 55.7, 55.2, 52.7, 46.8, 43.7, 42.0, 39.9. 
(1c) Prepared according to Scheme S2; 87% yield from 1f, 
2.1 g; pale yellow oil; 1H NMR (400 MHz, CDCl3):  8.15 
(s, 1H), 7.28 (m, 3H), 7.20 (m, 3H), 7.13 (m, 2H), 6.92 (m, 
2H), 5.50 (m, 1H), 4.44, 4.20 (ABq, JAB = 15.7 Hz, 2H), 
4.09 (d, J = 16.0 Hz, 1H), 3.86 (m, 2H), 3.78 (m, 1H), 3.67 (dd, J = 10.0, 4.5 Hz, 
1H), 3.56 (m, 3H), 3.14 (m, 1H), 2.66 (s, 3H), 1.02 (m, 21H); 13C NMR (100 MHz, 
CDCl3) :  167.6, 165.1, 155.2, 139.6, 138.2, 129.1, 128.5, 128.3, 127.4, 127.1, 
126.9, 96.4, 65.7, 64.8, 60.3, 57.2, 46.1, 45.3, 38.6, 18.1, 11.9. 
(1c’) Prepared according to Scheme S8; 96% yield from 1c, 
67.0 mg; colorless oil; 1H NMR (400 MHz, CDCl3):  8.19 (s, 
1H), 7.31 (m, 3H), 7.21 (m, 3H), 7.06 (m, 2H), 6.87 (m, 2H), 
5.67 (m, 1H), 4.45, 4.17 (ABq, JAB = 15.7 Hz, 2H), 3.95 (d, J = 
16.4 Hz, 1H), 3.88 (m, 2H), 3.71–3.63 (m, 1H), 3.49–3.34 (m, 3H), 3.32–3.26 (m, 
2H), 2.89 (br s, 1H), 2.65 (s, 3H); 13C NMR (100 MHz, CDCl3) :  167.9, 164.9, 
155.4, 138.8, 137.8, 129.3, 128.6, 128.5, 127.6, 127.4, 127.1, 95.0, 65.3, 61.7, 60.3, 
57.0, 45.0, 43.0, 38.6. 
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(1d) Prepared according to Scheme S2; 79% yield from 1c, 
171.6 mg; colorless oil; 1H NMR (400 MHz, CDCl3):  
8.16 (s, 1H), 7.38–7.25 (m, 5H), 5.38 (s, 1H), 4.72, 4.63 
(ABq, JAB = 16.0 Hz, 2H), 3.75 (dd, J = 9.8, 5.1 Hz, 1H), 
3.65 (m, 2H), 3.51 (m ,1H), 3.23 (m, 3H), 2.97 (s, 3H), 2.83 (d, J = 12.1 Hz, 1H), 
2.67 (m, 1H), 2.17 (m, 1H), 1.10 (m, 21H); 13C NMR (100 MHz, CDCl3) :  166.6, 
166.5, 155.3, 138.5, 128.7, 127.2, 127.2, 99.1, 78.7, 73.5, 64.4, 57.8, 57.4, 56.2, 
53.3, 47.7, 38.5, 18.1, 11.9. 
(1e) Prepared according to Scheme S2; 89% yield from 1c, 
194.1 mg; colorless oil; 1H NMR (400 MHz, CDCl3):  8.09 
(s, 1H), 7.34–7.24 (m, 5H), 5.76 (dddd, J = 16.8, 10.1, 6.6, 
6.6 Hz, 1H), 5.35 (m, 1H), 5.04 (dd, J = 18.0, 10.5 Hz, 2H), 
4.61 (d, J = 15.3 Hz, 1H), 4.35 (d, J = 15.7 Hz, 1H), 4.09 (d. J = 16.0 Hz, 1H), 
3.80–3.67 (m, 3H), 3.57 (m, 2H), 3.33 (dd, J = 13.7, 6.2 Hz, 1H), 3.18 (dd, J = 14.0, 
6.6 Hz, 1H), 3.05 (m, 1H), 2.78 (s, 3H), 1.05 (m, 21H); 13C NMR (100 MHz, 
CDCl3) :  167.3, 164.9, 155.1, 138.5, 136.4, 128.5, 127.7, 127.1, 117.5, 96.8, 65.1, 
63.8, 59.3, 56.8, 47.3, 44.6, 39.3, 18.1, 11.9. 
(1f) Prepared according to Scheme S2; 75% overall yield, 
2.1 g, off white solid; 1H NMR (400 MHz, CDCl3):  8.09 (s, 
1H), 7.35–7.24 (m, 5H), 5.22 (t, J = 4.3 Hz, 1H), 4.59, 4.54 
(ABq, JAB = 15.6 Hz, 2H), 3.98 (d, J = 15.3 Hz, 1H), 3.73–
3.63 (m, 3H), 3.58 (m, 1H), 3.30 (m, 1H), 3.16 (m, 1H), 2.88 (s, 3H), 2.04 (br s, 
1H), 1.06 (m, 21H); 13C NMR (100 MHz, CDCl3) :  166.3, 166.2, 154.7, 138.3, 
128.6, 127.5, 127.1, 100.8, 65.0, 60.3, 56.8, 46.1, 44.8, 39.1, 18.1, 11.9. 
(1g) Prepared according to Scheme S2; 66% overall yield, 
160.5 mg; pale yellow oil; 1H NMR (400 MHz, CDCl3):  8.14 
(s, 1H), 7.24 (m, 3H), 7.13 (d, J = 6.7 Hz, 2H), 5.46 (m, 1H), 
4.06 (d, J = 16.0 Hz, 1H), 3.87 (m, 2H), 3.70 (m, 2H), 3.58 (m, 
4H), 3.50 (m, 3H), 3.15 (m, 1H), 3.06 (m, 4H), 1.04 (m, 21H); 
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13C NMR (100 MHz, CDCl3) :  166.7, 165.1, 155.7, 139.3, 129.1, 128.2, 127.2, 
98.4, 66.8, 65.6, 64.6, 60.3, 49.9, 45.7, 45.1, 18.1, 11.9. 
(1h) Prepared according to Scheme S4; 43% overall yield, 2.3g; 
off white solid; 1H NMR (400 MHz, CDCl3):  8.05 (s, 1H), 5.44 
(m, 1H), 3.96 (d, J = 16.0 Hz, 1H), 3.91 (m, 1H), 3.83 (m, 1H), 
3.78 (s, 3H), 3.75 (m, 1H), 3.68 (m ,1H), 2.96 (s, 6H), 2.45 (br s, 
1H); 13C NMR (100 MHz, CDCl3) :  172.7, 166.3, 165.3, 154.6, 99.6, 61.1, 52.4, 
46.1, 43.9, 41.3. 
(1i) Prepared according to Scheme S4; 83% yield from 1j; 
1.5 g, pale yellow oil;  1H NMR (400 MHz, CDCl3):  8.13 
(s, 1H), 7.30–7.21 (m, 6H), 7.19–7.16 (m, 4H), 5.31 (s, 1H), 
4.66, 4.54 (ABq, JAB = 16.0 Hz, 2H), 3.66 (d, J = 13.7 Hz, 
1H), 3.61 (m, 1H), 3.54 (m, 2H), 3.46 (m, 2H), 3.20 (d, J = 13.3 Hz, 1H), 2.81 (s, 
3H), 2.72 (d, J = 12.5 Hz, 1H), 2.52 (m, 1H), 1.04 (m, 21H); 13C NMR (100 MHz, 
CDCl3) :  166.5, 166.3, 155.4, 138.6, 138.3, 129.3, 128.6, 128.3, 127.3, 127.2, 
127.0, 98.5, 64.7, 63.0, 57.6, 57.0, 55.4, 53.9, 38.1, 18.1, 11.9. 
(1j) Prepared according to Scheme S4; 61% overall yield, 1.6 
g, pale yellow oil;  1H NMR (400 MHz, CDCl3):  8.14 (s, 
1H), 7.36–7.23 (m, 5H), 5.35 (br s, 1H), 4.68, 4.50 (ABq, J 
AB = 15.7 Hz, 2H), 3.96 (d, J = 15.3 Hz, 1H), 3.80 (m, 1H), 
3.67 (m, 2H), 3.60 (d, J = 15.3 Hz, 1H), 3.06 (d, J = 12.1 Hz, 1H), 2.90 (s, 3H), 
2.86 (m, 1H), 2.17 (br s, 1H), 1.08 (m, 21H); 13C NMR (100 MHz, CDCl3) :  
166.2, 165.8, 155.0, 138.3, 128.6, 127.5, 127.2, 100.7, 63.8, 57.6, 56.9, 51.9, 47.0, 
38.9, 18.1, 11.9. , 
(1k) Prepared according to Scheme S4; 75% overall yield, 171.3 
mg; pale yellow oil; 1H NMR (400 MHz, CDCl3):  8.14 (s, 1H), 
7.36–7.27(m, 5H), 5.41 (s, 1H), 3.68 (m, 4H), 3.60 (m, 2H), 
3.50 (m, 4H), 3.27 (m, 4H), 3.20 (d, J = 13.3 Hz, 1H), 2.84 (m, 
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1H), 2.75 (m, 1H), 1.07 (m, 21H); 13C NMR (100 MHz, CDCl3) :  166.2, 165.9, 
155.8, 138.2, 129.4, 128.5, 127.7, 100.2, 66.8, 64.8, 63.5, 58.6, 54.6, 53.3, 49.8, 
18.1, 11.9. 
(1l) Prepared according to Scheme S3; 71% overall yield from 
1c, 524.3 mg, colorless oil; 1H NMR (400 MHz, CDCl3):  
8.30 (s, 1H), 7.30 (m, 3H), 7.21 (m, 3H), 7.01 (m, 2H), 6.89 (m, 
2H), 4.52 (d, J = 15.3 Hz, 1H), 4.14 (d, J = 15.3 Hz, 1H), 3.89 
(m, 2H), 3.78 (dd, J = 12.5, 4.7 Hz, 2H), 3.45 (m, H), 3.42–
3.32 (m, 3H), 3.29 (s, 3H), 3.28–3.20 (m, H), 2.89 (br s, 1H), 2.63 (s, 3H); 13C 
NMR (100 MHz, CDCl3) :  167.6, 164.3, 154.9, 138.6, 138.1, 129.2, 128.6, 128.5, 
127.6, 127.5, 127.0, 95.3, 62.7, 61.5, 59.9, 56.9, 53.3, 44.2, 38.9, 38.0. 
(1m) Prepared according to Scheme S3; 77% overall yield 
from 1c, 675.8 mg; colorless oil; 1H NMR (400 MHz, CDCl3): 
 8.32 (s, 1H), 7.36–7.27 (m, 8H), 7.23–7.19 (m, 3H), 7.00 (m, 
2H), 6.90 (m, 2H), 5.20, 4.79 (ABq, JAB = 15.3 Hz, 2H), 4.55, 
4.17 (ABq, JAB = 15.3 Hz, 2H), 3.91, 3.41 (ABq, JAB = 16.4 Hz, 
2H), 3.80, 3.72 (ABq, JAB = 12.5 Hz, 2H), 3.71 (m, 1H), 3.33 (m, 1H), 3.20 (m, 
3H), 2.86 (m, 1H), 2.65 (s, 3H); 13C NMR (100 MHz, CDCl3) :  168.0, 164.2, 
155.0, 138.6, 138.5, 138.0, 129.2, 128.7, 128.6, 128.5, 128.0, 127.6, 127.5, 127.4, 
127.0, 94.8, 62.9, 61.5, 59.9, 56.9, 52.4, 50.0, 44.0, 39.0.  
(1n) Prepared according to Scheme S3; 81% overall yield from 
1i, 598.1 mg; colorless oil; 1H NMR (400 MHz, CDCl3):  8.28 
(s, 1H), 7.33–7.23 (m, 8H), 7.17 (m, 2H), 4.70, 4.58 (ABq, JAB 
= 16.0 Hz, 2H), 3.85 (dd, J = 13.3, 1.6 Hz, 1H), 3.71 (dd, J = 
11.2, 7.2 Hz, 1H), 3.56 (m, 1H), 3.45 (m, 1H), 3.41, 3.29 (ABq, JAB = 12.9 Hz, 2H), 
3.19 (s, 3H), 2.97 (m, 1H), 2.91 (d, J =13.3 Hz, 1H), 2.86 (s, 3H), 2.34 (dd, J = 
12.3, 2.2 Hz, 1H), 2.20 (br s, 1H); 13C NMR (100 MHz, CDCl3) :  166.2, 165.6, 
154.9, 138.5, 138.4, 129.0, 128.7, 128.5, 127.4, 127.2, 127.1, 100.8, 64.1, 63.3, 
61.6, 57.2, 56.5, 56.4, 40.6, 38.2. 
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(1o) Prepared according to Scheme S5; 86% overall yield from 
1i, 424.5 mg, colorless oil.;  1H NMR (400 MHz, CDCl3):  
8.13 (s, 1H), 7.95 (d, J = 8.2 Hz, 2H), 7.54 (m, 1H), 7.40 (m, 
2H), 7.30 (m, 2H), 7.24–7.17 (m, 8H), 5.37 (br s, 1H), 4.69, 
4.58 (ABq, JAB = 16.0 Hz, 2H), 4.34 (m, 1H), 4.25 (m, 1H), 
3.84 (m, 1H), 3.47 (m, 4H), 2.85 (s, 3H), 2.81 (m, 1H), 2.75 (m, 1H); 13C NMR 
(100 MHz, CDCl3) :  166.4, 166.3, 165.5, 155.2, 138.3, 138.2, 133.3, 129.8, 129.6, 
129.1, 128.7, 128.5, 128.4, 127.4, 127.1, 98.7, 65.3, 63.0, 57.3, 57.0, 54.2, 53.1, 
38.2. 
(1p) Prepared according to Scheme S6; 71% overall yield, 
397.5 mg, colorless oil; 1H NMR (500 MHz, CDCl3, major 
isomer):  8.11 (s, 1H), 7.31–7.20 (m, 3H), 7.19–7.09 (m, 
3H), 6.93 (d, J = 7.0 Hz, 2H), 6.69 (d, J = 6.7 Hz, 2H), 5.18 
(d, J = 6.7 Hz, 1H), 4.32 (ABq, J = 16.0 Hz, 2H), 3.96 (dd, 
J = 10.2, 3.1 Hz, 1H), 3.87 (dd, J = 9.6, 2.9 Hz, 1H), 3.73 (m, 1H), 3.46 (m, 1H), 
3.12 (m, 1H), 3.02 (m, 2H), 2.88 (dd, J = 12.5, 2.7 Hz, 1H), 2.59 (s, 3H), 2.30 (s, 
3H), 1.06 (m, 21H); 13C NMR (100 MHz, CDCl3) :  168.0, 166.5, 154.6, 140.0, 
138.3, 129.1, 128.5, 127.9, 127.3, 126.9, 125.9, 103.0, 66.5, 64.5, 60.3, 57.9, 47.9, 
40.9, 38.1, 33.6, 18.1, 12.0. 
(1q) Prepared according to Scheme S6; 54% overall yield, 
343.4 mg; yellow oil;  1H NMR (400 MHz, CDCl3, 
diastereomeric mixture, 3.6:1):  8.11 (s, 1H, minor), 8.09 (s, 
1H, major), 7.37 (m, 3H, minor), 7.24–7.09 (m, 13H, 
major/minor), 6.80 (m, 4H, major), 6.74 (m, 2H, minor), 
6.63 (m, 2H, minor), 5.33 (br s, 1H, major), 5.02 (m, 1H, minor), 4.71 (s, 1H, 
minor), 4.39, 4.11 (Abq, J = 15.3 Hz, 2H, major), 4.15 (m, 1H, minor), 4.04 (m, 3H, 
minor), 3.85 (m, 3H, major/minor), 3.71 (d, J = 14.1 Hz, 1H, major), 3.64 (m ,2H, 
minor), 3.44 (m, 1H, major), 3.35 (d, J = 7.4 Hz, 2H, major), 3.16 (m, 3H, 
major/minor), 2.97 (m, 1H, minor), 2.90 (m, 1H, minor), 2.73 (m, 1H, minor), 2.64 
(m, 1H, minor), 2.49 (s, 3H, major), 2.26 (s, 3H, minor), 1.05 (m, 21H, minor), 
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0.90 (m, 21H, major); 13C NMR (100 MHz, CDCl3) :  167.4, 164.6, 154.9, 154.3, 
139.7, 139.6, 139.3, 139.2, 138.0, 137.8, 129.0, 128.9, 128.7, 128.5, 128.3, 128.2, 
128.2, 128.1, 127.9, 127.8, 127.4, 127.0, 126.9, 126.7, 125.9, 101.0, 64.3, 63.6, 
60.8, 58.4, 57.2, 43.8, 38.3, 36.6, 18.0, 17.8, 11.9, 11.7. 
(1r) Prepared according to Scheme S6; 68% overall yield, 
380.7 mg; pale yellow oil; 1H NMR (500 MHz, CDCl3, 
diastereomeric mixture, 2.7:1):  8.18 (s, 1H, minor), 8.10 (s, 
1H, major), 7.30–7.12 (m, 12H, major/minor), 7.08 (m, 2H, 
major/minor), 7.01 (m, 1H, major/minor), 5.40 (m, 1H, minor), 5.33 (m, 1H, 
major), 4.52 (d, J = 15.3 Hz, 1H, major), 4.31 (m, 1H, major/minor), 4.22 (m, 1H, 
major/minor), 3.88–3.63 (m, 3H, major/minor), 3.42 (m, 3H, major/minor), 3.05 
(m, 1H, major/minor), 2.65 (s, 3H, major), 2.54 (s, 3H, minor), 1.39 (d, J = 6.7 Hz, 
3H, major), 1.36 (d, J = 7.4 Hz, 1H, minor), 1.01 (m, 21H, minor), 0.90 (m, 21H, 
major); 13C NMR (100 MHz, CDCl3) :  166.9, 165.9, 164.6, 155.2, 155.0, 140.2, 
140.1, 138.4, 138.3, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 127.8, 127.5, 127.1, 
127.0, 127.0, 126.9, 104.7, 64.7, 64.5, 63.2, 60.9, 59.7, 58.8, 58.1, 57.5, 54.3, 53.3, 
46.1, 43.2, 39.6, 38.9, 18.1, 18.0, 17.2, 12.0, 11.9. 
(1s) Prepared according to Scheme S6; 76% overall yield, 
367.6 mg; pale yellow oil; 1H NMR (400 MHz, CDCl3, 
diastereomeric mixture, 3.6:1):  8.15 (s, 1H, minor), 8.13 
(s, 1H, major), 7.35–7.21 (m, 5H, major/minor), 5.22 (m, 
1H, minor), 5.14 (m, 1H, major), 4.49 (ABq, JAB = 15.7 Hz, 
2H, major), 4.39 (ABq, JAB = 15.3 Hz, 2H, minor), 4.22 (q, J = 6.7 Hz, 1H, major), 
4.11 (q, J = 7.0 Hz, 1H, minor), 3.90 (m, 1H, minor), 3.81 (dd, J = 9.8, 3.9 Hz, 1H, 
major), 3.70 (m, 1H, major/minor), 3.58 (m, 1H, major), 3.49 (t, J = 9.2 Hz, 1H, 
major), 3.33 (m, 1H, minor), 3.10 (m, 1H, major/minor), 2.99 (m, 1H, 
major/minor), 2.84 (s, 3H, major), 2.79 (s, 3H, minor), 2.37 (s, 3H, minor), 2.23 (s, 
3H, major), 1.27 (d, J = 7.0 Hz, 3H, minor), 1.23 (d, J = 6.7 Hz, 3H, major), 1.03 
(m, 21H, major/minor); 13C NMR (100 MHz, CDCl3) :  167.8, 167.4, 165.9, 165.6, 
157.3, 155.2, 154.9, 138.7, 138.6, 128.7, 128.6, 127.6, 127.4, 127.2, 127.1, 107.1, 
106.5, 66.1, 64.5, 62.4, 59.5, 58.8, 58.5, 58.0, 55.9, 45.7, 45.6, 43.6, 39.9, 39.4, 
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18.1, 14.4, 12.0. 
(1t) Prepared according to Scheme S7; 50% overall yield, 
607.3 mg; colorless oil; 1H NMR (400 MHz, CDCl3)  
8.15 (s, 1H), 7.15–7.05 (m, 5H), 6.99 (d, J = 8.6 Hz, 2H), 
6.80 (d, J = 8.2 Hz, 2H), 5.47 (m, 1H), 5.37 (m, 2H), 4.30 
(dd, J = 11.9, 2.2 Hz, 1H), 4.13 (m, 1H), 3.80 (s, 3H), 
3.75 (m, 2H), 3.72 (m, 1H), 3.39 (m, 4H), 3.11 (m, 1H), 2.80 (m, 1H), 2.59 (m, 3H), 
2.33 (m, 1H), 2.01 (m, 1H), 1.88 (m, 1H), 1.77 (m, 2H), 1.50 (m, 1H), 0.92 (m, 
21H); 13C NMR (100 MHz, CDCl3)  167.4, 165.0, 158.0, 155.4, 140.2, 132.1, 
131.6, 129.8, 128.8, 128.3, 128.2, 126.8, 113.9, 106.1, 64.5, 60.9, 59.2, 59.1, 57.6, 
55.3, 46.9, 43.8, 34.7, 29.2, 26.3, 23.8, 18.0, 11.9. The stereochemistry of this 
product was previously reported2. 
(1u) Prepared according to Scheme S7; 60% yield from 1t, 
140.9 mg; pale yellow oil;  1H NMR (400 MHz, CDCl3):  
8.27 (s, 1H), 7.17 (m, 2H), 7.07 (m, 3H), 7.00 (d, J = 8.2 Hz, 
2H), 6.81 (d, J = 8.2 Hz, 2H), 5.40 (td, J = 10.8, 5.1 Hz, 1H), 
5.29 (m, 1H), 4.38 (d, J = 10.2 Hz, 1H), 4.12 (m, 1H), 3.79 (s, 
3H), 3.75 (d, J = 8.2 Hz, 1H), 3.68 (d, J = 15.7 Hz, 1H), 3.43 (m, 3H), 3.30 (dd, J = 
14.5, 7.4 Hz, 1H), 3.18 (s, 3H), 3.14 (m, 1H), 2.75 (m, 1H), 2.67–2.51 (m, 3H), 
2.32 (m, 1H), 1.93 (br s, 1H), 1.79 (m, 4H), 1.31 (m, 2H) ; 13C NMR (100 MHz, 
CDCl3) :  166.9, 164.9, 158.0, 155.1, 139.7, 131.9, 131,6, 129.9, 129.1, 128.8, 
128.3, 127.2, 113.9, 107.4, 63.6, 60.5, 59.8, 59.7, 57.3, 55.5, 55.4, 47.3, 39.6, 34.8, 
27.4, 26.1, 23.8. 
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3.5.3. Synthesis and Characterization of Products 
Representative Procedure for the conversion of 1c into 2c: 
To a stirred solution of 1c (27.3 mg, 0.050 mmol) in Acetonitrile (0.5 mL) was 
added AuCl (1.2 mg, 0.005 mmol). The resulting mixture was heated under 
microwave irradiation (100 watt) at 80 °C for 30 min. The solvent was removed in 
vacuo and the residual oil was purified by flash chromatography to give 2c (24.6 
mg, 90% yield) of pale yellow oil. 
 
Intermediate trap; Procedure for the conversion of 1c into 6c: 
 
To a stirred solution of 1c (27.3 mg, 0.050 mmol) in Acetonitrile (0.5 mL) were 
sequentially added TMSCN (18.8 L, 0.15 mmol), AuCl (1.2 mg, 0.005 mmol). 
The resulting mixture was heated under microwave irradiation (100 watt) at 80 °C 
for 30 min, 3 times. The solvent was removed in vacuo and the residual oil was 
purified by flash chromatography to give 6c (11.5 mg, 40% yield) of clear oil with 
2c (9.2 mg, 34% yield). 
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(2a) 65% yield from 1a, 16.3 mg; as a white solid; 1H NMR (400 
MHz, CDCl3):  8.21 (s, 1H), 5.17 (s, 1H), 4.66 (d, J = 5.9 Hz, 
1H), 4.29 (d, J = 6.3 Hz, 1H), 3.75 (m, 1H), 3.66–3.55 (m, 4H), 
3.46–3.36 (m, 2H), 3.06 (s, 6H), 2.83 (br s, 1H), 2.27 (t, J = 2.2 
Hz, 1H); 13C NMR (100 MHz, CDCl3) :  162.5, 159.6, 157.2, 
80.3, 78.0, 73.9, 67.3, 61.3, 59.9, 46.7, 39.8, 37.4; HRMS(ESI+): Calcd for 
C13H20N5O+ [M+H]+ 262.1662, found 262.1662. 
(2b) 67% yield from 1b, 12.2 mg; as a white solid; 1H NMR (400 
MHz, CDCl3):  8.13 (s, 1H), 7.28–7.16 (m, 5H), 6.79 (m, 1H), 
5.17 (s, 1H), 4.40 (d, J = 5.9 Hz, 2H), 4.23 (m, 2H), 4.18 (s, 2H), 
3.48 (d, J = 2.0 Hz, 4H), 3.06 (m, 2H), 3.03 (s, 3H), 2.25 (t, J = 
2.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) :  170.0, 162.1, 159.9, 
157.3, 138.2, 128.7, 127.5, 127.4, 80.8, 78.2, 73.6, 67.1, 54.3, 50.9, 44.7, 43.2, 41.4, 
37.0; HRMS(ESI+): Calcd for C20H25N6O+ [M+H]+ 365.2084, found 365.2082. The 
exact structure of 2b was confirmed by X-ray crystallography. 
(2c) 90% yield from 1c, 24.5 mg; as a pale yellow oil; 1H 
NMR (400 MHz, CDCl3):  8.21 (s, 1H), 7.38–7.17 (m, 10H), 
5.16 (s, 1H), 4.78 (m, 2H), 4.48 (br s, 1H), 4.13 (d, J = 13.3 
Hz, 1H), 3.96 (m, 1H), 3.90 (dd, J = 10.0, 5.3 Hz, 1H), 3.71 
(dd, J = 10.0, 6.8 Hz, 1H), 3.65 (m, 1H), 3.59 (d, J = 13.3 Hz, 
1H), 3.34 (m, 1H), 3.22 (m, 1H), 2.97 (s, 3H), 1.05 (m, 21H); 13C NMR (100 MHz, 
CDCl3) :  162.4, 159.9, 157.5, 138.6, 138.2, 128.6, 128.5, 127.3, 127.2, 127.1, 
80.3, 69.4, 65.4, 64.4, 58.3, 52.5, 48.0, 35.6, 18.1, 12.0; HRMS(ESI+): Calcd for 
C32H48N5OSi+ [M+H]+ 546.3623, found 546.3621. 
(2c’) 95% yield from 1c’, 18.5 mg; as a white solid; 1H NMR 
(400 MHz, CDCl3):  8.20 (s, 1H), 7.39–7.12 (m, 10H), 5.18 
(s, 1H), 4.78 (s, 2H), 4.55 (m, 1H), 4.05 (d, J = 6.7 Hz, 1H), 
4.00 (d, J = 12.9 Hz, 1H) 3.73 (dd, J = 11.3, 3.9 Hz, 1H), 3.62-
3.54 (m, 3H), 3.41 (m, 1H), 3.28 (m, 1H), 2.97 (s, 3H); 13C 
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NMR (100 MHz, CDCl3) :  162.4, 159.8, 157.4, 138.0, 137.8, 128.7,128.6, 127.6, 
127.2, 127.1, 80.3, 68.4, 63.7, 60.1, 57.4, 52.4, 46.5, 35.5; HRMS(ESI+): Calcd for 
C23H28N5O+ [M+H]+ 390.2288, found 390.2288. 
(6c) 40% yield from 1c, 11.5 mg; as a clear oil; 1H NMR 
(400 MHz, CDCl3):  8.20 (s, 1H), 7.34–7.17 (m, 10H), 5.34 
(s, 1H), 5.07 (m, 1H), 4.79 (s, 1H), 4.06 (m, 1H), 3.99 (m, 
2H), 3.83 (d, J =13.7 Hz, 1H), 3.63–3.51 (m, 3H), 3.39 (m, 
1H), 3.15 (m, 1H), 3.00 (s, 3H), 1.08 (m, 21H); 13C NMR 
(100 MHz, CDCl3) :  162.9, 162.8, 157.8, 138.0, 137.2, 129.0, 128.9, 128.7, 128.0, 
127.2, 127.1, 117.1, 80.3, 62.4, 54.8, 52.5, 40.4, 39.0, 35.5, 18.1, 11.9; 
HRMS(ESI+): Calcd for C33H49N6OSi+ [M+H]+ 573.3732, found 573.3730. 
(2d) 80% yield from 1d, 19.7 mg; as a pale yellow oil; 1H 
NMR (400 MHz, CDCl3):  8.20 (s, 1H), 7.32–7.22 (m, 3H), 
7.18 (m, 2H), 5.30 (br s, 1H), 4.78 (m, 2H), 4.32 (m, 1H), 
4.11 (m, 1H), 4.02 (m, 1H), 3.92 (d, J = 8.6 Hz, 1H), 3.69 (t, 
J = 9.0 Hz, 1H), 3.49 (s, 2H), 3.21 (d, J = 9.0 Hz, 1H), 2.95 
(s, 3H), 2.94 (m, 1H), 2.22 (m, 1H), 1.03 (m, 21H); 13C NMR (100 MHz, CDCl3) : 
 162.4, 160.6, 160.3, 157.4, 138.0, 128.5, 127.0, 80.2, 78.2, 73.3, 67.7, 62.3, 58.2, 
53.2, 52.3, 40.9, 35.2, 17.9, 11.9; HRMS(ESI+): Calcd for C28H44N5OSi+ [M+H]+ 
494.3310, found 494.3309. 
(2e) 74% yield from 1e, 18.3 mg; as a pale yellow oil; 1H 
NMR (400 MHz, CDCl3):  8.24 (s, 1H), 7.33–7.17 (m, 5H), 
5.90 (m, 1H), 5.26–5.13 (m, 3H), 4.79 (s, 2H), 4.58 (m, 1H), 
3.99 (d, J = 5.9 Hz, 1H), 3.90 (dd, J = 10.0, 5.3 Hz, 1H), 3.67 
(dd, J =9.8, 7.0 Hz, 1H), 3.62–3.52 (m, 2H), 3.31 (m, 1H), 
3.16 (m, 1H), 3.09 (dd, J = 13.7, 7.0 Hz, 1H), 3.00 (s, 3H), 1.06 (m, 21H); 13C 
NMR (100 MHz, CDCl3) :  162.4, 159.9, 157.5, 138.2, 135.1, 128.6, 127.2, 127.1, 
117.9, 80.3, 69.1, 65.2, 64.2, 57.1, 52.5, 47.8, 35.5, 18.1, 12.0; HRMS(ESI+): 
Calcd for C28H46N5OSi+ [M+H]+ 496.3466, found 496.3467. 
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(2f) 84% yield from 1f, 19.1 mg; as a pale clear oil; 1H NMR 
(400 MHz, CDCl3):  8.23 (s, 1H), 7.32– 7.16 (m, 5H), 5.18 
(s, 1H), 4.78 (s, 2H), 4.62 (d, J = 7.0 Hz, 1H), 4.30 (d, J = 
8.2 Hz, 1H), 3.90 (m, 2H), 3.49–3.36 (m, 2H), 3.28 (t, J = 
8.2 Hz, 1H), 2.98 (s, 3H), 1.04 (m, 21H); 13C NMR (100 
MHz, CDCl3) :  162.5, 159.8, 157.6, 138.2, 128.7, 127.2, 127.1, 80.5, 63.8, 61.9, 
59.9, 52.5, 46.7, 35.5, 18.1, 12.0; HRMS(ESI+): Calcd for C25H42N5OSi+ [M+H]+ 
456.3153, found 456.3154. 
(2g) 84% yield from 1g, 21.5 mg; as a yellow oil; 1H NMR 
(400 MHz, CDCl3):  8.19 (s, 1H), 7.39–7.25 (m, 5H), 5.22 (s, 
1H), 4.47 (m, 1H), 4.15 (d, J = 13.3 Hz, 1H), 3.96 (m, 1H), 3.91 
(dd, J = 10.2, 5.1 Hz, 1H), 3.79–3.65 (m, 6H), 3.59 (d, J = 13.3 
Hz, 1H), 3.51 (t, J = 4.7 Hz, 4H), 3.37 (m, 1H), 3.23 (m, 1H), 
1.05 (m, 21H); 13C NMR (100 MHz, CDCl3) :  162.9, 160.1, 
157.5, 138.6, 128.6, 128.5, 127.4, 81.2, 69.4, 66.7, 65.4, 64.4, 58.3, 48.1, 44.6, 18.1, 
12.0; HRMS(ESI+): Calcd for C28H46N5O2Si+ [M+H]+ 512.3415, found 512.3417. 
(2h) 84% yield from 1h, 21.0 mg; as a pale yellow solid; 1H 
NMR (400 MHz, CDCl3):  8.21 (s, 1H), 5.16 (s, 1H), 4.66 (d, J 
= 7.8 Hz, 1H), 4.40 (d, J = 7.8 Hz, 1H), 4.15 (t, J = 7.0 Hz, 1H), 
3.80 (s, 3H), 3.75 (m, 1H), 3.49 (dd, J = 9.6, 6.8 Hz, 1H), 3.06 (s, 
6H); 13C NMR (100 MHz, CDCl3) :  172.2, 162.6, 159.5, 157.4, 
80.8, 63.2, 59.5, 52.7, 48.4, 37.4; HRMS(ESI+): Calcd for C11H18N5O2+ [M+H]+ 
252.1455, found 252.1454. 
(2i) 85% yield from 1i, 23.1 mg; as a pale yellow oil; 1H NMR 
(400 MHz, CDCl3):  8.21 (s, 1H), 7.38–7.15 (m, 10H), 5.28 
(br s, 1H), 4.78 (q, J = 15.7 Hz, 2H), 4.32 (br s, 1H), 4.01 (br s, 
1H), 3.92 (m, 2H), 3.77 (t, J = 9.0 Hz, 1H), 3.69 (m, 2H), 3.23 
(d, J = 8.2 Hz, 1H), 2.95 (s, 3H), 2.75 (m, 1H), 1.02 (m, 21H); 
13C NMR (100 MHz, CDCl3) :  162.5, 160.4, 157.6, 138.3, 138.2, 128.7, 128.5, 
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127.3, 127.2, 127.2, 80.3, 69.4, 62.5, 58.2, 58.0, 55.0, 52.4, 35.4, 18.1, 12.0; 
HRMS(ESI+): Calcd for C32H48N5OSi+ [M+H]+ 546.3623, found 546.3625. 
(2j) 57% yield from 1j, 13.0 mg; as a pale yellow oil; 1H NMR 
(400 MHz, CDCl3):  8.21 (s, 1H), 7.30–7.16 (m, 5H), 5.21 (s, 
1H), 4.76 (s, 2H), 4.42 (d, J = 8.2 Hz, 1H), 4.15 (d, J = 8.2 Hz, 
1H), 3.92 (m, 2H), 3.81 (m, 1H), 3.39 (d, J = 12.1 Hz, 1H), 3.09 
(dd, J = 11.9, 6.8 Hz, 1H), 2.98 (s, 3H), 1.00 (m, 21H); 13C NMR 
(100 MHz, CDCl3) :  162.5, 159.9, 157.6, 138.1, 128.7, 127.2, 127.1, 80.8, 64.9, 
64.0, 57.5, 52.6, 50.6, 35.6, 18.0, 11.9; HRMS(ESI+): Calcd for C25H42N5OSi+ 
[M+H]+ 456.3153, found 456.3153. 
(2k) 58% yield from 1k, 14.8 mg; as a yellow oil; 1H NMR (400 
MHz, CDCl3):  8.17 (s, 1H), 7.36–7.23 (m, 5H), 5.33 (s, 1H), 
4.30 (m, 1H), 4.02 (m, 1H), 3.91 (m, 2H), 3.80–3.65 (m, 7H), 
3.48 (m, 4H), 3.21 (m, 1H), 2.75 (dd, J = 9.0, 6.7 Hz, 1H), 1.03 
(m, 21H); 13C NMR (100 MHz, CDCl3) :  163.0, 160.6, 157.6, 
138.2, 128.6, 128.5, 127.4, 81.5, 69.3, 66.6, 62.7, 58.3, 58.0, 55.1, 44.6, 18.1, 12.0; 
HRMS(ESI+): Calcd for C28H46N5O2Si+ [M+H]+ 512.3415, found 512.3416. 
(3l) 61% yield from 1l, 12.3 mg; as a yellow oil; 1H NMR 
(400 MHz, CDCl3):  8.19 (s, 1H), 7.33–7.17 (m, 10H), 5.26 
(s, 1H), 4.79 (s, 2H), 4.37 (m, 2H), 4.01 (t, J = 7.2 Hz, 1H), 
3.71 (m, 2H), 3.61 (m, 1H), 3.51–3.35 (m, 3H), 2.99 (s, 3H), 
2.93 (s, 3H); 13C NMR (100 MHz, CDCl3) :  162.7, 162.4, 157.0, 139.1, 138.3, 
128.9, 128.7, 128.3, 127.3, 127.2, 86.0, 79.8, 67.0, 62.3, 59.7, 52.6, 52.0, 37.5, 
35.6; HRMS(ESI+): Calcd for C24H30N5O+ [M+H]+ 404.2445, found 404.2444. 
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(3m) 25% yield from 1m, 7.5 mg, (47 % brsm); as a yellow 
oil; 1H NMR (400 MHz, CDCl3):  8.19 (s, 1H), 7.31–7.08 (m, 
15H), 5.25 (s, 1H), 4.76–4.59 (m, 4H), 4.33 (ABq, JAB = 5.8 
Hz, 2H), 3.97 (t, J = 7.4 Hz, 1H), 3.69 (ABq, JAB = 12.9 Hz, 
2H), 3.56 (m, 2H), 3.36 (dd, J = 8.4, 4.1 Hz, 1H), 3.30 (dd, J 
= 13.7, 8.2 Hz, 1H), 2.89 (s, 3H); 13C NMR (100 MHz, CDCl3) :  162.7, 162.4, 
157.3, 139.0, 138.2, 138.0, 128.9, 128.7, 128.6, 128.3, 127.3, 127.2, 127.1, 126.8, 
85.9, 80.6, 67.1, 62.1, 59.8, 52.7, 52.6, 50.2, 35.6; HRMS(ESI+): Calcd for 
C30H34N5O+ [M+H]+ 480.2758, found 480.2759. 
(4n) 67% yield from 1n, 13.5 mg; as a pale yellow oil; 1H NMR 
(400 MHz, CDCl3):  8.25 (s, 1H), 7.35–7.16 (m, 10H), 5.36 (s, 
1H), 5.08 (m, 1H), 4.78 (s, 2H), 4.31, 4.22 (ABq, JAB = 9.8 Hz, 
2H), 4.03 (dd, J = 10.6, 4.3 Hz, 1H), 3.92, 3.86 (ABq, JAB = 
13.3 Hz, 2H), 3.70 (t, J = 10.2 Hz, 1H), 3.02 (m, 1H), 2.98 (s, 3H), 2.93 (m, 1H), 
2.88 (s, 3H); 13C NMR (100 MHz, CDCl3) :  163.1, 163.0, 157.2, 138.3, 138.2, 
129.0, 128.7, 128.5, 127.3, 127.2, 83.9, 80.1, 69.2, 56.4, 52.6, 52.0, 44.7, 35.6, 
30.7; HRMS(ESI+): Calcd for C24H30N5O+ [M+H]+ 404.2445, found 404.2444. 
(4o) 94% yield from 1o, 23.1 mg; as a clear oil; 1H NMR (400 
MHz, CDCl3):  8.24 (s, 1H), 8.02 (m, 2H), 7.55 (m, 1H), 7.41 
(m, 2H), 7.38–7.23 (m, 8H), 7.21 (m, 2H), 5.58 (br s, 1H), 4.81 
(m, 2H), 4.70 (d, J = 7.4 Hz, 1H), 4.44 (d, J = 4.7 Hz, 1H), 4.34 
(m, 2H), 3.87 (m, 1H), 3.77, 3.70 (ABq, JAB = 12.9 Hz, 2H), 
3.19 (d, J = 9.0 Hz, 1H), 3.00 (s, 3H), 2.80 (m, 1H); 13C NMR (100 MHz, CDCl3) : 
 166.5, 162.6, 160.3, 157.6, 138.2, 137.9, 133.1, 130.1, 129.8, 128.6, 128.6, 128.5, 
128.4, 127.4, 127.2, 127.1, 80.9, 69.2, 64.2, 57.9, 55.6, 55.3, 52.4, 35.6; 
HRMS(ESI+): Calcd for C30H32N5O2+ [M+H]+ 494.2551, found 494.2549. 
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(5p) 72% yield from 1p, 20.1 mg; as a clear oil; 1H NMR 
(400 MHz, CDCl3):  8.29 (s, 1H), 7.32–7.05 (m, 10H), 5.14 
(s, 1H), 4.80, 4.74 (ABq, JAB = 16.0 Hz, 2H), 4.55 (br s, 1H), 
3.68 (dd, J = 9.8, 5.1 Hz, 1H), 3.64 (m, 1H), 3.37 (dd, J = 9.8 
Hz, 7.0 Hz, 1H), 3.13 (m, 1H), 2.99 (s, 3H), 2.91 (m, 1H), 
2.79 (m, 1H), 2.46 (t, J = 9.6 Hz, 1H), 2.40 (s, 3H), 1.02 (m, 21H); 13C NMR (100 
MHz, CDCl3) :  162.5, 159.6, 157.5, 138.2, 137.6, 130.8, 128.7, 127.5, 127.2, 
127.1, 126.1, 81.5, 81.1, 66.0, 65.2, 52.6, 49.4, 40.7, 38.3, 35.6, 18.1, 12.0; 
HRMS(ESI+): Calcd for C33H50N5OSi+ [M+H]+ 560.3779, found 560.3777. The 
stereochemistry of this product was confirmed by NOESY spectroscopy.  
(5q) 81% yield from 1q, 25.7 mg; as a pale yellow oil; 1H 
NMR (400 MHz, CDCl3):  8.30 (s, 1H), 7.35–7.04 (m, 15H), 
5.14 (s, 1H), 4.95 (m, 1H), 4.77 (m, 2H), 3.82, 3.75 (ABq, 
JAB = 12.9 Hz, 2H), 3.70 (m, 1H), 3.38 (m, 1H), 3.19 (m, 1H), 
3.10 (m, 1H), 3.00 (s, 3H), 2.93 (m, 1H), 2.70 (m, 1H), 2.61 
(m, 1H), 0.94 (m, 21H); 13C NMR (100 MHz, CDCl3) :  162.3, 159.3, 157.3, 
139.0, 138.0, 137.7, 130.6, 129.3, 128.5, 128.2, 127.6, 127.2, 127.1, 127.0, 126.0, 
81.0, 80.6, 66.7, 63.9, 60.7, 52.6, 48.7, 39.6, 35.5, 17.9, 11.7; HRMS(ESI+): Calcd 
for C39H54N5OSi+ [M+H]+ 636.4092, found 636.4092. 
(5r) 70% yield from 1r, 16.9 mg; as a yellow oil; 1H NMR 
(400 MHz, CDCl3, diastereomeric mixture, 2:1):  8.24 (s, 
1H, major), 8.20 (s, 1H, minor), 7.41–7.15 (m, 15H, 
major/minor), 5.23 (s, 1H, major), 5.16 (s, 1H, minor), 4.95 
(m, 1H, minor), 4.84–4.71 (m, 3H, major/minor), 4.65 (m, 
1H, major), 4.09 (m, 1H, minor), 3.92–3.82 (m, 4H, major/minor), 3.68 (m, 2H, 
major/minor), 3.60 (m, 1H, minor), 3.53 (m, 1H, major), 3.46–3.34 (m, 2H, 
major/minor), 3.16 (m, 1H, major), 3.00 (s, 3H, major), 2.98 (s, 3H, minor), 1.25 (d, 
J = 5.1 Hz, 3H, major), 1.22 (d, J = 5.9 Hz, 3H, minor), 1.00 (m, 21H, 
major/minor); 13C NMR (100 MHz, CDCl3) :  162.4, 159.8, 159.5, 157.5, 157.4, 
139.5, 139.0, 138.3, 138.3, 128.9, 128.7, 128.6, 128.5, 128.4, 128.3, 127.3, 127.2, 
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127.2, 127.1, 81.2, 80.3, 76.2, 71.9, 66.7, 65.6, 64.7, 60.3, 59.3, 52.7, 52.6, 51.9, 
48.9, 48.7, 35.7, 35.6, 21.2, 18.1, 18.1, 13.8, 12.0, 11.9; HRMS(ESI+): Calcd for 
C33H50N5OSi+ [M+H]+ 560.3779, found 560.3779. 
(5s) 92% yield from 1s, 25.7 mg; as a yellow oil; 1H NMR 
(400 MHz, CDCl3, diastereomeric mixture, 1.1:1):  8.25 (s, 
1H, major), 8.24 (s, 1H, minor), 7.33–7.20 (m, 5H, 
major/minor), 5.24 (s, 1H, major), 5.19 (s, 1H, minor), 4.85–
4.72 (m, 2H, major/minor), 4.26 (m, 1H, minor), 4.19 (q, J = 
5.1 Hz, 1H, major), 3.92 (dd, J = 9.8, 4.7 Hz, 1H, major), 3.86 (m, 1H, minor), 3.81 
(m, 1H, major), 3.74–3.64 (m, 1H, major/minor), 3.24 (m, 1H, major/minor), 3.01 
(s, 3H, major), 3.00 (s, 3H, minor), 2.80 (m, 1H, major), 2.45 (s, 3H, major), 2.44 
(s, 3H, minor), 1.40 (d, J = 5.1 Hz, 3H, major), 1.07 (m, 21H, major/minor); 13C 
NMR (100 MHz, CDCl3) :  162.5, 162.4, 160.2, 159.6, 157.4, 157.3, 138.3, 138.2, 
128.7, 127.2, 127.1, 81.4, 80.3, 77.8, 74.4, 65.7, 65.5, 65.1, 61.7, 52.6, 50.2, 48.7, 
39.4, 35.7, 35.6, 35.1, 19.8, 18.1, 13.8, 12.0; HRMS(ESI+): Calcd for 
C27H46N5OSi+ [M+H]+ 484.3466, found 484.3465. 
(2t) 64% yield from 1t, 20.9 mg; as a pale yellow oil; 1H 
NMR (400 MHz, CDCl3):  8.25 (s, 1H), 7.36–7.23 (m, 
5H), 7.12 (d, J =8.2 Hz, 2H), 6.81 (d, J = 8.6 Hz, 2H), 5.34 
(m, 1H), 5.01 (s, 1H), 4.96 (m, 1H), 4.63 (dd, J = 11.3, 7.0 
Hz, 1H), 4.46 (d, J = 10.2 Hz, 1H), 3.95 (d, J = 12.9 Hz, 
1H), 3.85–3.74 (m, 3H), 3.77 (s, 3H), 3.66 (dd, J = 9.6, 4.9 Hz, 1H), 3.56 (m, 1H), 
3.34 (m, 1H), 3.23 (m, 1H), 3.03 (m, 1H), 2.86 (dd, J = 14.9, 6.7 Hz, 1H), 2.78 (m, 
2H), 2.35 (m, 1H), 2.12 (m, 1H), 1.89 (m, 1H), 1.79 (m, 1H), 1.66 (m, 1H), 1.49 (m, 
1H), 1.01 (m, 21H); 13C NMR (100 MHz, CDCl3) :  160.3, 160.1, 158.1, 157.9, 
139.3, 131.8, 130.5, 130.0, 129.4, 128.6, 128.3, 127.4, 113.9, 84.2, 76.7, 66.7, 64.7, 
60.4, 55.3, 51.5, 50.3, 47.8, 38.8, 34.6, 26.4, 23.4, 18.1, 11.9; HRMS(ESI+): Calcd 
for C39H58N5O2Si+ [M+H]+ 656.4354, found 656.4351. The stereochemistry of this 
product was confirmed by NOESY spectroscopy. 
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(3u) 97% yield from 1u, 24.9 mg; 1H NMR (400 MHz, CDCl3): 
 8.24 (s, 1H), 7.14 (m, 7H), 6.82 (d, J = 8.6 Hz, 2H), 5.92 (s, 
1H), 5.57 (m, 1H), 5.33 (m, 1H), 4.50 (dd, J = 6.1, 2.9 Hz, 1H), 
4.05 (dt, J = 13.8, 7.0 Hz, 1H), 3.97 (dd, J = 8.8, 7.2 Hz, 1H), 
3.78 (s, 3H), 3.72 (m, 2H), 3.66 (m, 1H), 3.51 (m, 2H), 3.39 (m, 
1H), 3.09 (m, 1H), 2.96 (m, 2H), 2.87 (m, 2H), 2.73 (s, 3H), 2.43 (m, 1H), 2.19 (m, 
1H), 2.08 (m, 2H), 1.56 (m, 2H); 13C NMR (100 MHz, CDCl3) :  163.5, 161.4, 
158.1, 157.3, 138.6, 132.4, 132.1, 130.0, 129.5, 128.2, 127.5, 125.2, 113.9, 98.4, 
80.7, 68.1, 61.2, 60.9, 56.2, 55.3, 50.2, 49.3, 36.4, 34.2, 34.1, 24.8, 22.1; 
HRMS(ESI+): Calcd for C31H40N5O2+ [M+H]+ 514.3177, found 514.3175. The 
stereochemistry of this product was confirmed by NOESY spectroscopy. 
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3.5.4. Structural Determination of Products 
The stereochemistry of these product were confirmed by NOESY spectroscopy. 
2D-NOE spectra supported the geometry as shown.  
 
Figure S1. NOESY spectra of compound 5p 
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Figure S2. NOESY spectra of compound 6t 
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Figure S3. NOESY spectra of compound 7u 
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3.5.5. X-ray crystallographic analysis data for 2b 
 
 
 
Figure S4. X-ray structure of 5p. Deposition number in Cambridge Structural 
Database: CCDC 1519179.  
Formula: C20 H24 N6 O1 
Unit Cell Parameters: a 9.4370(19) b 11.928(2) c 34.465(7) P212121 
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Chapter 4. Construction of structurally diverse 
pyrimidine-embedded medium/macro and bridged 
small molecules via the library-to-library strategy 
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4.1 Introduction 
Biopolymers in living organisms recognize molecules as three-dimensional (3D) 
surfaces of charges, polarities, and other specific bonding interactions.1 Thus, when 
constructing compound libraries it is important to include the skeletal and 
stereochemical diversity of their structures.2 To generate diverse molecular 
collections, the diversity-oriented synthesis (DOS) strategy was developed, which 
aims to populate new chemical space with drug-like compounds containing a high 
degree of molecular diversity.3 Furthermore, there is privileged substructure-based 
DOS (pDOS) for constructing a library of compounds with enhanced biological 
relevance.4 
The capability of a privileged substructure to act as a chemical “navigator” has 
been demonstrated with specific examples of novel bioactive small-molecule 
modulators discovered using the pDOS strategy.5 The excellent specificity of 
bioactive pDOS-derived compounds is presumably due to the importance of 
privileged substructures as a chemical “navigator" of biologically relevant 
chemical space as well as the unique 3D structures of polyheterocycles.6 
Currently, in our laboratory, the pDOS pathways have been developed using 
pyrimidine as a privileged substructure.7 From this pyrimidine-containing pDOS 
library, we identified novel bioactive small molecules that modulated the cellular 
level of lipid droplets7b or inhibited the protein-protein interaction between leucyl-
tRNA synthetase (LRS) and Ras-related GTP-binding protein D (RagD).7c  
Recently, we developed a new divergent synthetic pathway for skeletally distinct 
pyrimidine-containing medium-sized azacycles using the N-quaternized 
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intermediates.8 Easily accessible intermediates can be efficiently transformed to 14 
discrete scaffolds through selective bond cleavage or migration. With this strategy, 
we can obtain medium-sized rings in an efficient manner, which are difficult to 
obtain by conventional head-to-tail cyclization due to the entropy and enthalpy 
factors. To maximize the coverage of a chemical space with the pDOS strategy, we 
focused on the diversification of ring size and conformation in a 3D space. The 
core skeletons containing a medium- or large-cyclic framework can occupy the 
unexplored chemical space that the previously constructed pyrimidine libraries 
could not occupy.  
For this purpose, a transition-metal catalyst has been used to transform the 
molecular structure. In fact, transition-metal catalysis provides an efficient way to 
induce remarkable changes in the molecular frameworks in a single step.9 In our 
laboratory, we recently found that gold catalysis proceeds through the in situ 
generation of an acyclic iminium intermediate and the subsequent intramolecular 
nucleophilic cyclization.10 This provides a highly concise and effective protocol for 
skeletal diversification at the late stage of synthesis. Furthermore, we propose a 
library-to-library strategy (Figure 4-1), in which the constructed library compounds 
are used as a substrate for other libraries. An advantage of this strategy is that the 
intermediates need not be synthesized for each library, because the compounds that 
constitute one library can be transformed into compounds with completely different 
structures, and new libraries can be built in just one step using a gold catalyst. 
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Figure 4-1. Library to library strategy 
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4.2 Result and Discussion 
To prepare library # 2, library # 1 obtained through N-N bond selective cleavage is 
required. The N-N cleavage reaction robustly proceeds from N-quaternized 
azacycle in one step.8 Thus, using the functionalized alkyl halide in the N-
quaternization step, additional ring fusion can be used to construct library # 2. 
(Scheme 4-1) 
Scheme 4-1. Synthesis of the library #1 
 
In this pathway, co-treatment with base and hydride allowed the selective 
cleavage of the N–N bridge, forming pyrimidine-fused medium-sized diazacycles. 
Regardless of the size of the rings and the length of the side chain, the reaction 
proceeded robustly. (2a-2e) Structural diversity can be introduced in library # 2 by 
controlling the number of fused cyclic members and chain length of the alkyl 
halide, and functional group diversity by changing each of the N-substituents. So 
far, it has been confirmed that the compounds 4d and 4e can be formed from 
library # 1 obtained using 5/6, and 5/7 azacyclic precursors with O-silyl-protected 
iodoethanol and iodopropanol. (Scheme 4-2) 
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Scheme 4-2. Synthesis of the library #2 
 
Libraries # 3 and # 4 can be obtained by gold catalysis of a library # 2 compound. 
Library # 3 can be obtained from a library # 2 compound using an external 
nucleophile and a gold catalyst when it does not have an internal nucleophile 
(R≠H). The iminium intermediate induced by gold-catalyzed ring opening is 
trapped by the external nucleophile, resulting in a large-sized ring. So far, it has 
been confirmed that the desired compound 5d and 5e can be successfully obtained 
from compound 4d and 4e of library # 2. (Scheme 4-3) 
Scheme 4-3. Synthesis of the library #3 
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To visualize molecular diversity, in silico analysis was performed on the 
representative skeletal structure of each library. The energy minimized conformers 
were aligned to the pyrimidine substructure and overlaid on the 3D space (Figure 
4-2a); we demonstrated the structural diversity of each skeleton with wide spatial 
coverage. We also performed the principal-moment of inertia (PMI) analysis11 to 
show the shape-based distribution of molecules. As shown in Figure 4-2b, 
representative structure of each library was dispersed in the PMI plot, indicating 
diverse shapes of each library. Currently, substrate preparation is in progress and 
transformation will be tested. 
 
Figure 4-2. in silico analysis of library compounds. 
 
 123 
4.3 Conclusion 
Herein, we have proposed a new strategy for the construction of structurally 
diverse pyrimidine-embedded medium/macro-cyclic small molecule library using 
the library-to-library strategy. An advantage of the library-to-library strategy is that 
the constructed library compounds can be directly used as a substrate for other 
libraries. This strategy is possible due to the transformation of molecular 
frameworks in a single step by gold catalysis. The molecular diversity of each 
scaffold was confirmed by a series of computational studies, structural alignment 
of energy-minimized 3D conformers, and shape diversity studies by the PMI 
analysis. This strategy allows the efficient construction of a library with wide 
spatial occupation around pyrimidine as the privileged substructure that ensures 
high potential for molecular interactions with biopolymers. Further investigations 
on various substrates are currently underway. 
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국 문 초 록 
피리미딘 기반의 분자다양성이 확보
된 천연물 유사 저분자 물질의 개발 
 
서울대학교 대학원 
생물물리 및 화학생물학과 
구 재 영 
 
화학생물학 에서의 중요한 연구 목표는 생물학적 시스템을 교란할 수 
있는 저분자 화합물 조절자를 발굴하고, 이들이 작용하는 단백질간의 상
호작용을 밝혀 생물학적 시스템을 이해하는 데에 있다. 따라서 단백질간
의 상호작용을 선택적으로 조절할 수 있는 새로운 저분자 화합물 조절자
를 발굴하기 위해서는 분자 다양성이 풍부하며 생물학적 관련성이 높은 
약물 유사 저분자 화합물의 개발이 필수적이다. 본 연구에서는 위의 요
구에 적합한 화합물의 확보를 위하여 천연물의 특징을 도입한 분자를 제
안하였다. 높은 생물학적 관련성을 도입하기 위하여 피리미딘을 독점적 
구조로 포함하는 화합물을 이용하였고, 기존에 합성되어왔던 편평한 분
자들과는 차별화 된 다양한 3차원적 구조 다양성을 가지는 화합물을 발
굴하고자 하였다.   
1 장 에서는 생리활성 조절물질의 발굴 가능성을 높이기 위한 전략으
로 다양한 분자 구조를 가지며 생물학적 연관성이 높은 화합물 군을 확
보하기 위한 다양한 시도에 관하여 소개하고 있다. 
2 장 에서는 피리미딘을 포함하는 독점적 구조 기반 다양성 추구 조합 
화학 반응 경로의 개발에 관하여 서술하고 있다. 피리미딘과 7각 링이 
융합된 피리미도다이아지핀 구조를 출발물질로 하여 창의적인 3차원적 
구조를 점유하는 화합물들을 합성하는 경로에 대해 설명하였고, 이를 통
해 얻어진 화합물이 실제 단백질간의 상호작용을 조절할 수 있음을 증명
하였다. 
3 장 에서는 피리미도다이아지핀 구조에서 발굴된 금 촉매의 신규 반
응성에 관하여 서술하고 있다. 이 반응성을 이용하여 분자 구조를 한 단
계 반응으로 효율적으로 변형할 수 있으며, 합성적 접근이 어려운 거대
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고리구조에 손쉽게 접근이 가능함을 보였다. 
마지막으로 4 장 에서는 상기에 서술된 금 촉매 반응을 이용한 저분자 
화합물 라이브러리의 구축에 관하여 다루었다. 피리미딘이 포함된 중간
고리 화합물을 이용하여 금 촉매의 한 단계 반응을 통해 다른 형태를 갖
는 중간고리 구조 혹은 거대고리 구조로의 변형을 유도하여 풍부한 구조 
다양성을 갖는 저분자 화합물 라이브러리를 제안하였다.   
2 장부터 4 장까지의 연구를 통해 3차원적 구조 다양성을 포함하는 저
분자 화합물을 다수 확보하였고, 확보된 저분자 화합물 중에서 실제 단
백질간의 상호작용을 조절할 수 있는 저분자 물질을 발굴함으로써 화합
물의 유용성을 증명할 수 있었다. 따라서 본 연구에서 발굴된 피리미딘 
기반의 분자다양성이 확보된 천연물 유사 저분자 물질들은 추후 더 많은 
신규 생리활성 물질의 도출에 높은 잠재력을 가질 것으로 예상된다. 
 
 
 
주요어 : 분자다양성, 피리미딘, 독점적 구조 기반 다양성 추구 조합화학, 
금 촉매 반응, 중간고리 화합물, 거대고리 화합물, 화합물 라이
브러리, 
 
학   번 : 2013-30757 
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Appendix 
Copy of 1H and 13C NMR Spectra 
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3M_BN_13C.ESP
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1
6
2
.7
1
6
2
.5
1
5
7
.3
1
3
9
.1
1
3
8
.2
1
3
8
.0
1
2
9
.0
1
2
8
.7
1
2
8
.4
1
2
7
.3
1
2
7
.2
1
2
6
.9
8
5
.9
8
0
.6
6
7
.1
6
2
.2
5
9
.8
5
2
.8
5
2
.6
5
0
.3
3
5
.7
 
 
 
 175 
 
4N_1H.ESP
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
3.090.982.881.221.192.251.221.111.152.001.151.123.955.680.77
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4N_13C.ESP
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4O_1H.ESP
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
1.032.741.052.090.971.790.970.992.000.911.767.481.941.031.800.72
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4O_13C.ESP
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5P_1H.ESP
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
20.032.781.211.261.272.741.201.202.181.092.321.001.792.602.511.940.70
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5P_13C.ESP
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5Q-13C.ESP
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Chemical Shift (ppm)
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5R_MEBN_13C.ESP
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5S_MEME_13C.ESP
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
1
6
2
.5
1
6
0
.3
1
5
9
.7
1
5
7
.5
1
5
7
.4
1
3
8
.3
1
3
8
.3
1
2
8
.7
1
2
7
.2
1
2
7
.2
8
1
.4
8
0
.4
7
7
.8
7
4
.4
6
5
.8
6
5
.5
6
5
.2
6
1
.7
5
2
.6
5
0
.2
4
8
.8
3
9
.5
3
5
.6
3
5
.1
1
9
.9
1
8
.1
1
3
.9
1
2
.0
 
 
 181 
 
6T_1H.ESP
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
17.011.201.101.171.251.291.231.831.031.000.941.150.981.004.710.920.850.910.850.881.001.631.633.730.68
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6T_13C.ESP
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7U_1H).ESP
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
2.802.431.371.393.002.332.061.411.212.262.021.192.961.251.381.141.311.331.092.127.060.94
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7U_13C.ESP
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Chemical Shift (ppm)
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